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Vivianne C.G. Tjan-Heijnen 
 
Chapter 1 
Introduction and outline of the thesis 
 
Lung cancer is the leading cause of death from cancer. In the majority of patients it 
concerns non-small cell lung cancer, and in about one quarter small cell lung cancer 
(SCLC). In the Netherlands, SCLC is diagnosed in approximately 2000 patients a year 
[1]. Without treatment, survival of patients with SCLC is only 1-3 months. Prognosis 
has clearly improved with combination chemotherapy to a median survival time (MST) 
ranging from 7-18 months, though long-term survival remains poor [2]. It is apparent 
that we need better chemotherapy for SCLC.  
 
One approach to improve outcome may be the delivery of chemotherapy at increased dose-
intensity (DI), either by dose escalation for one or more cycles or by giving chemotherapy 
at shortened intervals (densification or acceleration). Both concepts have been evaluated in 
SCLC patients. DI is defined as the chemotherapy dose per unit time and is expressed as 
mg/m2/week [3]. The cumulative or total dose is the product of dose per cycle and 
number of cycles of chemotherapy. At the start of the studies described in this thesis, it 
was unclear whether DI, total dose, dose per cycle and number of cycles were all important 
factors for final outcome. 
 
The continuing confusion about the relevance of chemotherapy dose versus DI in SCLC 
is partly due to the fact, that a clear distinction between these issues has not always 
explicitly been taken into account. In chapter 2 the different ways of achieving 
intensification of chemotherapy, dose-escalation versus densification or acceleration, 
are highlighted. In 1997, the publication year of that first review, only a few randomised 
studies had been reported concerning dose and DI. From this review it became clear 
that, although it has become easier after the introduction of haematopoietic growth 
factors, several myelotoxicity related problems make densification or acceleration 
difficult.  
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Therefore, we performed a phase II study in SCLC to investigate the impact of 
granulocyte colony-stimulating factor (G-CSF) priming on recovery of peripheral blood 
cell counts. G-CSF primarily affects the peripheral counts of neutrophils. The efficacy of 
G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF) depends not only 
on dose but also on schedule of administration. At standard chemotherapy, a 7-10 day 
administration starting 1 day after the end of chemotherapy is optimal in reducing both 
degree and duration of leukopenia. A later onset is less effective; an earlier one aggravates 
leukopenia and thrombocytopenia. Importantly, the cycling rate of blood progenitor cells 
decreases dramatically below the pre-treatment level within 1 day after GM-CSF 
discontinuation and the cycling rate remains low for at least 7 days. This proliferation 
arrest after GM-CSF priming has been demonstrated to produce a chemoprotective effect 
on progenitor cells. To evaluate the impact of G-CSF priming on peripheral blood cell 
counts during standard-dose chemotherapy twelve patients with relapsed SCLC were 
treated with two 4-weekly chemotherapy cycles. Six patients received G-CSF priming only 
before the first cycle (group A) and the other six patients only before the second cycle 
(group B). The results of this study are presented in chapter 3. 
 
CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy 
regimens in the treatment of SCLC, with myelosuppression as dose-limiting toxicity. 
The addition of G-CSF facilitates CDE intensification [4]. In addition, G-CSF has been 
demonstrated to reduce the number of febrile complications, when added to 
conventionally dosed CDE [5]. An alternative approach for the prevention of febrile 
leukopenia (FL) may be the prophylactic use of antibiotics.  
 
In 1994, we started therefore a randomised phase III study (08923) on behalf of the Lung 
Cancer Group of the European Organization for Research and Treatment of Cancer  
(EORTC-LCG). Patients with chemo-naive SCLC were randomised to standard-dose 
CDE (C 1000 mg/m2 day 1, D 45 mg/m2 day 1,  E 100 mg/m2 days 1-3, intravenously, 
every 3 weeks, times 5) or to intensified CDE chemotherapy (125% dose, intravenously, 
every 2 weeks, times 4) with G-CSF 5 µg/kg/day days 4-13 of each cycle) (n=240 
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patients). Patients were also randomised by a 2x2 factorial design to prophylactic 
antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, b.i.d., days 4-13) or to 
placebo (first 163 patients).  
 
In chapter 4 the effect of antibiotics on the incidence of FL in this randomised placebo-
controlled double-blind study is described. The costs of prophylactic antibiotics in 
relation to cost-savings produced by a reduced number of hospitalisations for FL are 
reported in chapter 5.  
 
In the trial the total dose of CDE chemotherapy was planned to be equal in both arms, 
while in the densified arm the treatment was planned to be delivered in half the time in 
comparison with the standard arm. The main endpoint of this part of the study was to 
assess the impact of a nearly 100% DI increase on survival and response. The results are 
described in chapter 6. 
 
At the time of finalising this thesis far more randomised studies concerning dose and DI 
of chemotherapy in SCLC were reported during the preceding years. It was decided to 
perform an analysis of randomised studies only, in which dose or DI of chemotherapy in 
SCLC were the only variables tested. The studies were categorized according the 
classification: 1. number of cycles (treatment duration), 2. dose per cycle, 3. interval 
between cycles (dose-densification), and 4. a combination of these variables. Such 
classification may facilitate our understanding of the relationship between 
chemotherapy DI and survival. The results are reported in chapter 7. 
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Chapter 2 
Abstract 
 
The natural history of small cell lung cancer (SCLC) is characterised by early dissemina-
tion. Despite the high responsiveness to chemotherapy, the disease remains ultimately fatal 
in the majority of patients. One of the strategies to improve final outcome is the 
administration of intensified chemotherapy, either by dose escalation or by chemotherapy 
given at shortened intervals. By now, in only one randomised study, in which 
cyclophosphamide and cisplatin dosage was escalated by 30% in the first cycle only, a 
survival advantage was demonstrated in limited disease (LD) patients. The different ways 
of achieving intensification of chemotherapy are highlighted. The addition of growth 
factors in current dose-escalated or accelerated schedules seems to result in a relative dose 
intensity (DI) of no more than 150% when compared to optimally delivered conventional 
regimens. Whether such a moderate degree of dose intensification will improve survival 
rates has to be awaited from phase III trials. 
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Introduction 
 
Without treatment, median survival in small cell lung cancer (SCLC) is only 5 to 12 
weeks. In 1969 it was reported that cyclophosphamide prolonged the survival of patients 
with advanced SCLC [1]. In the 1970s several combination chemotherapy regimens were 
evaluated, and appeared to give higher response rates and longer survival than single drug 
therapy. Nowadays, cyclophosphamide / adriamycin / vincristine (CAV), 
cyclophosphamide / adriamycin / etoposide (CDE), cisplatin / etoposide (PE) and (vincris-
tine/) ifosfamide / carboplatin / etoposide (VICE or ICE) are the most frequently used 
combinations. At standard dose these combinations are considered to be more or less 
equipotent, although this is not proven by randomised trials. In limited disease (LD) an 
overall response (OR) rate of 80% to 95% and a complete response (CR) rate of at least 
50% to 60% with a median survival between 12 and 16 months can be achieved. 
Corresponding numbers in extensive disease (ED) are an OR rate of 60% to 80% and a CR 
rate of 15% to 30% with a median survival between 7 and 12 months. Thus, despite the 
high responsiveness to chemotherapy, the disease remains ultimately fatal in the majority 
of patients with a 2-year disease-free survival of 15% to 40% in LD and 0% to 5% in ED 
patients [2]. 
Initially, chemotherapy for SCLC was often administered until death or disease progressi-
on occurred. In the 1980s it had been questioned whether maintenance chemotherapy 
could indeed prolong survival. Comparisons between 5 or 6 to 8, 12 or 28 cycles 
demonstrated that five to six cycles of chemotherapy gave the same results as prolonged 
treatment, therefore six cycles should be accepted as a maximum [3-9]. Two other large 
randomised trials reported that 3 or 4 cycles of chemotherapy are probably too short to 
produce long-term disease-free survival [10,11]. 
Goldie and Coldman postulated a mathematical model concerning genetic resistance at the 
cellular level and argued that non-cross-resistant drug combinations should be used in an 
attempt to circumvent the development of drug resistance [12]. Several large randomised 
trials evaluated the impact of alternating regimens, but could not show any major survival 
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advantage [13,14]. However, in these trials only partial non-cross-resistant drugs were 
used and this may be insufficient to test the hypothesis [15]. 
There is still an on-going debate on the importance of dose in SCLC treatment. Skipper 
and Schabel showed a clear dose-response relationship for cyclophosphamide and other 
anticancer drugs in animal tumour models, suggesting that dose is critical to tumour cell 
kill [16]. The concept of dose intensification has been tested in patients with SCLC. Dose 
intensification can be achieved by delivering a higher dose per cycle and/or by shortening 
intervals between cycles. Higher doses per cycle can be delivered in the first cycle(s), i.e., 
early intensification, or last cycle(s), i.e., late intensification, or during all cycles. In the 
first part of this paper, we will discuss dose intensification studies performed in the pre-
growth factor period, with attention focused on randomised trials. In the second part we 
will review the role of granulocyte colony-stimulating factor (G-CSF) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) as adjuncts to standard-dose and 
intensified chemotherapy. 
Before discussing the individual studies, some general remarks concerning definitions 
have to be made. The amount of anticancer drugs given during a certain time period 
(mg/m2 per week or day) is referred to as dose-intensity (DI) [17]. Projected (planned) DI 
is obviously not the same as actually delivered DI, but the latter more important 
information is seldom reported. Another frequently used term is relative DI, i.e., the ratio 
of the DI of the investigated regimen and the DI of another usual standard regimen. The 
average DI for combination chemotherapy is calculated by the sum of DIs of each 
individual agent divided by the number of agents in that combination, with the assumption 
that the different drugs are equivalent active. It is important to note that the reported DI is 
often calculated only for those cycles that are indeed delivered. This may be misleading, 
when for example a substantial number of patients have discontinued treatment premature-
ly, because in these patients the DI may be high, although the delivered total dose is 
actually low. The delivered total dose is therefore valuable additional information, but this 
is often not separately reported. 
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Dose intensification without growth factors 
 
Dose-response relationship and schedule dependency for single agents in SCLC 
Cyclophosphamide is a commonly used agent in SCLC. Single-agent cyclophosphamide at 
conventional dose (1000 mg/m2) produces a response rate of 30% to 40% in SCLC 
patients, while a CR is seldom seen [19]. Souhami and colleagues showed that in untreated 
LD patients 160-200 mg/kg cyclophosphamide, administered during one cycle, produced 
an OR rate of 84% and a CR rate of 56%, indicating that there is a clear dose-response 
relationship [20]. These promising results could not be improved by giving a second cycle 
of high-dose cyclophosphamide, implying that there was a quick emergence of drug 
resistance [21]. Etoposide in a conventional dose has shown response rates of 40% to 60% 
in previously untreated SCLC patients [22]. When given at a higher dose conflicting data 
have been reported [23-25]. Other agents that do have anti-tumour activity in SCLC have 
not been studied for a dose-response correlation, when given as a single agent at a mega-
dosage. For etoposide a schedule dependency has been shown, with increasing activity 
when given over several consecutive days [26], which may also be the case for 
cyclophosphamide [27].  
 
Early intensification studies 
In a meta-analysis it was concluded that the DI of the first two cycles was not consistently 
correlated with response and survival in SCLC [28]. However, in this analysis studies in 
both chemo-naive and relapsed patients were taken together. Dose intensification studies 
were excluded, because the first two cycles would not be representative for the whole 
treatment period. When having a closer look at the tables, it shows that the majority of 
trials had a relative DI of smaller than 1 (compared to a reference regimen), indicating that 
in the majority of trials standard versus low dose was compared. Moreover, the range of 
relative DIs was small and it may have been difficult to assess any correlation at all. Others 
also questioned the validity of this kind of retrospective analyses [29]. The results of this 
analysis may therefore not be used as an argument against dose intensification studies. 
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In phase II studies of up-front early intensification, mega-doses cyclophosphamide (up to 
7.0 g/m2) and/or etoposide (up to 1.5 g/m2) were prescribed, with or without autologous 
bone marrow transplantation (ABMT) [30-34]. These regimens were very toxic and, 
despite promising high CR rates, survival seemed not to be improved. 
Direct comparisons of chemotherapeutic agents at different dosages have seldom been 
reported in SCLC. An old randomised study showed a benefit of increased dose of cyclo-
phosphamide, methotrexate and lomustine [35], but in this study a comparison between 
low and standard dose was made, while the pivotal question is not whether standard dose is 
better than low dose, but whether high dose is better than standard dose. To address this 
question, four randomised studies have assessed the impact of early intensification of 
commonly used agents (Table 1) [36-39].  
These trials differ in selection of patients, choice of regimen and degree of intensification. 
Patients were randomised to receive a number of initial cycles (1-4) at either intensified or 
standard dose. In the subsequent cycles all patients received chemotherapy at standard 
dose. The increase in delivered total dose was relatively larger than the increase in DI. As 
can be expected, toxicity was in general more severe in the intensified cycles, although this 
was manageable. A significantly better CR rate by early intensification was achieved in 
only one study, but this was not translated into a better survival [37]. The French trial was 
the only trial that showed an improved survival (2-year survival 43% versus 26% in favour 
of the intensified arm, P=0.02), with a nearly significant difference in median duration of 
CR (540 days versus 358 days, P=0.06) [38]. This trial was based on a retrospective 
analysis in 131 consecutive treated LD patients, which showed that a 20% increase in 
initial doses of cyclophosphamide and cisplatin produced an increase of 2-year survival of 
20% [40]. The survival benefit seen in the French trial is encouraging, but may be due to 
chance, as the difference in DI between both arms is remarkably small. On the other hand, 
it may be a fact that dose escalation is especially worthwhile in LD patients (low volume 
disease), and this may also explain the lack of any benefit in the other early intensification 
studies. Another explanation for these disappointing results may be the number of patients, 
which may have been too small to draw definite conclusions in three of four trials. 
Furthermore, the doses of a number of drugs were increased, although the phase II data of 
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these drugs are often incomplete when looking for a dose-response relationship in SCLC. 
Moreover, the degree of intensification may be still too low and mega doses as used in 
some phase II studies may still be worthwhile to evaluate in a randomised setting. 
 
 
Table 1. Randomised trials comparing identical induction regimens at different dosages 
in  SCLC  
No. of 
pts 
Standard 
regimen 
(mg/m2) 
No of 
high-
dose / 
total 
cyclesa 
Relative 
DI in 
high-
dose 
cyclesb 
(%) 
Relative 
dose 
in high-
dose 
cyclec 
(%) 
Grade 4 
neutropenia 
standard/ 
high-dose 
(% of 
cycles)d 
CR 
standard/ 
high-
dose  
(%) 
MST 
standard/ 
high-
dose 
(months) 
Ref 
103 
LD/ED 
C 1000 
A 50 
V 1 
4/4 
C + 47 
A + 12 
V - 10 
C + 56 
A + 18 
V - 6 
45/75e 22/21 12/13 [36] 
         
247 
ED 
C 1000 
A 40 
V 1 
3/6 AC+27 C + 16 A + 68 40/79
f 12/22f 8/7 [37] 
         
105 
LD 
C 900 
P 80 
A 40 
E 75 x 3 
1/6  C + 33 P + 25 23/39 54/67 14/18
g [38] 
         
90 
ED 
P 80 
E 80 x 3 2/4 PE+46 PE + 68 2/32
h 22/23 11/11 [39] 
 
a In both arms four to six cycles in total: all cycles either standard-dose or the first one to four 
cycles high-dose followed by standard-dose cycles; b Actually delivered increase/decrease in DI 
in the high-dose cycle when compared to standard-dose cycle, reported per agent or per 
regimen; c Actually delivered increase in dose in the high-dose cycle when compared to 
standard-dose cycle, reported per agent or per regimen; d Only compared for those cycles in 
which high-dose chemotherapy was prescribed; e P<0.003; f P<0.05; g P=0.02; h P<0.0001 
 
 
Late intensification studies 
Norton and Simon proposed a mathematical model, in which they argued that small 
tumours might be less sensitive to chemotherapy due to a reduced growth fraction [41]. 
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Therefore, they suggested administering intensified chemotherapy of a relative brief 
duration, in case a CR by the induction therapy had been obtained. To test their theory a 
number of small phase II trials were conducted [42-51]. In most of these trials only one 
high-dose cycle was given with cyclophosphamide (4.0-7.0 g/m2) and/or etoposide (1.0-
3.5 g/m2). In 20% to 50% of patients with a partial response (PR) after induction therapy, a 
CR after late intensification was achieved, although in general of short duration. In this 
highly selected patient population long-term disease-free survival varied from 5% to 20%, 
and therefore seems not superior to conventional regimens.  
In the one randomised late intensification study that has been reported by Humblet et al., it 
was assessed whether after five induction cycles (of six different drugs) a last intensified 
cycle would produce better results than an additional standard-dose cycle [52]. Patients 
were eligible for randomisation in case after induction a CR or PR was obtained in LD and 
a CR in ED. This was the case in only 40 of 101 registered patients; an additional five ED 
patients with PR were by error also randomised. The last standard-dose cycle consisted of 
cyclophosphamide 750 mg/m2, etoposide 120 mg/m2 x 5 orally and BCNU 60 mg/m2. In 
the intensified cycle the doses of these three agents were increased by 700%, 67% and 
4900%, respectively, with autologous bone marrow rescue. After the intensified cycle, the 
CR rate increased from 39% to 79%, while in the standard arm the response rate did not 
increase after the last conventional dosed cycle. Although median relapse-free survival 
after randomisation was significantly better in the intensified arm (28 versus 10 weeks, 
P=0.002), there was no more than a trend toward improvement in median overall survival 
(68 versus 55 weeks, P=0.13). This disappointing result may be explained by the small 
size of the study, the inclusion of ED patients and by the fact that during late intensification 
drugs were used that were also part of the induction regimen. Patients with a partial 
remission are unlikely to be cured by a last dose escalation; however, in this study among 
four long-term survivors two were partial responders to the induction regimen. Despite the 
support of ABMT 17% toxic deaths were seen during aplasia in the intensified arm, 
compared to no toxic deaths in the standard treatment arm, and this may also have 
contributed to the final bad outcome. Lastly, no thoracic irradiation was given and this 
appeared to be the primary site of relapse in the majority of patients.  
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Acceleration studies 
A third way to increase the DI is delivering chemotherapy at shortened intervals. In three 
phase II trials, four to seven drugs were administered weekly in an alternating fashion over 
a total of 9 to 16 weeks [53-55]. In these regimens, most drugs were delivered at an 
increased DI per cycle, but in comparison with conventional schedules sometimes at the 
cost of total dose. The regimens appeared to be feasible in the majority of patients and 
promising high response rates were reported. Only two phase III trials testing this concept 
have been reported [56,57]. In the first, 223 patients were randomised to receive either the 
weekly regimen (cyclophosphamide 500 mg/m2, doxorubicin 25 mg/m2 and etoposide 120 
mg/m2 in week 1, cisplatin 60 mg/m2 and vindesine 3 mg/m2 in week 2, vincristine 2 mg 
and methotrexate 100 mg/m2 in week 3; 6 times repeated) or six three-weekly cycles of 
CDE (1000, 50, 3x80 mg/m2, respectively) [56]. Response rates and survival showed no 
significant differences. Toxicity was tolerable in both arms. Grade 3 and 4 neutropenia 
occurred more frequently in the standard arm (59% versus 76% of patients, P=0.03). In 
another randomised trial, 438 patients received either weekly chemotherapy (12 alternating 
cycles of ifosfamide 2 g/m2 / doxorubicin 25 mg/m2 and cisplatin 50 mg/m2 / etoposide 
2x75 mg/m2) or six three-weekly alternating cycles of standard dose CAV/PE (600, 50, 2 
and 60, 3x120 mg/m2, respectively) [57]. Again, no differences in response nor in survival 
could be demonstrated. The weekly schedule was less feasible and more often treatment 
had to be reduced or delayed, with the consequence that only 74% of planned DI could be 
delivered, while 93% of planned DI of the standard regimen could be given. In these 
randomised studies different agents were used in the different arms. Therefore, no exact 
comparisons concerning delivered dose and DI can be made. The results of a collaborative 
trial conducted by the Eastern Cooperative Oncology Group, the Southwest Oncology 
Group, and the National Cancer Institute of Canada have to be awaited. In their study the 
weekly regimen consisting of cisplatin, vincristine, doxorubicin and etoposide (CODE) is 
compared with standard dose CAV/PE [55].   
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Role of growth factors in chemotherapy for SCLC 
 
Growth factors and chemotherapy-induced myelosuppression 
Colony stimulating factors are physiologically occurring glycoproteins that control 
proliferation and differentiation of multipotent and lineage-restricted haematopoietic 
progenitor cells and, furthermore, promote the functional activation of mature cells [58-
62]. G-CSF administered subcutaneous or intravenous at a dose of 0.3-60 µg/kg/day 
produces a 1.6- to 12-fold increase in absolute neutrophil count [63-65]. This increase is 
dose dependent, although there is a considerable overlap. After discontinuation a rapid fall 
in circulating neutrophils to pre-treatment levels is seen within 2-4 days. G-CSF primarily 
affects the peripheral counts of neutrophils. GM-CSF produces a similar dose-dependent 
increase in neutrophils and produces also a significant increase in monocytes and  
eosinophils [66,68]. Both growth factors produce an increased bone marrow cellularity 
with increased myeloid-erythroid ratio [60,67,68]. G-CSF is associated with only minimal 
toxicity, even at 60 µg/kg/day, essentially limited to bone pain [59,69]. In contrast, GM-
CSF often induces fever, musculoskeletal pain, malaise and anorexia. Capillary-leak 
syndrome and thrombosis have been observed at dose levels of 30 µg/kg/day or higher 
[59]. In vitro analyses have shown specific high-affinity binding sites of G-CSF and GM-
CSF to certain SCLC cell lines and sometimes colony forming stimulation [70,71], but in 
vivo a significant effect on tumour cell growth has never been reported.  
The augmentation of circulating neutrophils by G-CSF and GM-CSF suggested a role in  
improving recovery of myelopoiesis after chemotherapy. In a phase II study in SCLC 
patients, G-CSF was given to each patient for 14 days on alternate (odd or even) cycles of 
three-weekly chemotherapy. G-CSF dose varied from 1 to 40 µg/kg/day and was commen-
ced 24 h after the last chemotherapy dose [63]. While on G-CSF, the duration of 
chemotherapy-induced neutropenia was reduced considerably with normalisation of 
neutrophil count within 2 weeks after day 1 of chemotherapy. This resulted in a significant 
reduction in infectious episodes. GM-CSF was evaluated by a similar study design [72]. 
Despite partial abrogation of chemotherapy-induced neutropenia, GM-CSF failed to 
reduce the frequency of febrile episodes. In general 5-10 µg/kg/day G-CSF or GM-CSF is 
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advised when prescribed for standard-dose chemotherapy. The efficacy of G(M)-CSF 
depends not only on dose but also on schedule of administration. At standard chemothera-
py, a 7-10 day administration starting 1 day after the end of chemotherapy is optimal in 
reducing both degree and duration of leukopenia. A later onset is less effective; an earlier 
one aggravates leuko- and thrombocytopenia [73-75]. 
 
Growth factors as adjunct to standard-dose chemotherapy  
The combination of fever and neutropenia is a life-threatening complication of chemothe-
rapy. Despite immediate administration of broad-spectrum intravenous antibiotics, 
mortality remains approximately 10% among patients with documented infections and 2% 
for all cases of fever [76]. The most important prognostic factor for the risk of infection is 
the recovery of neutrophil counts [77]. In view of the influence of G-CSF and GM-CSF on 
neutropenia its impact on febrile neutropenia has been evaluated in six randomised trials in 
SCLC, four with G-CSF and two with GM-CSF (Table 2) [78-83].  
In the first, 199 patients were treated by six cycles of three-weekly CDE [78]. Treatment 
with G-CSF or placebo was given on days 4-17, at a dose of 230 µg/m2. Both severity and 
duration of neutropenia were significantly reduced and, concomitantly, a nearly 50% 
reduction in incidence of febrile neutropenia, in intravenous antibiotic use, hospitalisation 
and culture confirmed infections was observed. The duration of individual episodes of 
antibiotic use and hospital stay were similar in both treatment groups. The confirmatory 
trial demonstrated comparable results [79]. G-CSF in the weekly CODE regimen showed 
also a protective effect on number of febrile patients and episodes [80]. The incidence of 
infection was not reduced during another weekly chemotherapy regimen supported by G-
CSF, despite higher white blood cell counts [81].    
GM-CSF was studied at different dose levels in 238 SCLC patients [82]. Haematopoiesis 
was stimulated at all dose levels, but only patients who received 10 µg/kg GM-CSF 
required less intravenous antibiotics compared with the observation group. Overall fever 
occurred more frequently in both the 10 and 20 µg/kg GM-CSF groups, and this was 
considered to be a major side-effect of GM-CSF at these dose levels. This and other 
toxicities were the reason for more patients in the GM-CSF group than in the observation 
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group to drop out of the study. In the second GM-CSF trial, the incidence of grade 4 
neutropenia was not significantly different, despite higher neutrophil nadirs in the GM-
CSF arm [83]. More important, patients on GM-CSF spent significantly more days in the 
hospital, and had a higher incidence of fever, intravenous antibiotic usage, life-threatening 
thrombocytopenia, transfusions, toxic deaths and non-haematological toxicities. 
 
 
Table 2. Phase III trials with standard-dose chemotherapy evaluating the impact of G(M)-
CSF support 
 
No. of 
patients Regimen Support  
Febrile 
neutropenia 
(%)a 
RDI (%) Total dose (%) Reference 
199 CDE G-CSF without G-CSF 
40b 
77   [78] 
       
129 CDE G-CSF without G-CSF 
 26c 
        53 
96 
88  [79] 
       
63 CODE G-CSF without G-CSF 
 44d 
77 
66e 
35e  [80] 
       
40 PE/ID G-CSF without G-CSF NS 
84 
82 
88 
88 [81] 
       
238 CDE 
GM-CSF 5 
µg/kg 
10 µg/kg 
20 µg/kg 
without GM-CSF 
21 
 11d 
29 
29 
  [82] 
       
215 PE GM-CSF without GM-CSF 
39f 
22  
75 
85 [83] 
 
a For [78-80]: percent of patients with at least one episode of fever; for [82] and [83]: percent of 
patients requiring intravenous antibiotics through all cycles; b P<0.001, c P<0.002, d P<0.01, e Not 
relative DI, but percent of patients whose treatment was completed within 10 weeks (P<0.05); f 
P=0.04 
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In conclusion, there is a remarkable difference in the results obtained with G-CSF 
compared to GM-CSF: in three out of four G-CSF studies the incidence of febrile 
neutropenia was reduced by almost 50% when compared to no support, while conflicting 
results were reported with GM-CSF. The absence of any benefit in the trial of the 
Southwest Oncology Group [83] may be explained by the concurrent use of GM-CSF with 
chest radiotherapy, although on the other hand, amelioration of radiotherapy-induced 
neutropenia by growth factors has also been reported [84]. Another explanation may be, 
that the occurrence of fever was not infection-related but a side effect of GM-CSF, because 
the incidence of fever seemed to be GM-CSF dose dependent [82].  
The incidence of febrile neutropenia is important as it is the critical factor influencing cost 
effectiveness: the probability of hospitalisation would have to exceed 40% before the 
prophylactic use of growth factor will be cost-effective [85]. Febrile neutropenia after 
conventional CDE doses is reported to occur in 6% to 56% of all cycles [86]. The high rate 
of episodes of febrile neutropenia in the first study may reflect the unusual vigilant monito-
ring, a stricter definition of febrile neutropenia (i.e., temperature of 38.2oC or greater and 
absolute neutrophil count below 1.0 x 109/l) and the higher than usual chemotherapy 
dosage (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2 and etoposide 3x120 
mg/m2). The somewhat lower incidence in the second study may be due to different patient 
characteristics (younger, more often LD with a better performance status). The incidence 
of fever in the observation arm in the GM-CSF study was only 29%, probably due to the 
lower CDE dosage (doxorubicin 20% and etoposide 33% lower when compared with the 
other two CDE studies) [82].  
An alternative for prophylactic administration of growth factors may be delayed 
(therapeutic) administration of growth factors, i.e., not until fever has already occurred. 
The advantage is that over-treatment of patients that will never have fever will be 
prevented. In the few studies that have investigated this concept, both G-CSF and GM-
CSF produced a slightly accelerated neutrophils recovery, but this did not result in a 
reduction in duration of fever and hospitalisation [87-90]. A second alternative may be the 
prophylactic use of antibiotics. In SCLC patients prophylactic co-trimoxazole resulted in a 
reduced overall incidence of documented infections of 60% when compared with placebo, 
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especially in case neutrophil count was less than 0.1 x 109/l [36,91]. It may be worthwhile 
to compare directly the protective value of growth factors with that of antibiotics, 
especially from an economic point of view. 
The prophylactic use of growth factors may facilitate the delivery of planned chemothera-
py dose due to less dose reductions and delays, and this was indeed demonstrated in two 
out of four G-CSF studies, but only to a moderate degree (Table 2) [79,80]. Crawford et al. 
reported no data concerning delivered dose or DI [78]. For GM-CSF conflicting 
observations have been made. Hamm reported that more patients on GM-CSF were able to 
receive full-dose cycles (more than 55% of patients treated during cycles 2 and 3 with 
either 5 or 10 µg/kg GM-CSF compared with 36% of the observation patients). On the 
other hand, more patients in the observation arm were able to complete all six cycles (66% 
versus 60%, 42% and 33% of patients with 5, 10 and 20 µg/kg GM-CSF, respectively) 
[82]. In the trial of concurrent use of GM-CSF and chemo-radiotherapy, delivered total 
dose was even 10% lower in the GM-CSF arm as compared to the control arm [83].  
In none of these studies significant differences in response or survival were found, but as 
these were not primary endpoints, sample sizes may have been too small to detect small 
differences and this outcome may also be explained by the inclusion of ED patients. 
 
Growth factors as adjunct to high-dose chemotherapy  
It has been attempted to increase the maximum tolerated dose (MTD) by the support of 
growth factors (Table 3). In the study of Katakami et al. the MTD was not determined 
without G-CSF [94]. Therefore studies with the same chemotherapy regimen have been 
reported in Table 3 [92,93]. Although direct comparison is difficult, a moderate dose 
escalation of carboplatin seems possible with the addition of G-CSF. Luikart tried to 
escalate etoposide dose besides a constant carboplatin dose, but this was hardly possible 
with GM-CSF 10 or 20 µg/kg/day [95]. The Cancer and Acute Leukemia Group B 
reported two separate phase I studies, one without and one with the addition of G-CSF 
[97,98]. Despite the use of G-CSF, the MTD was the same due to the occurrence of febrile 
neutropenia as the major toxicity. On the other hand, with G-CSF the duration of neutrope-
nia was in general brief and recycling at a three-weekly interval was, therefore, mainly 
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possible in G-CSF-treated patients. The study reported by Paccagnella et al. had an 
interesting design [99]. The MTD of epirubicin was determined during the first cycle. In 
the first group of patients the MTD was determined without GM-CSF, and in the next 
group of patients it was attempted to increase the MTD by the addition of GM-CSF. The 
MTD could only be moderately increased with the addition of GM-CSF, i.e., from 60 to 70 
mg/m2. All patients were subsequently evaluated for feasibility during the next five cycles. 
Although this was not a randomised study, comparisons were made between patients 
treated at a lower epirubicin dose (45-60 mg/m2, without GM-CSF) and at a higher 
epirubicin dose (60-70 mg/m2, with GM-CSF). It was demonstrated that the higher dose 
with GM-CSF was not only feasible, but that GM-CSF also had reduced significantly the 
severity of neutropenia when compared to patients treated at a lower epirubicin dose 
without GM-CSF (grade 4 neutropenia 26% versus 57%, P<0.01). In patients on GM-CSF, 
neutropenia in the first cycle (in which MTD was determined) was more severe than in the 
next five cycles. Due to less dose reductions and delays for haematological toxicity, the 
actually delivered DI of epirubicin over six cycles was in the GM-CSF-treated patients 
substantially increased by 63% when compared to patients treated without GM-CSF. This 
resulted also in an increase of relative DI for cisplatin and etoposide of about 30%, despite 
the same planned dose for these two agents. Moreover, only 73% of planned cycles could 
be delivered in the control arm versus 86% of cycles supported by GM-CSF. Patients 
treated at lower dose levels had an OR rate of 72% (CR 24%), compared to an OR rate of 
95% (CR 40%) in patients treated at higher dose levels. 
In conclusion, in these few studies in SCLC it was shown that the MTD could not or only 
modestly be increased by the addition of G(M)-CSF. Nevertheless, due to less dose 
reductions and delays, the total relative DI over all cycles could be increased by 30% to 
60% in one phase II study. More studies are warranted in order to assess the exact role of 
growth factors in chemotherapy dose. 
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Table 3. Dose-finding studies with and without the addition of G(M)-CSF 
Regimen 
MTD without 
G(M)-CSF 
(mg/m2) 
MTD with 
G(M)-CSF 
(mg/m2) 
DLT with 
G(M)-CSF Reference 
Carboplatin 
Etoposide 
500 
3 x 100   [93] 
     
Carboplatin 
Etoposide 
350 
3 x 100   [93] 
     
Carboplatin 
Etoposide  
450 / 650a 
3 x 100 thrombocytopenia [94] 
     
Carboplatin 
Etoposide 
3 x 125 
3 x 200 
3 x 125 
3 x 250 thrombocytopenia [95] 
     
Cisplatin 
VM-26 
80 
5 x 60 
80 
5 x 120 
leukopenia / 
diarrhoea [96] 
     
Cisplatin 
Etoposide 
3 x 25 
3 x 200 
3 x 25 
3 x 200 febrile neutropenia [97, 98] 
     
Cisplatin 
Etoposide 
Epirubicin 
60 
3 x 120 
60 
60 
3 x 120 
70 
neutropenia [99] 
 
DLT = dose-limiting toxicity; a450 at age 70 or older, 650 at age below 70 years 
 
 
Growth factors as adjunct to accelerated chemotherapy (dose-densified) 
The feasibility of reducing intervals between full-planned-dose chemotherapy cycles by 
the addition of G(M)-CSF has been tested in a few phase II studies (Table 4). Ardizzoni et 
al. reported such an 'accelerated' chemotherapy regimen of CAV and PE, which was 
planned to be alternated weekly for a total of six cycles (cyclophosphamide 1000 mg/m2, 
doxorubicin 50 mg/m2, vincristine 2 mg on day 1; cisplatin 60 mg/m2 and etoposide 150 
mg/m2 on days 8 and 9) [100]. In the first five patients GM-CSF was given as soon as 
grade 4 leukopenia developed, while in five additional patients the same regimen was 
given without GM-CSF. Although not one patient was indeed able to receive the planned 
weekly regimen, the average number of days required to recycle was substantially reduced 
when compared to the standard interval of 21 days (10 days with and 13 days without GM-
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CSF). As a consequence treatment duration was limited to 57 days with GM-CSF and 73 
days without GM-CSF (standard projected 107 days), resulting in an almost 2- and 1.5-
fold increase in DI, respectively. Although the decrease in treatment duration in patients 
treated with GM-CSF was larger than without GM-CSF, it was disappointing that the 
absolute benefit of GM-CSF was not as large as expected. The authors suggested, that the 
'prophylactic' use of growth factors may be more suitable instead of 'on demand' use. Over 
all cycles, the mean white blood cell count and platelet nadirs were 0.60 and 46 x 109/l in 
the GM-CSF group versus 0.84 and 105 x 109/l in the controls, probably reflecting the 
higher DI in the GM-CSF-treated patients. The increase in DI was not associated with a 
worsening of non-haematological side effects. In a subsequent trial, the same group tried to 
accelerate standard CDE (cyclophosphamide 1000 mg/m2, doxorubicin 45 mg/m2, 
etoposide 3x100 mg/m2) by giving it every 2 weeks with prophylactic GM-CSF 10 
µg/kg/day from day 4 to 13 [101]. The Medical Research Council (MRC) Lung Cancer 
Working Party performed two comparable studies with CDE, but the chemotherapy was 
administered at a moderate higher dose for two agents (doxorubicin 50 mg/m2 and 
etoposide 3x120 mg/m2) [102,103]. Moreover, they prescribed G-CSF instead of GM-CSF 
(filgrastim 300 µg/day day 4-14 in 32 patients [102] and lenograstim 5 µg/kg/day day 4-14 
in 20 patients [103]). The mean chemotherapy interval was 17 days for all three studies.  
Ardizzoni et al. calculated that the delivered relative DI was 1.44 per cycle. It must be 
remembered that relative DI and intervals can only be calculated over cycles that are 
actually delivered. Approximately 80% of patients were able to receive at least four cycles, 
but only 55% were able to complete all six cycles. Premature discontinuation in all three 
studies was mainly due to progressive thrombocytopenia and anaemia, particularly severe 
after the fourth cycle. This was also the main reason for delays, which were concentrated 
towards the end of the treatment period. In the MRC studies grade 4 neutropenia occurred 
more often than in the study of Ardizzoni, probably due to the higher doses per cycle. 
Nevertheless, neutropenia had almost invariably resolved by the end of the 14-day period 
in all three studies and there was no evidence of increasing risk of neutropenia following 
subsequent cycles. Non-haematological toxicity was in general mild and manageable. 
Toxic deaths occurred in approximately 10% of patients in all three studies. Response rates 
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in the MRC studies seemed similar to conventional regimens. In conclusion, accelerating 
CDE is feasible but only for a limited (four) number of cycles, thereby compromising 
delivery of total cumulative dose as projected in standard three-weekly regimens of six 
cycles. A fifth acceleration study has been reported only in abstract form [104]. The 
authors concluded that the combination of epirubicin 80 mg/m2 and ifosfamide 5 g/m2 
could be given at two-weekly instead of three-weekly intervals due to the addition of G-
CSF. No details concerning actual mean interval were given. 
 
 
Table 4. Standard-dose chemotherapy delivered at shortened intervals with the addition 
of G(M)-CSF 
 
No. 
of 
pts 
Regimena 
Mean interval 
(range) 
in days 
Completion 
of four/six 
cyclesb 
Grade 4 
WBC 
(% of 
cycles) 
Grade 4 
platelets 
(% of 
cycles) 
RBCc 
(no. of 
patients) 
PLTd 
(no. of 
patients) 
Ref. 
5 CAV/PE GM-CSF 10 (6-19) 80/80   3 2 [100] 
         
5 CAV/PE - 13 (6-23) 100/100   3 0 [100] 
         
15 CDE GM-CSF 17 (13-22) 87/40 22 19 9 5 [101] 
         
32 CDE G-CSF 17 (14-30) 81/63   21 5 [102] 
         
20 CDE G-CSF 17 (14-42) 65/60 40 25 17 12 [103] 
 
a Regimen: see text; b Percent of patients; c Number of patients that received red blood cell 
transfusions; d Number of patients that received platelet transfusions 
 
 
These phase II studies support the feasibility of delivering chemotherapy at shortened 
intervals. However, the exact role of growth factor addition should preferably be 
determined in a randomised fashion and for this reason 65 patients were randomised to 
receive VICE (ifosfamide 5 g/m2, carboplatin 300 mg/m2, etoposide 120 mg/m2 on day 1 
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and 2, and 240 mg/m2 on day 3 orally, vincristine 2 mg) with or without G-CSF [105]. 
There was not a fixed treatment interval planned to maximize DI in both treatment arms in 
order to determine the exact contribution of G-CSF. Re-treatment was possible as soon as 
white blood cell count was 3.0 x 109/l or greater and platelet count was 100 x 109/l or 
greater. No dose reductions were allowed. It was demonstrated that in both arms DI could 
be increased compared to the conventional four-weekly schedule: over the first three 
cycles relative DI was 1.34 for the G-CSF arm and 1.17 for the control arm (P=0.001). 
Over all six cycles the average relative DI was 1.25 and 1.18 per cycle, respectively 
(P=0.03). When both arms were compared among each other, it was shown that only the 
first two intervals were shortened by 2-3 days in the G-CSF arm. Thus, the contribution of 
G-CSF to DI was rather disappointing, despite its statistical significance (1.25/1.18 x 100% 
= +6%). Fifty-five percent of patients completed 6 cycles in both arms. Neutrophil counts 
were consistently higher in G-CSF patients, but in both arms 70% of patients had at least 
one period of febrile neutropenia. There were more toxic deaths in the G-CSF arm (6 
versus 1). Response rates were similar, but 2-year survival was better in the G-CSF arm 
(32% versus 15%), although 32% is not better than usually reported in good prognosis 
patients. 
In conclusion, standard chemotherapy can be accelerated both with and without growth 
factor support, simply by giving chemotherapy as soon as blood counts are recovered. The 
magnitude of acceleration depends on the degree of myelosuppression produced by a 
specific regimen. G-CSF seems to improve DI by no more than 10% to 30% when compa-
red to a maximalized standard-dose regimen. It should be noted, that increased DI seems 
only feasible for the first four cycles due to cumulative thrombocytopenia and anaemia. As 
a consequence total dose in an intensified regimen may even be lower than in a conventio-
nal regimen. At present it is unclear whether total dose or DI is the most important 
parameter for final outcome. For this reason several collaborative groups have initiated a 
number of randomised trials. The European Organization for Research and Treatment of 
Cancer (EORTC) has started a study, in which three-weekly CDE is compared with two-
weekly CDE, which is supported with G-CSF. In this study standard CDE is given for 5 
cycles, while the accelerated CDE is given for only four cycles at an approximately 25% 
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higher dose per cycle. By this design the total dose will be equal in both arms, while in the 
accelerated arm the treatment will be delivered in half the time in comparison with the 
standard arm. The influence of the 100% DI increase on survival and response will be 
evaluated. 
 
Growth factors and peripheral blood progenitor cells 
We have discussed the influence of G(M)-CSF on peripheral neutrophil counts. An 
additional effect is a pronounced dose-related increase in peripheral blood progenitor cells 
(PBPC), not only including granulocyte-macrophage colony forming clones, but also 
erythroid and megakaryocyte colony forming clones [106,107]. The mechanisms by which 
cytokines increase PBPC are not well understood. Proliferation resulting in expansion of 
the population of progenitor cells, differentiation of stem cells into circulating progenitor 
cells, and an alteration in adhesion molecules on the cell membrane that regulate the 
release of cells from the marrow into the peripheral blood may all play a role [108]. 
Initially, PBPC were only used together with AMBT. It was demonstrated before that the 
application of growth factors after ABMT resulted in an accelerated neutrophil recovery, 
when compared to ABMT alone [109]. The addition of PBPC could not further accelerate 
neutrophil recovery, but platelet recovery was remarkably faster than in controls [110]. 
The use of PBPC may therefore facilitate much larger dose-intensifications than achieved 
by G(M)-CSF or by ABMT. Another theoretical advantage of PBPC over ABMT may be 
the lower risk for tumour cell contamination, although concomitant tumour cell 
recruitment upon mobilization of PBPC has been demonstrated in ED SCLC patients 
[111]. The biologic relevance of this observation is not completely understood. To 
mobilize PBPC, G(M)-CSF can be used either alone or in combination with high-dose 
cyclophosphamide or disease-specific chemotherapy. By the combination of a growth 
factor and chemotherapy an even higher number of PBPCs can be collected, thereby 
reducing the number of necessary leukaphereses [112,113]. Not all regimens are equally 
effective in mobilizing PBPC. It was demonstrated that PE produced a 10-fold increase of 
PBPC, 3-5 weeks after treatment, while no rebound phase occurred after CAV treatment 
[114]. In a phase II study in 18 LD patients, G-CSF plus two conventional-dose 
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chemotherapy cycles were prescribed (etoposide, ifosfamide, cisplatin and epirubicin) 
followed by one 2 hour leukapheresis procedure after the second cycle [115]. Subsequently 
one high-dose cycle (300% of the conventional schedule, with the replacement of cisplatin 
by carboplatin) was administered and this showed to be feasible with PBPC infusion. 
However, if cure is the goal to be achieved, more than one high-dose cycle is probably 
needed. Shea et al. demonstrated, that multiple cycles of high-dose chemotherapy were 
feasible by the repeated administration of PBPC [116]. In SCLC one study has reported the 
sequential administration of PBPC [117]. Twenty-five SCLC patients were treated with six 
cycles of ICE with G-CSF 300 µg on days 4-15. PBPC were collected during each cycle 
on day 15, by leukapheresis in cohort 1 (cryopreservation) and 2 (stored at 4oC), and by 
venasection in cohort 3 (500-750 ml whole blood stored at 4oC), and reinfused on day 3 of 
the next cycle. Patients in cohort 1 were treated every three weeks, and in cohorts 2 and 3 
every two weeks. ICE chemotherapy with G-CSF was effective in mobilizing blood 
progenitors, with a median of 120-fold above baseline. The planned DI was 134% for 
cohort 1 and 200% for cohort 2 and 3. This could indeed be delivered in the first three 
cycles, but only half of patients in cohorts 2 and 3 completed all six cycles, compared to 
two-thirds in cohort 1. Toxicity was not significantly different between the three cohorts. 
The authors concluded that PBPC collected in whole blood without cryopreservation is a 
practical and attractive procedure in chemotherapy regimens of short duration, using drugs 
of short half-life that are effective in mobilizing blood progenitors and have low toxicity 
for blood stem cells. The group has opened a phase III study with the cohort 3 schedule as 
the investigational arm.  
 
 
  35 
Chapter 2 
Discussion 
 
It is apparent that we need better chemotherapy for SCLC, considering the fact that the 
majority of patients will ultimately die of their disease. One approach to improve outcome 
may be the delivery of chemotherapy at increased DI, either by dose escalation for one or 
more cycles or by giving chemotherapy at shortened intervals. Both concepts have been 
evaluated in SCLC patients. By giving chemotherapy at shortened intervals the delivery of 
total dose may be compromised. At present, it is unclear whether DI or total dose is the 
most important parameter for final outcome and both factors should therefore be evaluated 
separately in future trials. 
 
Despite promising phase II data concerning mega doses chemotherapy, a survival benefit 
was seen in only one out of four randomised early-escalation studies (in LD patients) [36-
39]. In the one randomised late-escalation trial in SCLC, the relapse-free survival after 
randomisation was significantly better after one high-dose cycle, but there was no more 
than a trend toward improved median overall survival [52]. In two reported phase III 
acceleration studies no survival benefit was demonstrated; however, in both studies DI was 
not the sole variable, which precludes definite conclusions [56,57]. One explanation of 
these disappointing results may be the relative small size of most of these trials. 
Furthermore, a survival advantage in some patients may not have been demonstrated due 
to the inclusion of patients likely to have a less favourable outcome (like ED patients). 
Moreover, the schedules investigated may not have been the most suitable ones, i.e., type 
of intensification, number of intensified cycles and choice of agents.  
 
It is important to reconsider the two ways to achieve intensification: (1) escalation and (2) 
acceleration. Although these two approaches may seem comparable, as they are both being 
used to increase DI, the underlying mechanisms of their action are probably quite different. 
This distinction is often not recognized and both approaches are frequently mixed up in the 
literature. 
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Significant dose-escalation may overcome intrinsic drug resistance, which can be proven 
by a response after high-dose chemotherapy, not seen after the same chemotherapy at 
standard dose. The efficacy of high-dose chemotherapy was initially demonstrated in 
patients with acute myeloid leukaemia. High-dose chemotherapy was not yet able to 
increase survival in SCLC, but the doses in the phase III trials were substantially lower 
than the mega doses in the earlier (promising) phase II trials. In more recent years high-
dose chemotherapy has been increasingly used with the support of PBPC and growth 
factors, in different solid tumours like breast cancer and germ cell tumours. By now, it is 
not known how many high-dose cycles are needed, but it is in general believed that it 
should be more than one cycle. The use of very high-dose chemotherapy is only logical for 
those agents that have a S-shape dose-response curve of which the plateau level has not yet 
been reached. Cyclophosphamide has been demonstrated to produce a three-fold increase 
in response rate at a seven-fold increase in dose above standard. Ifosfamide is at an 
approximately four times higher dose equivalent in activity to cyclophosphamide. In soft 
tissue sarcoma high-dose ifosfamide was demonstrated to circumvent the resistance to 
standard-dose ifosfamide, while at this dose treatment was still manageable using routine 
clinical support [118]. For etoposide the dose-response data are conflicting [23-25]. Few 
clinical studies have related exposure of doxorubicin to antitumor effect [119]. A major 
problem for significant dose-escalation is cardiotoxicity, which is the most important 
chronic dose-limiting toxicity. The analog epirubicin, when compared with doxorubicin, 
causes less myelo- and cardiotoxicity, thus allowing dose intensification. Such dose-
intensive regimens of epirubicin have produced high response rates in a number of 
malignancies including SCLC [99,120]. Cisplatin is another important drug in SCLC. The 
dose of cisplatin can be increased to 200 mg/m2 every four weeks, but further dose 
escalation is limited by cumulative neurotoxicity [121]. Although high-dose cisplatin 
seemed promising in several phase II studies, it was recently demonstrated that with 200 
mg/m2 per cycle no survival advantage was seen in non-small cell lung cancer and poor-
risk germ cell tumours [122,123]. As noted earlier, in a randomised trial in SCLC dose 
escalation of both cisplatin and cyclophosphamide with approximately 30% for one cycle 
only, resulted in a significant survival benefit [38]. This observation remains difficult to 
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interpret and needs to be confirmed before any conclusion can be made. Carboplatin is the 
most important cisplatin analog, and is less nephro-, neuro- and ototoxic when given at a 
conventional dose. The major side effect is myelosuppression, especially thrombocyto-
penia. It is one of the most frequently used agents in high-dose schedules, often in 
combination with high-dose cyclophosphamide and thiotepa, of which the phase II results 
are encouraging. However, in patients with advanced (relapsed and previously untreated) 
ovarian carcinoma, it was demonstrated that, although the likelihood of tumour response 
increased with higher carboplatin dose, this relationship was non-linear and did not 
increase significantly above a carboplatin area under the curve (AUC) of 7 mg/ml x 
minutes (more or less comparable with 560 mg/m2) [124,125]. Methotrexate and 5-
fluorouracil are both anti-metabolites with increased activity at a higher dose, but these two 
agents do not play a major role in the treatment of SCLC. Significant dose escalation of 
vincristine is restricted by cumulative neurotoxicity. Adequate high-dose studies with new 
antineoplastic agents, like the taxanes and topo-isomerase I inhibitors, have to be awaited.  
 
By the second approach, i.e., giving chemotherapy at shortened intervals, efficacy may be 
increased by preventing tumour regrowth during the intervals and also by preventing the 
development of intrinsic drug resistance during the interval. This approach may be 
especially worthwhile for tumours like SCLC that are characterized by rapid growth and 
marked chemosensitivity. This application may also be useful for drugs that are already at 
their maximum response level. 
 
It is obvious that substantial dose intensification is only possible for those anti-cancer 
drugs that have myelosuppression as main side effect. In the older intensification studies 
ABMT was used as rescue, but this procedure was still accompanied with a significant 
degree of morbidity and mortality. Because G-CSF and GM-CSF are able to reduce 
duration and severity of neutropenia, it was suggested that the delivery of intensified 
chemotherapy supported by these factors might be more feasible. However, the addition of 
growth factors in current dose-escalated or accelerated schedules seems to result in a 
relative DI of no more than 150% when compared to optimally delivered conventional 
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regimens. At this point cumulative thrombocytopenia becomes a major problem. With the 
sequential administration of PBPC repeated cycles at 200% relative DI can be delivered; at 
this level both haematological and non-haematological toxicity become dose limiting. 
Whether such a degree of dose-intensification will improve survival rates has to be awaited 
from phase III trials. However, when reduction of neutropenia and/or febrile neutropenia 
will remain the most important effects of these haematopoietic growth factors, 
prophylactic administration of antibiotics as adjunct to standard-dose chemotherapy or 
application of chemotherapy dose reductions or delays may be more appropriate.  
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Chapter 3 
Abstract 
  
Purpose: To evaluate the impact of granulocyte colony-stimulating factor (G-CSF) 
priming on peripheral blood cell counts during standard-dose chemotherapy. 
Patients and methods: Twelve patients with relapsed small cell lung carcinoma (SCLC) 
were treated with two chemotherapy cycles. Six patients received G-CSF priming only 
before the first cycle (group A) and the other six patients only before the second cycle 
(group B). Each patient served as his own control. Patients were treated with 
cyclophosphamide, epirubicin, and etoposide (CEE), or with vincristine, ifosfamide, 
mesna and carboplatin (VIMP) every 4 weeks. G-CSF was administered subcutaneous 5 
µg/kg/day for 6 days until 48 hours before the first or second chemotherapy cycle.   
Results: Priming caused a lowering of white blood cell (WBC) nadir with a median value 
of 0.95 x 109/l (P=0.004) and of absolute neutrophil nadir, with a median value of 0.48 x 
109/l (P=0.03). There was a trend for a lower platelet (PLT) nadir after G-CSF priming 
(P=0.09). G-CSF priming resulted in a prolonged duration of WBC count less than 3.0 x 
109/l of +4.25 days (P=0.04), and of WBC count less than 1.0 x 109/l of +0.50 days 
(P=0.03). The duration of neutropenia less than 0.5 x 109/l seemed longer in primed cycles 
(+3.75 days, P=0.18). The duration of PLT counts less than 100 x109/l was prolonged by 
1.5 days (P=0.04). Haemoglobin (Hgb) levels were not influenced by G-CSF priming. 
Conclusion: G-CSF administration until 48 hours before the next chemotherapy cycle 
increases chemotherapy-associated leukopenia and thrombocytopenia. This may be of 
special concern when G-CSF is administered during dose-densified chemotherapy. 
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Introduction 
 
Chemotherapy has improved survival in patients with metastasised solid tumours, but the 
actual cure rate remains disappointingly low in the majority. Whether intensification of 
chemotherapy can improve final outcome is not yet clear. The main obstacle for substantial 
dose-intensification is haematological toxicity, which is the dose-limiting side effect of 
most chemotherapy regimens. Haematopoietic growth factors have been demonstrated to 
reduce myelotoxicity. These are physiologically occurring glycoproteins that control 
proliferation and differentiation of multipotent and lineage-restricted haematopoietic 
progenitor cells and, furthermore, promote the functional activity of mature cells [1-4]. 
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) produce a dose-dependent increase of peripheral blood 
neutrophils, and GM-CSF also of monocytes and eosinophils [5,6].  
Growth factor support delivered after standard-dose chemotherapy was evaluated in six 
randomised trials in patients with small cell lung cancer (SCLC), four with G-CSF [7-10] 
and two with GM-CSF [11,12]. In three of four 4 G-CSF studies, it was demonstrated that 
the incidence of febrile neutropenia, hospitalisation, and use of intravenous antibiotics was 
reduced by almost 50% due to the prophylactic use of G-CSF [7-9], while there was, 
besides a faster neutrophil recovery in one of the two GM-CSF studies, unexpectedly no 
protective effect of GM-CSF on clinical end points [11,12]. A 7- to 10-day administration 
of G-CSF, starting 1 day after the end of chemotherapy, is considered optimal in reducing 
the severity of neutropenia. A later onset is less effective, and an earlier one aggravates 
leukopenia and thrombocytopenia [13,14]. In general, it is advised that G-CSF should not 
be given concurrent with chemotherapy and that it should be discontinued at least 24 hours 
before the start of the next chemotherapy cycle [15]. It was recently reported that the 
administration of GM-CSF several days before each chemotherapy cycle (priming) is an 
alternative approach for reducing bone marrow suppression [16-19]. It is unclear if 
priming with G-CSF would have the same beneficial effect as GM-CSF. Prior studies have 
shown differential kinetics for GM-CSF and G-CSF, in that progenitor cells continued to 
remain in high proliferative state up to 72 hours after discontinuation of G-CSF [16, 20]. 
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This finding raised the potential concern of enhanced toxicity of priming with G-CSF. On 
the other hand, it was also observed that the number of progenitor cells not in S-phase was 
also increased, which might counterbalance a possible increased toxicity of G-CSF 
priming on the dividing progenitor cells. Therefore, the optimal timing between 
discontinuation of G-CSF and initiation of the next chemotherapy remains to be defined. 
We planned a phase I study to evaluate the impact of G-CSF priming on haematological 
recovery after chemotherapy. 
 
 
Patients and methods 
 
This study was a non-randomised prospective trial, designed as a cross-over experiment. 
Twelve patients with relapsed SCLC were treated with two chemotherapy cycles. In six 
assessable patients, G-CSF priming was given before the first chemotherapy cycle (group 
A), and in the other 6 assessable patients, G-CSF priming was given before the second 
chemotherapy cycle (group B). Each patient served as his own control and was considered 
to be assessable after two chemotherapy cycles delivered at the same dosage. In fact, this 
study was started as a standard phase I study aimed at increasing the dose of chemotherapy 
in the subsequent steps in patients treated with a regimen designed in the same way as the 
regimen of group B. For the first two steps, patients were randomly allocated to regimen A 
or B. Due to toxicity, the study had to be stopped after treatment of the patients described 
in this report. 
 
Patients  
Patients were entered from July 1995 to December 1996 at three University Hospitals in 
The Netherlands (University Medical Centre Nijmegen, Vrije Universiteit Medical Centre 
Amsterdam, and University Medical Centre Rotterdam). Included patients had histological 
or cytological documented SCLC, either limited or extensive disease, with a relapse after 
chemotherapy. Inclusion criteria were performance status of 0 to 2 (Eastern Cooperative 
Oncology Group [ECOG]), age ≥ 18 and ≤ 75 years, WBC count ≥ 3.0 x 109/l, PLT count 
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≥ 100 x 109/l, Hgb level ≥ 6.0 mmol/l, creatinine concentration ≤ 140 µmol/l, and bilirubin 
level < 35 µmol/l. Patients were excluded in case of symptomatic cerebral metastases, 
evidence of active infection, uncontrolled hypertension or symptomatic cardiovascular 
disease, and presence of other (previous) malignancies. Written informed consent was 
obtained from all patients. The protocol was approved by the different institutional review 
boards. 
 
Chemotherapy 
First-line chemotherapy consisted of cyclophosphamide 1000 mg/m2 on day 1, 
doxorubicin 45 mg/m2 on day 1, and etoposide 100 mg/m2 on days 1,3, and 5 or on days 1, 
2, and 3 (CDE). If progression occurred more than 3 months after first-line chemotherapy 
(so-called chemosensitive tumours), patients were treated with cyclophosphamide 1000 
mg/m2 on day 1, epirubicin 75 mg/m2 on day 1, and etoposide 100 mg/m2 on days 1 to 3, 
every 4 weeks (CEE). In case of progression within 3 months after first-line chemotherapy 
(so-called resistant tumours), patients were treated with vincristine 2 mg bolus 
administration on days 1 and 8, ifosfamide 3 g/m2 infused over 24 hours on day 1 (with 
mesna during 36 hours), and carboplatin 300 mg/m2 intravenously over 30 minutes on day 
1 every 4 weeks (VIMP) [21]. Chemotherapy was delayed for a period of 1 week or 
longer, as necessary, if WBC counts were less than 3.0 x 109/l and/or PLT less than 100 x 
109/l. When the delay was more than 2 weeks, the patient was taken off study. Dose 
adjustments were not allowed to remain comparable with the first cycle. At least two 
cycles were to be given to all patients, unless serious complications or progressive disease 
after the first cycle prohibited continuation of treatment (Figure 1). Initially, only two 
cycles per patient were planned. During the study accrual period, it was decided that 
reinclusion for a second time was permitted and this was the case for two patients, who 
were treated with 4 cycles of either VIMP or CEE (both were responding and therefore 
continued on the same regimen, each included once in group A and once in group B, and 
described as if they were four different patients, i.e., patient no. 6 is the same as no. 7, and 
patient no. 5 is the same as no. 8). Eight patients received only two cycles.  
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Figure 1. Scheme of study design (groups A and B). Chemotherapy, CEE or VIMP, 
every 4 weeks for two cycles (cycles I and II). G-CSF 5 µg/kg/day, days 
–6 to -1 before cycle I (A) or cycle II (B). Note: Cycle II (A) or G-CSF 
(B): not started until WBC ≥ 3.0 x 109/l and PLT ≥ 100 x 109/l 
cycle II 
G-CSF
-1 0 1 2 3 4 5 6 7 8
weeks
cycle I
           
           
cycle II 
 
 
 
Recombinant Human Methionyl G-CSF 
G-CSF priming (Filgrastim; Amgen/Roche, Mijdrecht, The Netherlands) was given at a 
dose of 5 µg/kg/day for a total of 6 days and delivered subcutaneously once daily until 48 
hours before the administration of chemotherapy. We did not prescribe postchemotherapy 
G-CSF. G-CSF priming was given either before the first or before the second cycle. We 
choose an interval of 48 hours between the last G-CSF dose and the subsequent chemothe-
rapy cycle, because this was in general considered to be a safe interval [15]. The start of G-
CSF priming before the second cycle was delayed for a period of 1 week or longer, as 
necessary, if WBC counts were less than 3.0 x 109/l and/or PLT counts less than 100 x 
109/l, in order not to influence the comparison of the duration of myelosuppression 
between the first and second chemotherapy cycle (Figure 1). 
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Clinical and laboratory monitoring 
To evaluate bone marrow suppression, peripheral blood cell counts and differentiation 
were measured three times per week during the whole treatment period. Hospitalisation for 
neutropenic fever, i.e., a temperature ≥ 38.5oC with neutrophils less than 0.5 x 109/l was 
documented.   
 
 
Statistical methods 
By giving G-CSF priming either before the first or before the second cycle, it is possible to 
calculate the impact of G-CSF priming and also the periodic effect of the two successive 
chemotherapy cycles. The periodic effect reflects the increased toxicity in the subsequent 
chemotherapy cycle due to the toxicity produced by the preceding chemotherapy cycle. 
The magnitude of both effects can be calculated as follows.  
In group A, the median (M1) of the difference "toxicity cycle 2 - toxicity cycle 1" (II-I) is 
an estimate for the difference in periodic effect and G-CSF effect. In group B, the median 
(M2) of the difference II-I is an estimate for the sum of periodic effect and G-CSF effect. 
Therefore, the periodic effect is estimated by (M1+M2)/2 and the G-CSF effect by (M2-
M1)/2.  
The significance of this latter effect is obtained by comparing the differences II-I in group 
A and B with the Mann-Whitney rank-sum test. A two-tailed P value of less than 0.05 was 
considered to be statistically significant. 
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Results 
 
Patients 
Fifteen patients were included and considered eligible. Three patients were not assessable, 
because they received only one chemotherapy cycle. Only one of these 3 patients did 
receive G-CSF priming before the first cycle. The tumour in one patient was rapidly 
progressive after the first chemotherapy cycle (given without G-CSF priming), which was 
the reason for premature discontinuation of treatment. Two patients died after the first 
cycle. One of these experienced an unexplained clinical detoriation during leukopenia in 
absence of fever or microbiologically documented infection. This patient was treated with 
G-CSF priming before the first cycle. The second death was due to a septic shock during 
leukopenia, and this patient did not receive G-CSF priming before the first cycle.  
The patient characteristics of the twelve assessable patients were well balanced (Table 1). 
However, it is important to consider that each patient served as his own control, and 
therefore group A was not directly compared with group B. As first-line chemotherapy 
CDE had been given in all, but one patient who had also been treated with six cycles of 
teniposide. During this trial, one patient was treated with four CEE cycles, the first two 
cycles at the planned dose, and the second coupled two cycles at 75% of the planned dose, 
because of serious myelosuppression during the preceding two cycles. Nine assessable 
patients were treated with VIMP, of whom one was reincluded for two more cycles. The 
restart of the second chemotherapy cycle was planned at day 29, but four patients started at 
day 22 because blood counts were normalised by then. In one patient, re-treatment was 
delayed till day 31 due to reduced blood values. The remaining seven patients started the 
second cycle at day 29. One patient received G-CSF for only 5 days. We considered these 
as minor protocol violations and therefore considered all patients who received (at least) 
two cycles as assessable. 
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Table 1. Patient characteristics 
 
Characteristic 
Group A: 
G-CSF priming 
before first cycle 
(n=6) 
Group B: 
G-CSF priming 
before second cycle 
(n=6) 
Age, years   
 
Median  
Range 
55 
49-64 
57 
53-62 
Performance status (ECOG 0/1/2) 2 / 4/ 0 1 / 4 / 1 
Female / male 3 / 3 2 / 4 
Prior radiotherapy 3 3 
No. of prior chemotherapy cycles    
 
Median 
Range 
6 
3-8 
5 
5-9 
Blood values    
 WBC count, x 109/l    
 
Median  
Range 
5.1 
3.0-6.2 
6.7  
5.5-15.6 
 PLT count, x 109/l   
 
Median 
Range 
246  
142-323 
242  
152-357 
 Hgb level, mmol/l   
 
Median 
Range 
7.9  
6.7-8.1 
8.3  
5.6-8.9 
Chemotherapy regimen  5 x VIMP 
1 x CEE 
5 x VIMP 
1 x CEE 
 
  59 
Chapter 3 
Haematological reaction 
As expected, G-CSF treatment led to an increase in WBC counts. These counts were still 
elevated just before the start of chemotherapy, with a median WBC count of 33.0 x 109/l 
(range 12.8 to 50.4 x 109/l) in group A at cycle 1 and of 30.2 x109/L (range 12.0 to 57.2 x 
109/l) in group B at cycle 2 (Figure 2). The WBC and absolute neutrophil counts (ANC’s) 
were more severely reduced in the primed cycles compared with the non-primed cycles 
(Figure 2).  
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 Figure 2. Median WBC day 1 and nadir values 
  
B = second cycle primed
 
When comparing the nadir values between cycles I and II for each patient (Table 2), the 
influence of priming with G-CSF on peripheral blood cell counts can be precisely 
calculated by the formula described in the statistical methods section. Priming caused a 
lowering of the WBC nadir with a median value of 0.95 x 109/l compared with non-primed 
cycles (P=0.004). The ANC was not measured by mistake in two of six patients, but the 
detrimental effect of G-CSF priming on the ANC nadir was still significant (P=0.03). 
There as a trend for a lower PLT nadir after G-CSF priming (P=0.09). The WBC nadir 
showed a trend to occur 1.5 days earlier in the G-CSF primed cycles (P=0.09).  
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Table 2. Haematological nadir values after cycle I and II, with (+) and without (–) G-
CSF priming  
 
 WBC Nadir 
(x109/l) 
 ANC Nadir 
(x109/l) 
 PLT Nadir 
(x109/l) 
 WBC Nadir 
on Day 
Patient 
No. 
I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
Group A  
1 
2 
3 
4 
5 
6 
 
median 
 
1.0 
0.6 
1.0 
0.6 
1.5 
0.9 
 
1.0 
 
1.7 
1.4 
1.0 
1.8 
3.5 
1.1 
 
1.6 
  
 
 
0.3 
0.0 
0.2 
0.2 
 
0.2 
 
 
 
0.0 
0.5 
2.2 
0.1 
 
0.3 
  
87 
105 
21 
25 
182 
82 
 
85 
 
137 
145 
14 
41 
137 
164 
 
137 
  
13 
10 
10 
10 
9 
12 
 
10 
 
13 
15 
14 
16 
8 
12 
 
13 
 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
Group B 
7 
8 
9 
10 
11 
12 
 
median 
 
1.6 
1.9 
1.9 
2.8 
1.7 
2.8 
 
1.9 
 
0.2 
1.9 
0.9 
1.0 
1.3 
1.5 
 
1.2 
  
1.1 
0.7 
0.6 
2.4 
0.4 
1.8 
 
0.9 
 
0.0 
0.4 
0.2 
0.2 
0.1 
0.1 
 
0.2 
  
142 
151 
127 
125 
46 
298 
 
135 
 
43 
113 
90 
56 
92 
257 
 
91 
  
8 
8 
13 
15 
13 
13 
 
13 
 
10 
11 
12 
14 
10 
11 
 
11 
 
 
Priming 
effect 
 
Pa 
 
 
–0.95 
 
0.004 
 
  
 
–0.48 
 
0.03 
  
 
–33.8 
 
0.09 
  
 
–1.5 
 
0.09 
 
a Mann-Whitney test 
 
 
 
A similar deleterious effect of G-CSF priming was seen with regard to the duration of 
leukopenia and thrombocytopenia (Table 3). G-CSF priming resulted in a prolonged 
duration of WBC count less than 3.0 x 109/l of +4.25 days (P=0.04), and of WBC counts 
less than 1.0 x 109/l of +0.50 days (P=0.03). The duration of neutropenia seemed longer in 
primed cycles, but this difference was not significant (+3.75 days, P=0.18), probably due 
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to the smaller number of patients in whom ANC data were available. The duration of PLT 
counts less than 100 x109/l was prolonged by 1.5 day (P=0.04). The regimen did not 
produce grade 4 thrombocytopenia. Hgb levels were not influenced by G-CSF priming 
(data not shown). 
 
Table 3. Duration of leukopenia and thrombocytopenia (in days) after cycle I and II, 
with (+) and without (–) G-CSF priming 
 
 WBC < 3.0 
(x109/l) 
 WBC < 1.0 
(x109/l) 
 ANC < 0.5  
(x109/l) 
 PLT < 100 
(x109/l) 
Patient 
No. 
I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
 I + 
Priming 
II – 
Priming 
Group A  
1 
2 
3 
4 
5 
6 
 
median 
 
5 
14 
12 
15 
8 
10 
 
11 
 
3 
8 
10 
16 
0 
5 
 
6.5 
  
1 
3 
0 
1 
0 
1 
 
1 
 
 
0 
0 
0 
0 
0 
0 
 
0 
  
 
 
2 
7 
5 
6 
 
5.5 
 
 
 
10 
0 
0 
5 
 
2.5 
  
3 
0 
17 
16 
0 
1 
 
2 
 
0 
0 
12 
5 
0 
0 
 
0 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
 I –
Priming 
II + 
Priming 
Group B 
7 
8 
9 
10 
11 
12 
 
median 
 
8 
2 
12 
1 
7 
2 
 
5 
 
6 
7 
9 
10 
12 
10 
 
9.5 
  
0 
0 
0 
0 
0 
0 
 
0 
 
5 
0 
1 
0 
0 
0 
 
0 
 
  
0 
0 
0 
0 
1 
0 
 
0 
 
5 
1 
8 
6 
5 
3 
 
5 
  
0 
0 
0 
0 
3 
0 
 
0 
 
5 
0 
2 
3 
2 
0 
 
2 
 
 
Priming 
effect 
 
Pa 
 
 
+4.25 
 
0.04 
 
  
 
+0.50 
 
0.03 
  
 
+3.75 
 
0.18 
  
 
+1.50 
 
0.04 
 
a Mann-Whitney test 
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The increased toxicity due to the preceding chemotherapy cycle was much smaller than the 
G-CSF priming effect, and for most items even negligible (data not shown). For example, 
the WBC nadir count was 0.2 x109/l lower in the second cycle when compared with the 
first cycle. 
 
Clinical endpoints 
Neutropenic fever with hospitalisation occurred in three of twelve primed cycles compared 
with one of 12 non-primed cycles. These patients with neutropenic fever were all treated 
with intravenous broad-spectrum antibiotics. In addition, two other patients received oral 
antibiotics because of fever without neutropenia (one primed cycle and one non-primed 
cycle). No PLT transfusions were necessary. Red blood cell (RBC) transfusions were 
administered to three patients after non-primed cycles (a total of 8 U) and also to three 
patients after primed cycles (a total of 6 U). 
 
 
Discussion 
 
In the phase I study reported here, we evaluated the effect of G-CSF priming delivered 
until 48 hours before the start of chemotherapy on chemotherapy-induced bone marrow 
suppression. We observed that at a 48-hour interval between the last G-CSF administration 
and the next chemotherapy cycle the chemotherapy-induced myelotoxicity was increased.  
 
It was recently reported that the administration of GM-CSF several days before each 
chemotherapy cycle (priming) is myeloprotective [16-19]. To explain why GM-CSF 
priming is myeloprotective and G-CSF priming is not, one should reconsider the different 
effects of these two growth factors on the bone marrow progenitor-cell level. It was 
demonstrated that GM-CSF at a dose of 15 to 500 µg/m2/day for 14 days increased both 
the total number and the cycling rate of the granulocyte-macrophage progenitor cells, 
consistent with an increase in neutrophil counts in the peripheral blood [22]. More 
importantly, the same investigators observed that the cycling rate decreased dramatically 
below the pretreatment level within 1 day after GM-CSF discontinuation and that the 
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cycling rate remained low for at least 7 days, while in this period the bone marrow 
cellularity was still elevated [16]. A similar although smaller effect was seen after short-
term GM-CSF priming, i.e., 8 µg/kg/day for 3 days [17]. This proliferation arrest after 
GM-CSF priming would theoretically implicate a chemoprotective effect on progenitor 
cells. The efficacy of short-term GM-CSF priming was indeed confirmed in two clinical 
trials [18,19]. 
 
It is noteworthy that the bone marrow response to G-CSF is totally different when 
compared with GM-CSF. Two to 4 days after cessation of G-CSF treatment, the progenitor 
cells are still rapidly proliferating, with progenitor cells in S-phase ranging from 38% ± 5% 
to 63% ± 8%, compared with 26% ± 9% to 39% ± 8% before G-CSF treatment [20]. A 
similar observation was made in 30 patients with advanced breast cancer treated with an 
intensified regimen of fluorouracil, epirubicin, and cyclophosphamide (FEC) at a 21-day 
interval [23]. 
 
Only a few studies evaluated the myelotoxicity of G-CSF priming by measuring peripheral 
blood counts. The first study to evaluate the impact of pretreatment with G-CSF was 
reported by Morstyn et al. [24]. Three patients were treated with only postchemotherapy 
G-CSF (days 2 to 13) after melphalan on day 1, while three other patients were treated 
with both posttreatment G-CSF (days 2 to 13) and pretreatment G-CSF (days –9 to -2). 
With an interval of 72 hours between last G-CSF administration and subsequent melphalan 
administration, the investigators observed a lower nadir in the patients pretreated with G-
CSF compared with patients who only received postchemotherapy G-CSF. In another G-
CSF priming-study, 15 patients were treated with high-dose chemotherapy supported by 
G-CSF before and also after chemotherapy [25]. The authors concluded that the duration 
of myelotoxicity seemed to be the same as in historical controls (in whom autologous bone 
marrow infusion with growth factors were used) and that after G-CSF priming a higher 
WBC count at start of chemotherapy predicted an earlier recovery of neutrophils. The 
outcome of the study is difficult to interpret due to the lack of a control arm and the 
concurrent use of G-CSF after each chemotherapy cycle. Unfortunately, no information 
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was given about the interval between priming and the next chemotherapy cycle. G-CSF 
priming could not prevent chemotherapy-induced myelotoxicity in 14 patients with non-
Hodgkin's lymphomas [26]. In this trial, the increased risk for haematological complicati-
ons can be explained by the short interval between the last G-CSF administration and the 
following chemotherapy cycle, which was only 3 to 4 hours. This observation confirms an 
earlier finding that concurrent use of chemotherapy and growth factors enhances 
myelotoxicity [27]. At present, there are two studies reported in which, like in our trial, an 
interval of 48 hours was chosen [28,29]. In the first trial, in 32 breast cancer patients 
receiving adjuvant treatment, G-CSF priming was given not to increase the nadir values, 
but to maintain dose-intensity in subsequent cycles of chemotherapy after a prior episode 
of prolonged neutropenia [28]. The neutrophil counts at day 1 of chemotherapy became 
increasingly higher after one, two, and three primed cycles (from a median of 3.1 x109/l at 
cycle 1, to a median of 12.3 x109/l at cycle 3). Due to less delays, the delivered dose-
intensity after G-CSF priming was indeed significantly higher than before the start of G-
CSF. The nadir values were not reported. In our study, G-CSF priming resulted also in an 
increase in day 1 neutrophil values (i.e., immediate G-CSF-effect), but concurrently it 
produced a lowering of the nadir values. In other words, the immediate G-CSF effect on 
day 1 values may indeed enable the delivery of chemotherapy on time for a number of 
cycles; however, G-CSF priming might ultimately lead to bone marrow exhaustion as 
demonstrated by the reduced nadir values possibly preventing the delivery of all planned 
cycles. In the second trial in which a 48-hour interval was used, 36 breast cancer patients 
were randomised to receive G-CSF before and after chemotherapy or only after chemo-
therapy [29]. Like in our trial, G-CSF priming was not myeloprotective. They found 
significantly more severe thrombocytopenia after G-CSF priming, with a non-significant 
trend of more severe neutropenia. The investigators argued that a detrimental effect on 
neutrophil counts might have been masked by the high incidence of severe neutropenia in 
both study arms, as well as a beneficial effect due to the post-chemotherapy G-CSF 
support. A deleterious effect on the PLT counts was also observed in our trial. This may 
seem surprising. However, it is well known that in addition to a faster WBC recovery, a 
faster PLT recovery is also seen after re-infusion of peripheral blood progenitor cells 
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mobilised with a similar schedule of G-CSF. The observed decline in blood values in our 
and their trial might be explained by a damage of these progenitor cells. The investigators 
of the latter trial discussed the detrimental effect of G-CSF priming on PLT counts after a 
comment on their priming report [30,31].  
 
In conclusion, G-CSF priming until 48 hours before the next chemotherapy cycle increased 
the chemotherapy-associated leukopenia and thrombocytopenia. Other investigators have 
observed that 2 to 4 days after cessation of G-CSF treatment, the progenitor cells are still 
rapidly proliferating [20,23], the period in which the chemotherapy is being administered. 
This probably explains the detrimental effect on peripheral blood counts of the 
aforementioned G-CSF priming schedule. A major implication of these observations might 
be that the clinical benefit of post-chemotherapy G-CSF might be enhanced by increasing 
the window of time between interruption of the G-CSF and re-initiation of chemotherapy 
beyond the mentioned 48 to 72 hours. This may be of special concern for chemotherapy 
regimens prescribed at shortened intervals, because in these regimens, G-CSF is often 
discontinued only shortly before the next chemotherapy cycle [32,33].  
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Abstract  
 
Purpose: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard 
chemotherapy regimens in the treatment of small cell lung cancer (SCLC), with 
myelosuppression as dose-limiting toxicity. In this trial the impact of prophylactic 
antibiotics on incidence of febrile leukopenia (FL) during chemotherapy for SCLC was 
evaluated.  
Patients and methods: Patients with chemo-naïve SCLC were randomised to standard-
dose CDE (C 1000 mg/m2 day 1, D 45 mg/m2 day 1,  E 100 mg/m2 days 1-3, 
intravenous, every 3 weeks for 5 cycles) or to intensified CDE chemotherapy (125% 
dose, every 2 weeks for 4 cycles with filgrastim 5 µg/kg/day days 4-13) to assess the 
impact on survival (n=240 patients). Patients were also randomised to prophylactic 
antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, b.i.d., days 4-13) or to 
placebo in a 2x2 factorial design (first 163 patients). This manuscript focuses on the 
antibiotics question. 
Results: The incidence of FL during the first cycle was 25% of patients in the placebo 
and 11% in the antibiotics arm (P=0.010; one-sided), with an overall incidence through 
all cycles of 43% versus 24% respectively (P=0.007; one-sided). There were less gram-
positive (12 versus 4), gram-negative (20 versus 5) and clinically documented (38 
versus 15) infections in the antibiotics arm. The use of therapeutic antibiotics was 
reduced (P=0.013; one-sided), with less hospitalisations due to FL (31 versus 17 
patients, P=0.013; one-sided). However, the overall number of days of hospitalisation 
was not reduced (P=0.05; one-sided). The number of infectious deaths was nil in the 
antibiotics versus five (6%) in the placebo arm (P=0.022; two-sided).  
Conclusions: Prophylactic ciprofloxacin plus roxithromycin during CDE chemotherapy 
reduced the incidence of FL, the number of infections, the use of therapeutic antibiotics 
and hospitalisations due to FL by approximately 50%, with reduced number of 
infectious deaths. For patients with similar risk for FL, the prophylactic use of 
antibiotics should be considered. 
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Introduction 
 
CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy 
regimens in the treatment of SCLC. The dose-limiting toxicity is myelosuppression, 
with an incidence of febrile neutropenia (FN) or leukopenia (FL) varying at the most 
commonly used dose from 40% to 53% and 77% at a slightly higher dose [1-3]. This is 
a potentially life-threatening complication of chemotherapy. The addition of the 
haematopoietic growth factor G-CSF was shown to shorten the duration of neutropenia, 
resulting in reduction of the incidence of FN, hospitalisation and use of intravenous 
therapeutic antibiotics by approximately 50% [2,3]. Primarily based on these two 
pivotal studies, the American Society of Clinical Oncology recommended the use of G-
CSF in case the incidence of FN is expected to be more than 40% [4]. However, G-CSF 
is expensive and requires daily subcutaneous injections.  
Prophylactic antibiotics have also been used in combination with chemotherapy to 
prevent FN, although its role has not been clearly established. Co-trimoxazole has been 
shown to be effective, also in SCLC [5,6], but the emergence of resistance, allergic 
reactions, and the risk of prolonged neutropenia are important disadvantages [7]. During 
the last decade, fluoroquinolones have increasingly been used, mostly in patients with 
haematological malignancies [8,9], showing a significant reduction in the incidence of 
fever and of bacteraemia caused by gram-negative bacilli. There was, however, no 
reduction in clinically documented infections or infection-related deaths.  
Associated with the use of prophylactic quinolones, the increased use of central venous 
catheters and more severe oromucositis due to intensified chemotherapy, a shift toward 
an increased prevalence of gram-positive infections has been observed [10]. 
Documented bacteraemia occurs in approximately 25% to 30% of febrile episodes in 
neutropenic patients. Gram-positive micro-organisms presently cause 60% of these 
bacteraemias. Therefore, a new strategy of prophylaxis against both gram-negative and 
gram-positive micro-organisms may be more appropriate. The addition of a penicillin, 
vancomycin or macrolide to a quinolone significantly reduced the occurrence of gram-
positive bacteraemia [9].  
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We report here the results of a double-blinded placebo-controlled randomised trial in 
patients with SCLC treated with CDE chemotherapy, in which the prophylactic role of 
the combination ciprofloxacin plus roxithromycin for the prevention of FL was 
evaluated [10].  
 
 
Patients and methods 
 
Patient selection  
Patients had to meet the following inclusion criteria: histologically or cytologically 
proven SCLC, either extensive disease (ED) or limited disease (LD), measurable or 
evaluable disease, no prior treatment, ECOG performance status (PS) 0-1, 19-70 years, 
able to undergo treatment and follow-up, white blood cell counts (WBC) ≥ 4 x 109/l, 
platelets (PLT) ≥ 100 x 109/l, haemoglobin (Hgb) ≥ 6.0 mmol/l, creatinine ≤ 140 µmol/l 
and bilirubin < 35 µmol/l.  
Patients were excluded in case of symptomatic cerebral metastases, evidence of active 
infection or fever ≥ 38.3oC, uncontrolled hypertension, symptomatic cardiovascular 
disease within 3 months prior to enrolment, previous malignancy, except basal or 
squamous cell skin carcinoma or adequately treated carcinoma in situ of the cervix, any 
evidence or history of hypersensitivity or other contraindications to the drugs to be 
investigated in this trial. The investigational protocol was approved by the EORTC 
Protocol Review Committee and the ethical committee of each institution. Informed 
consent was obtained from each patient according to the national regulations.  
For each patient the pre-treatment information was obtained by the medical history, 
physical examination, laboratory investigations (blood cell counts, albumin, renal and 
liver functions), chest X-ray, CT-thorax, CT-scan or ultrasound upper abdomen, 
bronchoscopy and bone marrow biopsy. As soon as a lesion was detected to diagnose 
ED, no further investigations were indicated. 
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Study design  
This was a phase III trial with a 2 x 2 factorial design (Figure 1). SCLC patients were 
randomised to standard-dose or intensified chemotherapy in order to assess the impact 
of dose-intensification on survival. Results of this part of the study will be reported 
separately. Secondly, patients were randomised in a double blind fashion to 
prophylactic antibiotics or to placebo. The primary endpoint of this comparison was to 
compare the incidence of FL during the first cycle. FL was defined as a combination of 
WBC < 1.0 x 109/l and an increased temperature (an oral temperature ≥ 38.3oC on one 
occasion or ≥  38.0oC on two or more occasions during a 12 hour period (minus 0.5oC 
for axillary temperature). Secondary endpoints were impact of prophylactic antibiotics 
on the incidence of FL in the second and subsequent cycles, on the number of days with 
fever, on the number of days from start of chemotherapy until the onset of fever in the 
first cycle, on the number of documented gram-positive and gram-negative infections, 
on the number of days of intravenous therapeutic antibiotics and on the number of days 
of hospitalisation.  
 
 
 
A. Standard CDE 
Ciprofloxacin-Roxithromcyin  
B. Intensified CDE + G-CSF  
Ciprofloxacin-Roxithromcyin 
C. Standard CDE 
2 placebo antibiotics 
D. Intensified CDE + G-CSF  
2 placebo antibiotics 
 
I. 
    
 
  
II.   
             
I.  Impact of prophylactic antibiotics on febrile leukopenia (A+B vs. C+D) 
II.  Impact of dose-intensification on survival (separate report) (A+C vs. B+D) 
 
Figure 1. Scheme of  2 x 2 factorial study design 
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Over a period of 3½ years, 161 eligible patients were randomised from 13 European 
centres. At that point, the antibiotic-placebo randomisation was prematurely stopped 
following the recommendation of an Independent Data-Monitoring Committee. We 
report here the final results of the antibiotic part of this trial.  
Data-management and monitoring were carried out by the EORTC. 
All patients were asked to keep a diary for registration of orally or axillary measured 
temperature, every morning. In case of increased temperature (see above), patients were 
instructed to contact the hospital and be checked for blood cell counts and cultures of 
serum samples and/or a suspected source, with susceptibility tests against both 
ciprofloxacin and roxithromycin, as well as the routine antibiogram. In case of FL, 
ciprofloxacin-roxithromycin (verum or placebo) was interrupted and replaced by  
intravenous antibiotics, that is a combination of aminoglycosides and a second or third 
generation cephalosporine. Complete blood cell counts were to be performed daily until 
resolution of FL. Intravenous antibiotic treatment was discontinued when all signs of 
infection and/or fever were resolved, at the discretion of the treating physician. Febrile 
episodes were classified as microbiologically documented infections, when a micro-
organism was isolated from the site of infection or serum; clinically documented 
infections, when there was clinical or radiological evidence of infection; and fevers of 
unknown origin, when both microbiological and clinical evidence of infection were 
absent. In subsequent cycles the prophylaxis (verum or placebo) were to be restarted in 
a double blind fashion.  
 
Chemotherapy regimen  
Standard CDE chemotherapy consisted of cyclophosphamide 1000 mg/m2 on day 1, 
doxorubicin 45 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1-3 intravenously, 
every three weeks for five cycles. Intensified CDE chemotherapy consisted of 
cyclophosphamide 1250 mg/m2 on day 1, doxorubicin 55 mg/m2 on day 1 and etoposide 
125 mg/m2 on days 1-3 intravenously, every two weeks for four cycles [11].  The total 
dose of chemotherapy was the same in both arms, but the planned DI was double in the 
intensified arm by increasing dose size and reducing treatment intervals. Chemotherapy 
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was prematurely discontinued in case of treatment failure, unacceptable toxicity or 
patient refusal. Dose adjustments in chemotherapy were based on day 1 blood count 
levels and on WBC and/or PLT nadir. Blood counts were measured on days 8, 12, and 
15 during intensified CDE and on days 8, 12, 15, 19, and 22 during standard CDE. 
 
G-CSF 
In the intensified arm, G-CSF (filgrastim) was added on days 4-13 at a dose of 300 
µg/day if body weight was ≤ 75 kg and at a dose of 5 µg/kg/day if body weight was > 
75 kg. G-CSF was not added in order to reduce febrile complications, but to facilitate 
dose-intensification. 
 
Antibiotic prophylaxis 
The antibiotic prophylaxis consisted of a combination of ciprofloxacin and 
roxithromycin. The antibiotics were given as verum, i.e., active compounds, or as 
placebo (antibiotics-placebos were provided free by the sponsor). The placebo matched 
the active drugs in appearance, taste and weight. The active compounds and the placebo 
were supplied in treatment packs which represented the complete antibiotic drug 
regimen per patient, to be taken during the chemotherapy cycles, i.e., ciprofloxacin 750 
mg b.i.d. per os and roxithromycin 150 mg b.i.d. per os, days 4-13. Counts were to be 
made of dose units remaining at the end of therapy, so that an indication of compliance 
could be obtained. A sealed envelope for each box specifying the antibiotic-placebo 
schedule was lodged by the pharmacist of each hospital. This envelope was only to be 
opened in case of an emergency. At randomisation the EORTC Data Centre assigned a 
unique treatment pack to the patient. 
 
Radiation therapy 
Local sequential radiation therapy in case of complete response (CR) in LD patients was 
allowed, with the remark that each institute had to follow one strategy. Prophylactic 
cranial irradiation at the end of chemotherapy in case of CR in LD patients was also 
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allowed according to institutional policy, and participants were advised to take part in 
the EORTC study 08921. 
 
Statistical considerations  
The trial was designed as a 2 x 2 factorial design. It was calculated that a total of 192 
deaths would permit the detection of an increase in median survival from 12 months in 
the standard CDE arm to 18 months in the intensified CDE arm at a two-sided 
significance level of 5% and with a power of 80%. A total of 240 (60 in each strata) 
needed to be randomised to observe this number of events. Computer simulations 
showed that given a sample size of 240 patients, we should be able to demonstrate a 
20% absolute decrease in the risk of FL when patients are treated with the prophylactic 
antibiotics with a statistical power of approximately 90%, using a two-sided 
significance level of 5%.  
After inclusion of 163 patients, the EORTC - Lung Cancer Group decided to perform an 
unplanned interim analysis because of concerns with respect to the incidence of FL. The 
results were submitted to an Independent Data Monitoring Committee. They 
recommended to prematurely stopping the antibiotic-placebo part of the protocol on 
ethical grounds. Following this recommendation a protocol amendment to close this 
part of the study was written and approved by the EORTC Protocol Review Committee. 
At the time of analysis 161 eligible patients had been entered. Given a sample size of 
161 patients we should have been able to demonstrate the above assumed reduction with 
a power of approximately 80%, using a one-sided significance level of 5% (Cochran-
Mantel-Haenszel test). A one-sided significance level was chosen, as it was not 
expected that giving prophylactic antibiotics would show an increase in the risk of FL. 
The interim analysis covered all aspects of the trial. Randomisation was done using the 
minimization technique stratifying patients according to their institution, age (> 60 
versus ≤ 60 years) and stage of disease (LD versus ED) [12]. The trial was analysed as a 
2 x 2 factorial design. Thus, for all statistical comparisons the effect of prophylactic 
antibiotics was analysed after stratification for the regimen (standard or intensified). The 
number of days with FL, the number of days of intravenous therapeutic antibiotics, and 
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the number of days of hospitalisation were compared between the two treatment groups 
using a stratified Wilcoxon-Mann-Withney test. The analysis was performed on all 
eligible patients according to the treatment arm they were allocated to by randomisation 
independently of the treatment they actually received. For analysis of toxicity data and 
description of treatment compliance, the analysis was based on the treatment the patient 
actually received. For analysis of all pre-specified protocol endpoints relating to the 
antibiotics question a one-sided test was used. For the comparison of the number of 
toxic deaths a two-sided test was chosen, as it was not possible to hypothesize a priori in 
which direction the difference would be. An analysis of prognostic factors was 
performed to investigate which baseline factors were predictive for the occurrence of 
FL. The logistic regression model was used with a two-sided test at the 5% significance 
level to test the prognostic value of each variable [13]. A step-down variable selection 
procedure was used for building the multivariate model. The importance of a prognostic 
factor was expressed by the percentage of patients presenting with FL, odds ratio (OR: 
the odds of having FL versus no FL in patients with that specific value as compared to 
the odds in the reference category), its 95% confidence interval (95% CI) and the P-
value of the Chi-square statistic. 
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Results 
 
A total of 163 patients were randomised to receive placebo (n=80) or verum antibiotics 
(n=83). Two patients, one in each arm, were considered ineligible: one due to an 
incorrect diagnosis and one due to double registration by error. The characteristics of 
eligible patients are shown in Table 1. Both arms were well balanced. The majority of 
patients had LD. All patients started treatment within eight days after randomisation.  
 
Table 1. Patient characteristics at baseline 
 
 Placebo  
n=79  
Antibiotics 
n=82 
Characteristics Standard 
CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
 
Standard 
CDE 
  n=41 (%) 
Intensified 
CDE 
n=41 (%) 
 
Age (years)a 
      
 median  
(range) 
60 
(33-69) 
60 
(35-70) 
 61 
(43-69) 
60 
(45-69) 
 
Sex 
   Male 
   Female 
 
 
29 (76) 
9 (24) 
 
 
31 (76) 
10 (24) 
 
 
 
 
 
 
 
29 (71) 
12 (29) 
 
 
31 (76) 
10 (24) 
 
ECOG PS 
   0 
   1 
 
 
16 (42) 
22 (58) 
 
 
23 (56) 
18 (44) 
 
 
 
 
 
 
19 (46) 
22 (54) 
 
 
19 (46) 
22 (54) 
 
Stage 
   Limited 
   Extensive 
 
 
22 (58) 
16 (42) 
 
 
22 (54) 
19 (46) 
 
 
 
 
 
 
27 (66) 
14 (34) 
 
 
25 (61) 
16 (39) 
 
Median weight loss  
over last 3 months (%)b 
(range) 
 
 
 
3.6 
(-7 to17) 
 
 
2.1 
(-2 to 19) 
 
 
 
 
 
4.3 
(-4 to 22) 
 
 
1.4 
(-8 to 14) 
 
a Median age is 60 (range 33-70) in the placebo arm and 61 (range 43-69) in the antibiotics arm. 
b Median weight loss over last three months is 2.5% (range –7 to 19) in the placebo arm and 
2.1% (range –8 to 22) in the antibiotics arm (negative weight loss means weight gain) 
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Delivered chemotherapy 
Nearly 80% of patients in both arms completed the planned number of cycles. The 
median delivered DI for cycles actually delivered was 96.7% of planned (range 53.1% - 
102.8%) for the placebo arm and 97.0% (range 44.3% - 165.5%) for the antibiotics arm.    
 
Delivered antibiotic prophylaxis (verum or placebo) 
Seventy-one percent of patients in the antibiotics arm compared to 54% of patients in 
the placebo arm received the planned prophylactic medication for chemotherapy cycles 
given (Table 2). One of the main causes of this difference was a higher incidence of FL 
in the placebo arm. In cycles with FL the prophylaxis was temporarily interrupted and 
replaced by intravenous antibiotics.  
 
 
Table 2. Reasons for discontinuation or interruption of antibiotic prophylaxis 
 
 Placebo 
n=79 
 Antibiotics  
n=82 
Reasons Standard 
CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
 
Standard 
CDE 
n=41 (%) 
Intensified 
CDE 
n=41 (%) 
 
Completion of protocol 
Patient non-compliance 
Protocol violation 
Early death 
Febrile leukopenia 
Fever without leukopenia 
Infection 
Other toxicity 
        dyspnoea 
        skin allergic reaction 
        nausea/vomiting 
        reduced liver function 
        renal failure 
Unknown 
 
27 (71) 
2 (5) 
2 (5) 
2 (5) 
0 (0) 
2 (5) 
0 (0) 
2 (5) 
1 
1 
0 
0 
0 
1 (3) 
 
16 (39) 
3 (7) 
0 (0) 
1 (2) 
16 (39) 
2 (5) 
2 (5) 
0 (0) 
0 
0 
0 
0 
0 
1 (2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 (76) 
2 (5) 
0 (0) 
1 (2) 
4 (10) 
1 (2) 
0 (0) 
2 (0) 
0 
1 
0 
1 
0 
0 (0) 
 
27 (66) 
2 (5) 
0 (0) 
1 (2) 
6 (15) 
0 (0) 
1 (2) 
3 (7) 
0 
0 
2 
0 
1 
1 (2) 
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Toxicity  
The worst overall toxicity during all cycles is demonstrated in Table 3a and Table 3b.  
Myelosuppression was not significantly different between the two arms: the median 
WBC nadir over all cycles was 0.6 x 109/l  (range 0.0-5.1) in the placebo arm versus 0.7 
x 109/l (range 0.1-13.5) in the antibiotics arm, again with a rather consistent duration of 
leukopenia (WBC < 1.0 x 109/l) of three days in both arms. Thrombocyte nadirs were: 
52 x 109/l  (range 0.0-280) in the placebo arm versus 50 x 109/l (range 1-273) in the 
antibiotics arm. For Hgb: 5.2 mmol/l (range 1.8-8.9) in the placebo arm versus 5.1 
mmol/l (range 2.9-9.2) in the antibiotics arm. There was no difference in number of 
transfusions. Myelosuppression was more severe in patients treated with intensified 
chemotherapy compared to those treated with standard chemotherapy (Table 3a). 
 
Table 3a. Worst haematological toxicity (NCIC-CTC grade 3-4, per patient) 
 
 Placebo 
n=79 
 Antibiotics  
n=82 
Grade Standard 
CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
 
Standard 
CDE 
n=41 (%) 
Intensified 
CDE 
n=41 (%) 
 
White Blood Cell 
   3 
   4 
 
 
19 (50) 
17 (45) 
 
 
5 (12) 
35 (85) 
 
 
 
 
 
 
17 (42) 
22 (54) 
 
 
6 (15) 
33 (81) 
 
Platelet 
   3 
   4 
 
 
6 (16) 
2 (5) 
 
 
9 (22) 
21 (51) 
 
 
 
 
 
 
5 (12) 
7 (17) 
 
 
12 (29) 
17 (42) 
 
Haemoglobin 
   3 
   4 
 
 
4 (11) 
2 (5) 
 
 
16 (39) 
0 (0) 
 
 
 
 
 
 
9 (22) 
2 (5) 
 
 
18 (44) 
4 (10) 
 
 
Non-haematological toxicities were in general mild (Table 3b). More patients in the 
antibiotics arm suffered from nausea grade 2-3, and this was the reason for 
discontinuing the antibiotic prophylaxis in two patients (grade 2: not presented in Table 
3b). Stomatitis, mucositis and diarrhoea ≥ grade 2 occurred less frequently in the 
antibiotics arm, probably reflecting the efficacy of antibiotics in preventing mucosal 
infections.  
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Table 3b. Worst non-haematological toxicity (NCIC-CTC grade 3-4, per patient) 
 
 
n=79 
 
 
Antibiotics 
n=82 
Grade Standard 
CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
 
Standard 
CDE 
n=41 (%) 
Intensified 
CDE 
n=41 (%) 
Placebo 
Haemorrhage 
    3 
    4 
 
0 (0) 
0 (0) 
 
0 (0) 
2 (5) 
 
 
 
 
0 (0) 
0 (0) 
 
2 (5) 
0 (0) 
Flu-like symptoms 
    3 
 
0 (0) 
 
1 (2) 
 
 
 
0 (0) 
 
Renal and Bladder 
    3 
 
0 (0) 
 
0 (0) 
 
 
 
0 (0) 
 
1 (2) 
Creatinine 
    3 
    4 
 
2 (5) 
2 (5) 
 
4 (10) 
2 (5) 
 
 
 
 
2 (5) 
0 (0) 
 
1 (2) 
0 (0) 
Anorexia 
    3 
 
0 (0) 
 
2 (5) 
 
 
 
0 (0) 
 
1 (2) 
Nausea 
    3 
 
2 (5) 
 
3 (7) 
 
 
 
0 (0) 
 
2 (5) 
Vomiting 
    3 
    4 
 
1 (3) 
0 (0) 
 
4 (10) 
0 (0) 
 
 
 
 
0 (0) 
1 (2) 
 
2 (5) 
0 (0) 
Stomatitis-mucositis 
    3 
 
0 (0) 
 
3 (7) 
 
 
 
0 (0) 
 
2 (5) 
Diarrhoea 
    3 
 
0 (0) 
 
1 (2) 
 
 
 
0 (0) 
 
0 (0) 
Liver 
    3 
 
1 (3) 
 
0 (0) 
 
 
 
1 (2) 
 
1 (2) 
Cardiac 
    3 
    4 
 
1 (3) 
1 (3) 
 
0 (0) 
0 (0) 
 
 
 
 
0 (0) 
0 (0) 
 
1 (2) 
1 (2) 
Pulmonary 
    4 
 
0 (0) 
 
2 (5) 
 
 
 
1 (2) 
 
0 (0) 
Neurologic 
    3 
 
0 (0) 
 
0 (0) 
 
 
 
2 (5) 
 
1 (2) 
Others 
    3a 
    4b 
 
1 (3) 
0 (0) 
 
4 (10) 
1 (2) 
 
 
 
 
0 (0) 
1 (2) 
 
1 (2) 
0 (0) 
 
0 (0) 
 
a Lumbar pain, vesicular eruption, exanthema, epidermiolysis, fatigue, weight loss;  
b Hypercalcaemia and bad general status, hypopotassaemia and dermatitis 
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Death due to infection occurred only in the placebo arm (see next section). Two patients 
in the antibiotic arm died from cardiac disease. One patient had a cardiac failure after 
the first day of chemotherapy prior to starting antibiotics, most probably related to acute 
doxorubicin toxicity. The second patient died suddenly at home, most probably due to a 
cardiac infarction five days after the second chemotherapy cycle. Both patients had a 
history of cardiovascular impairment. One patient in the placebo arm had a fatal 
haemoptysis. Although grade 4 leukopenia and thrombocytopenia were observed on 
date of death, haemorrhage was considered to be caused by tumour erosion into one of 
the lung arteries.  
 
Febrile leukopenia and sequelae of fever 
Prophylactic ciprofloxacin and roxithromycin significantly reduced the overall 
incidence of FL by nearly 50% (Table 4, Figure 2). The highest incidence of FL was 
seen among the group of patients who received intensified chemotherapy; this group 
seems to benefit the most from prophylactic antibiotics.  
Most patients suffered only once from a period of FL. It is of note that in the placebo-
intensified group 7 (17%) patients had two to four episodes of FL.  
In total 48 episodes of FL occurred in the placebo arm (15% of 320 chemotherapy 
cycles) versus 23 in the antibiotics arm (7% of 335 cycles). The incidence of FL was the 
highest during cycle 1 and decreased thereafter, in both arms. 
The duration of FL was significantly shorter for the antibiotics arm (P=0.007; one-sided 
test), however, based on patients who actually developed FL, the duration of FL was not 
different (median of two versus three days).  
The time from start of chemotherapy to the onset of fever in the first cycle was not 
different between both arms: median in placebo was nine days (range 0-15) and median 
in antibiotics was nine days (range 2-17) (P-value=0.459; one-sided test). 
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Table 4. Incidence and duration of febrile leukopenia (FL) 
 
 Placebo 
n=79 (%) 
Antibiotics 
n=82 (%) 
95% CI on 
differences 
Stratified 
P-valuea 
Patients with FL in (%):     
 first cycle 20 (25) 9 (11) 2.6% - 26.1% 0.010 
 subsequent cycles 20b (27) 12c (15) -1.5% - 24.1% 0.049 
 overall incidence 34 (43) 20 (24) 4.3% - 33.0% 0.007 
 Placebo, n=79  Antibiotics, n=82 
 
Standard CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
Standard CDE 
n=41 (%) 
Intensified 
CDE 
n=41 (%) 
Patients with FL in 
(number, %) 
     
 first cycle  6 (16) 14 (34)  5 (12) 4 (10) 
 subsequent cycles 5 d (14) 15e (38)  5f (13) 7g (18) 
 overall incidence 11 (29) 23 (56)  10 (24) 10 (24) 
Number of episodes  
per patient  
     
      0 
1 
2 
3 
4 
27 (71) 
10 (26) 
1 (3) 
0 (0) 
0 (0) 
18 (44) 
16 (39) 
3 (7) 
2 (5) 
2 (5) 
 
 
 
 
 
31 (76) 
8 (20) 
2 (5) 
0 (0) 
0 (0) 
31 (76) 
9 (22) 
1 (2) 
0 (0) 
0 (0) 
Number of episodes  
per cycle  
     
 Cycle 1          
Cycle 2    
Cycle 3         
Cycle 4         
Cycle 5 
6 (16) 
1 (3) 
2 (6) 
3 (9) 
0 (0) 
14 (34) 
11 (28) 
5 (14) 
6 (18) 
0 (0) 
 
 
 
 
 
5 (12) 
3 (8) 
3 (8) 
0 (0) 
1 (3) 
4 (10) 
3 (9) 
1 (3) 
3 (9) 
0 (0) 
Duration of FL      
 median number of 
days h (pts with FL) 
(range) 
 
2 
(1-4) 
 
4 
(1-11) 
 
 
 
3 
(1-6) 
 
3 
(1-9) 
a One-sided stratified Cochran-Mantel-Haenzel test; b Of 75 pts, who received subsequent 
cycles; c Of 78 pts, who received subsequent cycles; d Of 36 pts, who received subsequent 
cycles; e Of 39 pts, who received subsequent cycles; f Of 40 pts, who received subsequent 
cycles; g Of 38 pts, who received subsequent cycles. h Median number of days of FL is two 
(range 1-11) in the placebo arm and three (range 1-9) in the antibiotics arm 
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Figure 2. Kaplan-Meier curves for the proportion of patients remaining free of FL 
during treatment (from randomisation) 
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The incidence of fever was higher in the placebo arm (Table 5), the efficacy of 
antibiotics again being most obvious for the intensified CDE group.  
Death due to infection occurred only in the placebo arm: 6% of all placebo patients 
versus 0% of verum patients (P=0.022; two-sided) representing 10% of placebo patients 
who developed fever. Infectious deaths occurred with both intensified and standard 
chemotherapy and this was equally effectively prevented by the use of prophylactic 
antibiotics. The majority of deaths due to infection occurred in the first two cycles of 
treatment: two after the first, two after the second and one after the fourth cycle. All five 
patients had developed a pneumonia, and three of them had a positive blood or 
bronchoalveolar lavage culture (Ps. Aeruginosa, H. Influenzae, S. Pneumonia), which 
was shown to be sensitive to one of the two antibiotic agents used in the other, 
antibiotics, arm. No cultures were made from the other two patients.  
There were 38 clinically documented infections in the placebo arm versus 15 in the 
antibiotics arm, with mainly less respiratory and urinary infections in the antibiotics 
arm. There was a reduction in the number of microbiologically documented infections: 
32 in the placebo arm versus 9 in the verum arm, i.e., 10 versus 5 in the standard and 22 
versus 4 in the intensified group of patients. The largest gain was observed for gram-
negative infections in the group of patients who received intensified chemotherapy. 
Table 6 shows the number of days of hospitalisation and of intravenous antibiotics. 
There was a significant difference in number of days of hospitalisation due to FL 
(P=0.013; one-sided) and use of intravenous antibiotics (P=0.013; one-sided), in favour 
of the antibiotics arm. However, the overall number of days of hospitalisation was not 
reduced (P=0.05; one-sided). Again, the largest differences were observed in the group 
of patients who received intensified chemotherapy. 
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Table 5. Fever, clinically and microbiologically documented infections 
 
 Placebo 
n=79 
 
 
Antibiotics 
n=82 
 Standard 
CDE 
n=38 (%) 
Intensified 
CDE 
n=41 (%) 
 
 
 
Standard 
CDE 
n=41 (%) 
Intensified 
CDE 
n=41 (%) 
Fever overall 17 (45) 32 (78)  22 (54) 17 (41) 
Shock due to infection 3 (8) 3 (7)  0 (0) 0 (0) 
Death due to infection 2 (5) 3 (7)  0 (0) 0 (0) 
Site of infection (number of 
episodes) 
     
  
 
Upper respiratory 
Lower respiratory 
Intra-abdominal  
Urinary 
Skin 
Sepsis 
No clinical site identified 
3 
2 
1 
3  
1 
1 
15 
5 
12 
0 
4 
2 
4 
31  
 
 
 
 
 
 
 
4 
1 
0 
2 
0 
0 
20 
1 
5 
0 
0 
0 
2 
13 
Gram-positive infections 
over all cycles 
     
 Number of patients 
Number of infections 
4 
6 
4 
6 
 
 
2 
2 
2 
2 
  Susceptibility to 
roxitromycin        
     
  Sensitive 
Resistant     
Unknown 
 1 
1 
4 
4 
1 
1 
 
 
 
0 
1 
1 
0 
2 
0 
Gram-negative infections 
over all cycles 
     
 Number of patients 
Number of infections 
3 
4 
7 
16 
 3 
3 
2 
2 
  Susceptibility to 
ciprofloxacin 
     
  Sensitive 
Resistant 
Unknown 
1 
0 
3 
8 
0 
8 
 2 
0 
1 
1 
1 
0 
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Table 6. Hospitalisation and use of intravenous therapeutic antibiotics 
 Placebo 
n=79  
Antibiotics 
n=82  
Stratified 
P-valuea  
Hospitalisation    0.050 
 Number of patients (%) 50 (63) 44 (54)  
 Number of days per patient, 
median (range) 
 
9 (1-62) 
 
6 (1-44) 
 
Hospitalisation due to FL        0.013 
 Number of patients (%) 31 (39) 17 (21)  
 Number of days per patient, 
median (range) 
 
4 (1-34) 
 
5 (2-18) 
 
Hospitalisation at ICU        
 Number of patients (%)      5 (6) 2 (2)  
 Number of days per patient, 
median (range) 
 
7 (1-30) 
 
2 (2-2) 
 
I.v. therapeutic antibioticsb        0.013 
 Number of patients (%)      43 (54) 31 (38)  
 Number of days per patient, 
median (range) 
 
8 (1-43) 
 
7 (3-26) 
 
 Placebo 
n =79 
 
 
Antibiotics 
n =82 
  Standard 
CDE 
n =38 
Intensified 
CDE 
n =41 
 
 
 
Standard 
CDE 
n =41 
Intensified 
CDE 
n =41 
Hospitalisation       
 Number of patients (%)  17 (45) 33 (80)  20 (49) 24 (59) 
 Number of days per patient 
median (range) 
 
6 (1-44) 
 
12 (2-62) 
 
 
 
8 (2-44) 
 
6 (1-25) 
Hospitalisation due to FL      
 Number of patients (%)  10 (26) 21 (51)  8 (20) 9 (22) 
 Number of days per patient 
median (range) 
 
1 (1-6) 
 
5 (1-34) 
 
 
 
4 (2-18) 
 
6 (3-11) 
Hospitalisation at ICU      
 Number of patients (%)      2 (5) 3 (7)  1 (2) 1 (2) 
 Number of days per patient, 
median (range) 
 
2 (1-3) 
 
19 (7-30) 
 
 
 
2 (2-2) 
 
2 (2-2) 
I.v. therapeutic antibioticsa           
 Number of patients (%)      14 (37) 29 (71)  17 (41) 14 (34) 
 Number of days per patient, 
median (range) 
 
6 (2-19) 
 
8 (1-43) 
 
 
 
7 (3-26) 
 
8 (3-19) 
 
a One-sided stratified Wilcoxon-Mann-Withney test; b Note that the number of days of 
intravenous antibiotics may include all types of intravenous antibiotic treatments, i.e., not only 
for treatment of FL 
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Baseline prognostic factors for the occurrence of febrile leukopenia 
Factors included in the logistic regression were age (<60 versus ≥ 60 years), weight loss 
(≤ 5% versus >5%), PS (0 versus 1), disease status (LD versus ED), antibiotics (placebo 
versus verum), chemotherapy regimen (standard versus intensified) and a term for 
interaction between chemotherapy and antibiotics treatment. The step-down variable 
selection procedure removed from this model the interaction term (P=0.130), PS 
(P=0.063), weight loss (P=0.072) and the chemotherapy regimen (P=0.07). Table 7 
presents the final multivariate model. This model indicated that having ED (P=0.007) 
and being older than 60 years (P=0.0425) are prognostic factors for FL as well as being 
randomised to the placebo arm (P=0.017). The fact that the interaction between 
chemotherapy and antibiotics treatment has not been found to be significant was 
expected, as we do not have enough power to test this interaction.  
 
 
Table 7. Baseline prognostic factors for the occurrence of febrile leukopenia  
Prognostic 
factor FL
a (%) Odds Ratiob 95%CI P-value 
Age (years)           
 
<60c  
≥ 60 
21 of 79 
33 of 82 
(27) 
(40) 
1.00 
2.07 (1.03-4.17) 0.043 
Disease status      
 Limited
c 
Extensive 
24 of 96 
30 of 65 
(25) 
(46) 
1.00 
2.60 (1.29-5.21) 0.007 
Antibiotics      
 Placebo
c 
Verum 
34 of 79 
20 of 82 
(43) 
(24) 
1.00 
0.43 (0.21-0.86) 0.017 
a  Number of patients with febrile leukopenia per number of patients. b Multivariate. c Reference 
category 
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Discussion 
 
This placebo-controlled randomised trial demonstrates that prophylactic ciprofloxacin 
and roxithromycin during CDE chemotherapy in patients with SCLC can reduce the 
incidence of FL, the number of documented infections, hospitalisation due to FL and 
use of therapeutic antibiotics by approximately 50%, with reduced number of infectious 
deaths.  
 
The present study was designed to address two SCLC treatment issues at the same time: 
1. The impact of chemotherapy dose intensification on survival; and 2. The role of 
antibiotic prophylaxis in the prevention of FL.  
 
The antibiotic-placebo randomisation was halted, far before its planned accrual of 240 
patients, as results of interim-analysis showed excessive toxicity in the placebo arm. It 
should be emphasized that all analyses were made under strict double-blinded 
conditions, and that the results were evaluated by an Independent Data Monitoring 
Committee before the decision to terminate this part of the study was made. With the 
number of randomised patients there was enough statistical power to analyse the 
antibiotics endpoint. The trial was continued for the main endpoint of survival as a two-
arm study (standard versus intensified dose) with all the remaining patients receiving 
prophylactic antibiotics as suggested by the Independent Data Monitoring Committee. 
The results concerning the impact of chemotherapy DI on survival will be reported 
separately.  
 
The incidence of FL was higher in the intensified chemotherapy arm when compared to 
the standard chemotherapy arm. Moreover, the protective effect of antibiotics was 
especially seen in the intensified arm, with a larger reduction in incidence of FL and 
documented infections compared to the standard arm. Infectious deaths occurred with 
both intensified and standard chemotherapy and this was equally effectively prevented 
by the antibiotic prophylaxis. The outcome seems to indicate an interaction between the 
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efficacy of prophylaxis and the DI of chemotherapy, which was not anticipated 
beforehand. However, we have no power to test this possible interaction. The data 
presented in the tables are stratified by chemotherapy DI.   
 
In this patient population the presence of ED and elderly age were predictive for FL. For 
example, the overall incidence of FL was 19 of 35 (54%) in the placebo arm and 11 of 
30 (37%) in the antibiotics arm in ED patients, compared with respectively 15 of 44 
(34%) and 9 of 52 (17%) in LD patients (data not shown). One may hypothesize that 
ED and elderly patients, given the higher risk of developing FL, are the best candidates 
for antibiotic prophylaxis. It should be emphasized that these were all patients with an 
excellent PS. 
 
Two meta-analyses have recently addressed the role of antibiotic prophylaxis in 
neutropenic cancer patients [8,9]. Engels et al. evaluated 18 trials, which included 1408 
subjects [8]. Compared with no prophylaxis, quinolones significantly reduced the 
incidence of gram-negative bacterial infections (relative risk 0.21), total infections 
(0.54) and episode with fevers (0.85) in patients who had a mean duration of 
neutropenia ranging from 7 to 32 days. Quinolone prophylaxis alone did not reduce 
clinically documented infections or infection-related deaths. A combination of a 
quinolone plus prophylaxis against gram-positive bacilli (penicillin, vancomycin, or 
macrolides) compared to a quinolone alone significantly reduced gram-positive 
bacteraemia (relative risk 0.46) without affecting the incidence of fever-related 
morbidity or mortality [9].  In other words, although both antibiotics were demonstrated 
to be effective in reducing microbiologically documented infections, each of them used 
separately demonstrated only a small benefit, if any, when looking at fever-related 
morbidity and mortality with conflicting data concerning the subsequent effect on 
antibiotic usage, hospitalisation and cost-effectiveness [14-16]. Consequently, the use of 
antibiotic prophylaxis has not gained widespread acceptance, certainly not for patients 
with only modest leukopenia, i.e., not for patients with solid tumours treated with 
standard dose chemotherapy. 
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To our knowledge, this is the first trial in which double antibiotic prophylaxis was 
compared to placebo, in contrast to the above-mentioned trials in which double 
antibiotics prophylaxis was always compared to one other antibiotic agent or single 
antibiotic prophylaxis compared to placebo. The sum of protective effects of both drugs 
in our trial may explain the significant reduction in fever-related morbidity and 
mortality.  
 
Whether the reduced need for intravenous antibiotics and less hospitalisations will 
outweigh the costs of prophylactic antibiotics at this infection rate, has been a subject of 
separate cost-effectiveness analysis [17]. 
 
Although this was not an endpoint of this study, an important observation was the 
absence of death due to infection in the antibiotics arm compared with 6% in the 
placebo arm, for both intensified and standard chemotherapy. A reduction in death due 
to infection rate was in general not demonstrated by the addition of a single antibiotic 
prophylaxis agent, nor in the haematopoietic growth factor trials [2,3,8.9]. Six percent 
deaths due to infection seems rather high for the degree of leukopenia seen, but this 
figure is in concordance with the literature [3]. All five patients had developed 
pneumonia, and bacteraemic pneumonia in neutropenic cancer patients is known to be 
associated with a poor outcome [18]. It must be emphasized that this is a multi-centre 
trial, and it is well known that mortality in such large studies is often higher in 
comparison to single institution trials. Furthermore, this is a relative elderly patient 
population with frequently additional smoking-associated morbidity like emphysema, 
besides increased risk of postobstructive pneumonia due to the tumour. A British trial in 
610 SCLC patients observed 71 (12%) deaths in the first three weeks after start of 
chemotherapy, corresponding to the onset of neutropenia and related to a worse PS [19].  
 
The antibiotics were protective through all cycles with a consistent 50% relative 
difference in occurrence of FL between both arms. The incidence of FL declined over 
the subsequent cycles, which cannot be explained by chemotherapy dose reductions 
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with less myelosuppression, since the nadir WBC counts were quite consistent during 
the whole treatment period (non presented data). The declining incidence of FL and 
infectious mortality may reflect patient selection during treatment and tumour response 
in this chemo-sensitive disease with less risk for postobstructive pneumonia during later 
cycles. One may question the value of prophylactic antibiotics during later cycles, as the 
absolute difference between the two arms diminishes during cycles 2-5. 
 
Grade 4 leukopenia was seen in 23% of delivered chemotherapy cycles in the placebo 
arm, with FL occurring in 49% of these leukopenic cycles. In a retrospective analysis of 
patients treated with standard-dose chemotherapy for solid tumours, it was seen that 
leukopenia occurred in 7% of cycles [20]. In case of leukopenia the incidence of FL 
without prophylaxis was 34% [22]. Both latter figures are much lower compared to our 
observation in the placebo arm. It may be concluded that the risk for infection and the 
efficacy of antibiotic prophylaxis in our study is partly related to the type of tumour 
(lung cancer with risk for obstructive pneumonia), in addition to the degree of 
chemotherapy-induced leukopenia. The conclusion that the efficacy of antibiotic 
prophylaxis is related to chemotherapy-induced leukopenia and not only to tumour-
related infections is also supported by the observation of a significant difference 
between the incidence of FL (48 episodes in the placebo arm versus 23 in the antibiotics 
arm), but no difference between the incidence of febrile episodes without leukopenia 
(30 episodes in placebo arm versus 29 episodes in antibiotic arm). 
 
 A major criticism to many previous antibiotic trials is that a reduction in 
microbiologically documented infections frequently results in a shift toward more 
clinically documented infections and episodes of fever of unknown origin, of which the 
microbiological source is masked by the prophylactic antibiotic. This was not the case 
in our trial, with overall less febrile episodes. As could be expected by the tumour 
location and by the smoking behaviour of these patients, the majority of infections were 
seen in the respiratory tract. In this respect, it is important to realize that ciprofloxacin 
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and roxithromycin achieve high tissue levels when administered orally [21,22], with no 
antagonistic interactions [23].  
 
The design and outcome of our study is quite similar to the G-CSF studies in SCLC 
[2,3]. The guidelines of the American Society of Clinical Oncology concerning the use 
of prophylactic G-CSF is primarily based on these two pivotal studies [4]. The CDE 
regimen in the G-CSF studies was higher dosed than our standard CDE regimen, but 
had a lower DI than our intensified, G-CSF-supported, CDE regimen [2,3]. In their 
placebo non-G-CSF arms, however, the degree of myelosuppression was more severe, 
and this explains partly the higher incidence of FN in the placebo arms of these studies 
(77% and 58%), besides the use of a more stringent definition of FN (i.e., a temperature 
≥ 38.2oC and neutrophils (not WBC counts) < 1.0 x 109/l) and differences in patient 
characteristics, with more patients having an ED and PS 2. As stated above, one may 
speculate that especially these patients, with an increased risk for FN due to high-dose 
CDE and more often ED and worse PS [2,3], were able to benefit from G-CSF 
prophylaxis.  
 
With the outcome of our trial, it can be hypothesized that antibiotics can be an 
alternative to G-CSF for the prevention of FL. Prophylactic antibiotics are also less 
expensive than G-CSF and subcutaneous injections can be avoided. Some support for 
the hypothesis that G-CSF and antibiotics give similar results can be found in the 
literature. In a retrospective analysis 62 patients with ovarian cancer receiving a 
paclitaxel-based chemotherapy regimen were prophylactically treated with either 
ciprofloxacin or G-CSF, while a third group received no prophylaxis. There were two 
episodes of FN in the antibiotic group and three in the G-CSF group, compared with 15 
in the observation group [24]. Recently, a prospective comparison between G-CSF 
versus ciprofloxacin and amphothericin B in patients with breast cancer treated with 
high-dose chemotherapy has been reported [25]. The incidence of FL was comparable, 
while the treatment with G-CSF was six times more expensive. In another prospective 
trial, 59 patients were randomised to either G-CSF alone or G-CSF plus a quinolone 
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[26]. With a median duration of WHO grade 4 leukopenia of four days, FL occurred 
three times as often in the G-CSF only arm compared to the experimental arm. As these 
trials were either retrospective or included too few patients, firm conclusions cannot be 
drawn. Well-designed prospective trials should be launched to investigate which type of 
prophylaxis (antibiotics or G-CSF or both) represents the optimal strategy for specific 
groups of patients based on their risk of developing FL. 
 
In conclusion, this study has demonstrated that prophylactic ciprofloxacin and 
roxithromycin are well tolerated and effective in reducing FL and infections in SCLC 
patients receiving CDE chemotherapy. The protective effect of antibiotics was 
especially seen in patients who were treated with intensified chemotherapy. In this 
patient population with an excellent PS, patients with an ED and elderly age had an 
increased risk for FL. Similarly to G-CSF, ciprofloxacin-roxithromycin antibiotic 
prophylaxis can be recommended to prevent infectious complications in patients with an 
increased risk for FL during chemotherapy.  
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Abstract  
 
Purpose: To determine whether the cost of prophylactic antibiotics during 
chemotherapy is offset by cost savings due to a decreased incidence of febrile 
leukopenia (FL).  
Patients and methods: Small cell lung cancer (SCLC) patients were randomised to 
standard or intensified chemotherapy to assess the impact on survival (n=244). In 
addition, patients were randomised to prophylactic ciprofloxacin and roxithromycin or 
placebo to assess the impact on FL (n=161). The economic evaluation examined the 
costs and effects of patients taking antibiotics versus placebo. Medical resource 
utilization was documented prospectively, including 33 patients from 1 centre in the 
Netherlands (NL) and 49 patients from 1 centre in Germany (GE). The evaluation takes 
the perspective of the health insurance systems and of the hospitals. Sensitivity analyses 
were performed. 
Results: In the main trial, prophylactic antibiotics reduced the incidence of FL, 
hospitalisation due to FL and use of therapeutic antibiotics by 50%. In GE, the 
incidence of FL was not reduced by prophylaxis. This resulted in an average cost-
difference of only 35 Euro (95%CI:(-) 1713 - 2263) in favour of prophylaxis (not 
significant). In NL, prophylaxis reduced the incidence of FL by nearly 50%, comparable 
to the results of the main trial, resulting in a cost difference of 2706 Euro (95%CI:(-) 
810 - 5948), demonstrating savings in favour of prophylactic antibiotics of nearly 45%. 
Sensitivity analyses indicate that, with an efficacy of prophylaxis of 50%, and with 
expected costs of antibiotic prophylaxis of 500 Euro or less, cost-savings will incur over 
a broad range of baseline risks for FL, that is a risk above 10% to 20% for FL per cycle.  
Conclusion: Giving oral prophylactic antibiotics to SCLC patients undergoing 
chemotherapy is the dominant strategy in both GE and NL, demonstrating both cost-
savings and superior efficacy. The sensitivity analyses demonstrate that, due to the 
efficacy of prophylactic antibiotics and their low unit cost, cost-savings will incur over 
a broad range of baseline risks for FL. 
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Introduction  
 
The most frequent dose limiting toxicity of chemotherapy is febrile leukopenia (FL). 
CDE (cyclophosphamide, doxorubicin, etoposide), one of the standard chemotherapy 
regimens in the treatment of small cell lung cancer (SCLC), is associated with an 
incidence of FL varying from 43% to 77% of patients having at least one episode of FL 
[1-3]. FL may be indicative of a bacterial infection that can cause significant morbidity 
and mortality in these patients. The mainstay of treatment for FL is hospitalisation and 
intravenous antibiotics. The administration of oral prophylactic antibiotics may have 
clinical benefits for patients by reducing the incidence of FL and at the same time 
produce cost savings. An economic evaluation is a useful tool to help determine 
whether it is worthwhile to give prophylactic antibiotics in terms of costs and benefits to 
patients and to the health care system.  
We have previously reported the results of a randomised trial in patients with SCLC 
treated with CDE chemotherapy, in which the role of prophylactic antibiotics was 
evaluated [1]. We demonstrated that with prophylactic antibiotics during CDE 
chemotherapy the incidence of FL, the number of documented infections, the use of 
therapeutic antibiotics and hospitalisations were reduced by approximately 50%, with a  
reduced number of infectious deaths. We report here the results of the economic 
evaluation of this prospectively randomised trial. Importantly, we also performed 
sensitivity analyses to place the outcome in a broader perspective. 
 
 
Patients and methods 
 
A more detailed report of the clinical trial has been reported elsewhere [1,4]. In brief, 
patients with chemo-naïve SCLC with ECOG performance status 0-1 were randomised 
to standard-dose CDE (cyclophosphamide 1000 mg/m2 day 1, doxorubicin 45 mg/m2 
day 1, etoposide 100 mg/m2 days 1-3, intravenous, q 3 weeks, times 5) or to intensified 
CDE chemotherapy (125% dose, q 2 weeks, times 4, with filgrastim 5 µg/kg/day days 
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4-13) to assess the impact of dose-intensification on survival (n=244). Patients were 
also randomised to prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 
150 mg, bid, days 4-13) or to placebo in a 2x2 factorial design (n=161) with as primary 
endpoint the incidence of FL during the first cycle. In case of FL, prophylaxis was 
interrupted and replaced by intravenous broad-spectrum antibiotics. After inclusion of 
161 eligible patients, the antibiotic/placebo part of the trial was prematurely terminated 
on advise of an Independent Data Monitoring Committee. 
 
 
Study design of the economic evaluation 
 
The prospective economic evaluation was conducted alongside the trial. This evaluation 
concerned only the randomisation of prophylactic antibiotics versus placebo. Patients 
were included from October 1994 until December 1997. All prices were adjusted to 
1998 prices. No discounting of costs was necessary because treatments were given over 
a period of 4-6 months. Although the clinical trial was conducted in 13 centres 
throughout Europe, Heidelberg in Germany (GE), and ’s-Hertogenbosch in the 
Netherlands (NL), were both expected to recruit the highest number of patients and thus 
were chosen for the cost assessments (n=82, 51% of total sample size).  
The objective of the analysis was to determine whether the costs of prophylactic 
antibiotics were offset by cost savings associated with the expected decrease in 
incidence of FL, fever, documented infections, days of intravenous antibiotics and days 
of hospitalisation. Protocol driven costs were not included in the analysis.  
 
The economic evaluation  
The economic evaluation involved calculating the average clinical effect for each arm 
and determining the difference, and calculating average total costs for each arm of the 
trial and determining the difference. For the economic evaluation, the most patient-
relevant outcome measure was the absolute risk reduction in percentage of FL. Costs are 
calculated for the time the patient was on the trial. The economic evaluation was 
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primarily based on the incidence of FL per patient. In addition, we looked at the 
incidence of FL per cycle of delivered chemotherapy.  
 
Uncertainty analysis 
The skewness of cost data means that producing confidence intervals by parametric 
methods is inappropriate. Therefore, the cost data were analysed using the non-
parametric bootstrap, specifically employing the bias corrected and accelerated 
bootstrapping method [5]. The number of bootstrap replications for each sample was 
5000. These calculations yielded an average cost per patient and cycle for both arms 
with their corresponding 95% confidence interval (95% CI). The difference in average 
cost between the antibiotic and placebo arms for both sites was also calculated in this 
manner.  
 
Resource utilization  
Resource use included those items that were associated with direct medical treatment 
costs and did not include patient out-of-pocket costs, non-medical costs, indirect costs 
or quality of life issues.  
 
Unit cost data  
Patients were assumed to be treated as public patients. Unit costs were applied from two 
perspectives, that of each country’s health care system and that of the hospital (Table 1). 
The rationale for this approach was that per diem costs in Heidelberg (GE) and in ’s-
Hertogenbosch (NL) include the ‘hotel’ cost (e.g. administration, overheads, occupation 
of a bed, etc) and also pharmaceuticals and transfusions. In GE, the per diem cost 
additionally includes the cost of diagnostic tests and microbial cultures. Where it was 
not possible to obtain the pertinent hospital prices for some items, such as 
pharmaceuticals, which are subject to negotiated prices and considered commercially 
sensitive information, the listed tariff prices had to be used. The costs were expressed as 
Euro (1 Euro = 1.96 DM = 2.20 fl = 0.86 US $  as of  28 June 2001).  
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Table 1. Sources of unit costs 
 
 Heidelberg (GE) ’s-Hertogenbosch (NL) 
From perspective of 
health care system 
 
  
 Hospital per diem cost Reimbursed amount by 
health insurances a  
Reimbursed amount from 
health insurances a  
From perspective of 
hospital 
 
  
 Pharmaceuticals 
 
Rote List, , Service 
Gmbh, 1998 
KNMP, 1998. “Koninklijke 
Nederlandse Maatschappij 
ter bevordering der 
Pharmacie” 
 
 Transfusions Local blood bank prices 
paid by the hospital 
Local blood bank prices 
paid by the hospital 
 
 Diagnostic Tests DKG-NT Band 1b 
“Tarif der Deutschen 
Krankenhausgesellschaft”
1997 
 
COTG, 1998 
“Centraal Orgaan Tarieven 
Gezondheidszorg” 
 
 Microbial cultures 
 
Hospital’s own records Hospital’s own records 
 
a  Centre specific 
b These 1997 prices were adjusted by additional 3% to convert them to 1998 prices 
 
 
Hospitalisations  
The per diem rates in both countries are hospital specific and based on their annual 
budgets; therefore per diem rates cannot only vary between countries but also within 
countries. Hospital budgets are influenced by their relative size, whether it is a 
university hospital and also whether the hospital is specialized in certain diagnostic 
areas (e.g. thoracic clinic). In Heidelberg (GE), the rate for one day (no overnight stay) 
and also per diem (including overnight stay) was 280 Euro, while the per diem rate of 
intensive care was 765 Euro. The figures in ’s-Hertogenbosch (NL) were 170, 625 and 
1416 Euro, respectively. For this economic evaluation only hospitalisations for fever, 
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FL, transfusion and for treatment of adverse events were included. That is, 
hospitalisation for chemotherapy administration was not taken into account, as this was 
considered to be comparable for the placebo and prophylactic antibiotics arm.  
 
Pharmaceuticals  
The unit costs of the prophylactic antibiotics were applied as if the patient had bought 
the antibiotics from their local pharmacy. A course of ciprofloxacin 1500 mg daily and 
roxithromycin 300 mg daily for 10 days costs 180 Euro in Heidelberg (GE) and 110 
Euro in ’s-Hertogenbosch (NL). For all medication other than the prophylactic 
antibiotics, a per tablet/capsule price was assigned as these medications would have 
been administered while the patient was an in-patient. National public tariff prices were 
applied to all medications.  
 
Transfusions  
For Heidelberg (GE), the unit cost of a transfusion indicates the cost of the blood 
product, while the cost of administering the transfusion is an additional 19 Euro 
regardless of how many units of blood product are transfused at one time. In ’s-
Hertogenbosch (NL), the unit price for a transfusion includes the transfusion cost, 
product cost and overheads, but it was not possible to break down these components. In 
GE, transfusion with either one unit of red blood cells or one unit of platelets (six 
donors) was 50 Euro, while in NL this was 86 and 273 Euro respectively. 
 
Diagnostic tests and pathology  
In Heidelberg (GE), we used the tariffs from ‘DKG-NT Band 1, Tarif der Deutschen 
Krankenhausgesellschaft’. In ’s-Hertogenbosch (NL), we used the listed ‘Centraal 
Orgaan Tarieven Gezondheidszorg’ (COTG) tariffs, with in addition a physician’s fee 
when these tests were carried out in the outpatient setting.  
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Microbial cultures  
In Heidelberg (GE), the cost of a single culture depends upon the number of tests that 
need to be carried out, ranging from 20 Euro per sputum culture to 42 Euro for culture 
of pleural effusion. In ’s-Hertogenbosch (NL), the costs of the tests depend upon 
whether the sample tests was positive (52 Euro) or negative (31 Euro), regardless of the 
source of the culture. 
 
 
Sensitivity analyses 
 
In addition to the economic evaluation, a threshold and three-way sensitivity analysis 
were performed.   
 
Threshold analysis  
The following formula was used to calculate cost-neutrality [6,7,8]: 
(FL risk x relative reduction) x (unit cost x days hosp.) = (unit cost x days prophylaxis) 
 
In the left part of the formula, the cost-savings of prophylactic antibiotics are 
determined by taking ‘the avoided number of FL  episodes’ times ‘the average cost of 
hospitalisation per FL episode’. At the right, the costs of prophylaxis are calculated. 
There is cost-neutrality, in case cost-savings is equal to the costs of prophylaxis itself. 
In a threshold analysis, all parameters but one are kept unchanged. The threshold of this 
parameter is the value, at which point there is cost-neutrality. Prophylactic antibiotics 
will produce cost-savings, in case the parameters at the left do in reality have values 
above their threshold value, or in case the values at the right have values below their 
threshold value.  
Note, that the numbers in the threshold and sensitivity analyses refer to costs and 
incidences per cycle, in contrast to the efficacy and economic evaluation in which 
primarily incidences per patient were used as was specified in the prospective trial.  
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The baseline assumptions for the threshold and sensitivity analyses were based on the 
incidence of FL, the efficacy of prophylaxis (relative reduction in FL), and the duration 
of hospitalisation due to FL as seen in the main trial, and not those of only one or two 
subgroups (GE and/or NL), as such subgroups may not be representative for the whole 
patient population [6].  
The thresholds were calculated for both GE and NL separately, as the unit costs were 
not the same for these countries. The costs used, were those that determined the 
outcome from a Health Insurance Perspective. Cost variations in cultures and diagnostic 
tests were not included for NL, as these accounted for less than 5% of total costs. 
 
Three-way sensitivity analysis  
A three-way sensitivity analysis was conducted by varying the average baseline risk for 
hospitalisation due to FL per cycle, the average cost of an hospitalisation due to FL and 
the cost of antibiotic prophylaxis per cycle. The baseline risk for hospitalisation due to 
FL was varied from 10% to 50%, by step increments of 10%. The average cost of 
hospitalisation due to FL was varied from 2000 tot 20000 Euro, with step increments of 
2000 Euro. The cost of prophylaxis per cycle was varied from 100, 250, 500 to 1000 
Euro.  
By the above mentioned formula, the hospitalisation cost for which there is cost-
neutrality can be calculated per cost of prophylaxis for one baseline risk for 
hospitalisation due to FL (threshold point), but also over a range of baseline risks for FL 
(threshold line). Several threshold lines can be calculated for different unit costs of 
prophylaxis. Any combination in the area above a given threshold line favours 
prophylaxis on a cost basis. In contrast, any combination below the threshold line does 
not favour prophylaxis on a cost basis. 
Such three-way sensitivity analyses enables extrapolation of results to different 
countries, with different unit costs of hospitalisation and/or prophylaxis, and to different 
chemotherapy regimens with different risk for FL.  
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Results 
 
Efficacy 
The mean clinical outcomes for each of the sites, Heidelberg (GE) and ’s-
Hertogenbosch (NL), were compared to the results for the whole trial minus that 
specific site, Heidelberg (GE) or ’s-Hertogenbosch (NL), to determine whether there 
were any statistically significant differences.  
The patient baseline characteristics were comparable for both sites, except for stage of 
disease with more limited disease (LD) in patients from Heidelberg (GE) (Table 2). 
 
Table 2.  Patient characteristics at baseline 
 
Characteristics Heidelberg (GE) n=49 (%) 
‘s-Hertogenbosch (NL) 
n=33 (%) 
P-value 
 
Median age (yrs) 
    (range) 
59 
(35-69) 
57 
(33-70) 0.238
 a 
    
Sex 
    Male 
    Female 
 
37(76) 
12(24) 
 
26(79) 
7(21) 
 
0.795 b 
    
ECOG PS 
    0 
    1 
 
25(51) 
24(49) 
 
16(48) 
17(52) 
 
0.174 b 
    
Stage 
    Limited 
    Extensive 
 
35(71) 
14(29) 
 
16(48) 
17(52) 
 
0.021 b 
    
Median weight loss  
over last 3 months 
(%) 
    (range) 
 
2.5 
(-7 to 12)c 
 
4.8 
(-8 to 22) c 
 
0.244 a 
 
a  Wilcoxon two-sample test; b Fisher's exact test; c negative weight loss means weight gain 
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The first efficacy comparison concerned the incidence of FL in the first cycle, the 
incidence of FL in the second and subsequent cycles, the overall incidence of FL, the 
number of patients treated with intravenous therapeutic antibiotics and the number of 
patients hospitalised for FL and the incidence of fever. In almost all instances, each of 
the subgroups, when compared separately to the main trial results, had a similar rate of 
outcome, although there were some differences, especially for Heidelberg (GE) (Table 
3a and 3b).  
 
In a second comparison, we looked at the average incidence of FL per cycle. In the main 
clinical trial (n=161), in total 48 episodes of FL occurred in the placebo arm (15% of 
320 chemotherapy cycles) versus 23 in the antibiotics arm (7% of 335 cycles). This 
reflects a  55% relative decrease in risk for FL (taking all cycles into account). 
In ‘s-Hertogenbosch (NL), the average incidence of FL per cycle was 16% versus 5% in  
the antibiotics arm, which is comparable with the main trial. However, in Heidelberg 
(GE) the outcome was quite different with incidences of 8% and 9%, respectively.  
 
The third comparison concerned the average duration of hospitalisation due to FL, of 
intravenous antibiotic administration and of hospitalisation for any reason except 
chemotherapy delivery (Table  4). For Heidelberg (GE), these 2 first items significantly 
differed from the main trial, with  a prolonged duration of hospitalisation due to FL and 
longer intravenous antibiotic treatment in the prophylactic arm. In ‘s-Hertogenbosch 
(NL), the average duration of intravenous antibiotics in the placebo arm was higher than 
in the main trial.  
 
Finally, we looked at the number of chemotherapy cycles actually delivered. The 
average number of chemotherapy cycles for patients treated in Heidelberg (GE) 
(regardless of treatment arm) was 3.71 (S.D. = 1.32), whilst in ‘s-Hertogenbosch (NL) 
was 4.33 (S.D. = 0.69), P<0.01. 
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Table 3a. Clinical outcome comparisons for the whole trial minus Heidelberg (All-GE) 
and Heidelberg (GE)  
 
Placebo Antibiotics Heidelberg  
(GE) All-GE 
(n =53) 
GE 
(n =26) P-value 
All-GE 
(n =59) 
GE 
(n =23) P-value 
Incidence of FL 
in first cycle a 16 4 0.180 
b 7 2 1.000 b 
Incidence of FL 
in subsequent 
cyclesc 
17 3 0.054 b  8 4 0.490 b 
Overall incidence 
of FL 27 7 0.055 
b 15 5 1.000 b 
Hospitalisation 
due to FL 23 8 0.333 
b   12 5 1.000 b 
Incidence of fever 36 13 0.144 b  26 13 0.336 b 
IV antibiotics d 32 11 0.154 b 22 9 1.000 b 
N° of FL episode 
0 
1 
2 
3 
4 
 
26 
19 
4 
2 
2 
 
19 
7 
0 
0 
0 
 
 
 
 
 
0.025 e 
 
44 
14 
1 
0 
0 
 
18 
3 
2 
0 
0 
 
 
 
 
 
0.869 e 
N° of 
Hospitalisations f 
0 
1 
2 
3 
4 
 
 
18 
19 
8 
6 
2 
 
 
11 
8 
6 
1 
0 
 
 
 
 
 
 
0.410 e 
 
 
33 
16 
8 
1 
1 
 
 
5 
13 
4 
0 
1 
 
 
 
 
 
 
0.023 e 
 
a For one patient, incidence of FL is missing at cycle 1; b Fisher's exact test; c Incidence of FL is 
missing for 10 patients; not including 8 patients, who only received the 1st  cycle of CDE 
chemotherapy; d Not only for FL; e Wilcoxon two-sample test;  f For FL, fever, transfusion, and 
for treatment of adverse events, but not for chemotherapy; missing data for one patient  
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Table 3b. Clinical outcome comparisons for the whole trial minus ‘s-Hertogenbosch 
(All-NL) and ’s-Hertogenbosch (NL) 
 
Placebo Antibiotics ‘s-Hertogenbosch 
(NL) All-NL 
(n =63) 
NL 
(n =16) P-value 
All-NL 
(n =65) 
NL 
(n =17) P-value 
Incidence of FL 
in first cycle a 17 3 0.749 
b 7 2 1.000 b 
Incidence of FL 
in subsequent 
cycles c 
14 6 0.341 b  10 2 1.000 b 
Overall incidence 
of FL 28 6 0.779 
b 16 4 1.000 b 
Hospitalisation 
due to FL 23 8 0.333 
b   12 5 1.000 b 
Incidence of fever 37 12 0.265 b  28 11 0.172 b 
IV antibiotics d 34 9 1.000 b 21 10 0.054 b 
N° of FL episode 
0 
1 
2 
3 
4 
 
35 
24 
1 
1 
2 
 
10 
2 
3 
1 
0 
 
 
 
 
 
0.962 e 
 
49 
13 
3 
0 
0 
 
13 
4 
0 
0 
0 
 
 
 
 
 
0.861 e 
N° of 
Hospitalisations f 
0 
1 
2 
3 
4 
 
 
24 
23 
11 
4 
1 
 
 
5 
4 
3 
3 
1 
 
 
 
 
 
 
0.215 e 
 
 
32 
23 
7 
1 
2 
 
 
6 
6 
5 
0 
0 
 
 
 
 
 
 
0.236 e 
 
a For one patient, incidence of FL is missing at cycle 1; b Fisher's exact test; c Incidence of FL is 
missing for 10 patients; not including 8 patients, who only received the 1st  cycle of CDE 
chemotherapy; d Not only for FL; e Wilcoxon two-sample test;  f For FL, fever, transfusion, and 
for treatment of adverse events, but not for chemotherapy; missing data for one patient  
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Table 4. Comparison of duration of FL and of main resource utilizations for the whole 
trial minus Heidelberg (All-GE) and Heidelberg (GE) and for the whole trial 
minus ‘s-Hertogenbosch (All-NL) and ’s-Hertogenbosch (NL)  
 
Heidelberg  
(GE) Placebo Antibiotics 
Duration (days, 
average +/- SD) 
All-GE 
(n=53) 
GE 
(n=26) 
P- 
value a 
All-GE 
(n=59) 
GE 
(n=23) 
P- 
value a 
IV antibiotics b 16±10.4 13.1±4.3 0.521 10.5±6.5 17.4±10.2 0.036 
Hospitalisation 
due to FL 
 
5±6.7 
 
6.4±5.0 0.178 4.6±2.3 9.8±5.1 0.014 
Hospitalisation c 15.1±14.1 12.3±11.2 0.345 11.5±10.0 11.2±11.3 0.565 
   
‘s-Hertogenbosch 
(NL) Placebo Antibiotics 
Duration (days, 
average +/- SD) 
All-NL 
(n=63) 
NL 
(n=16) 
P- 
value a 
All-NL 
(n=65) 
NL 
(n=17 ) 
P- 
value a 
IV antibiotics b 13.5±7.4 21.9±12.8 0.021  14.3±9.6 9.1±2.7 0.144   
Hospitalisation 
due to FL 5.6±6.8 4.5±3.5 0.919 6.8±4.3 3.8±1.5 0.123  
Hospitalisation c 13.4±13.1 17.3±14.0 0.201 10.8±10.2 13.1±11.5 0.271  
 
a  Kruskall Wallis test; b Intravenous antibiotics not only for FL; c For FL, fever, transfusions, 
treatment of adverse events, but not for chemotherapy  
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Costs  
 
In ’s-Hertogenbosch (NL) no patient spent time in intensive care, whilst two patients in 
Heidelberg (GE) had days in intensive care. One of these patients (in placebo arm) spent 
30 days in intensive care at a cost of 22959 Euro.  
The cost of treating an episode of FL in either Heidelberg (GE) or ’s-Hertogenbosch 
(NL) with intravenous antibiotics was about the same on a daily basis (44 Euro and 45 
Euro, respectively).  
Relatively more patients underwent cultures and diagnostic tests in the placebo and 
antibiotics arms of ‘s-Hertogenbosch (NL) compared to the placebo and antibiotics arms 
of Heidelberg (GE) (Table 5).  
 
 
Table 5. Total resource use in Heidelberg (GE) and ’s-Hertogenbosch (NL) 
 
 Heidelberg (GE) ’s-Hertogenbosch (NL) 
 Placebo (n =26) 
Antibiotics 
(n =23) 
Placebo 
(n =16) 
Antibiotics 
(n =17) 
Resource Total No. a 
No. of 
pts 
Total 
No. a 
No. of 
pts 
Total 
No. a 
No. of 
pts 
Total 
No. a 
No. of 
pts 
RBC 
transfusions 32 9 46 12 21 8 18 6 
PLT 
transfusions 14 3 37
 b 4 3 3 7 5 
Chest x-rays 28 c 4 3 3 15 6 3 3 
Abd.  
ultrasound 0 0 2 2 1 1 0 0 
Blood 
cultures 15 10 12 8 34 8 22 9 
Urine 
cultures 7 4 4 2 28 9 11 8 
Faeces 
cultures 0 0 0 0 6 4 3 2 
 
a Number of transfusions or investigations; b 1 patient had 16 platelet (PLT) transfusions; c 1 
patient had 24 x-rays 
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Table 6. Average Costs (Euro) of all patients included for Heidelberg (GE) and ‘s-
Hertogenbosch (NL), for both the Health Insurance Perspective as the 
Hospital Perspective 
 
 Average Costs (Euro) for Heidelberg (GE)  Health Insurance Perspective 
n=49 Placebo (95% CI)a Antibiotics (95% CI)a    Difference (95% CI)a 
Hospital 2405  (1112−5114) 1750  (1037−2665) 655 ((-)990–3100) 
Antibiotics − 619 (517–713) -619 ((-)517–(-)713) 
TOTAL 2405 (1112−5114) 2369 (1550–3340) 35 ((-)1713−2263) 
 Average Costs (Euro) for ’s-Hertogenbosch (NL)   Health Insurance Perspective 
n=33 Placebo (95% CI)a Antibiotics (95% CI)a Difference (95% CI)a 
Hospital 5672 (2763−9101) 2669 (1659–3723) 3003 (8–6579) 
Tests b 272 (122−458) 95 (49−145) 177 (24−374) 
Antibiotics − 474 (428−500) -474 ((-)428−(-)500) 
TOTAL 5944 (3359−9655) 3238 (2195–4311) 2706 (810–5948) 
 Average Costs (Euro) for Heidelberg (GE)  Hospital perspective 
n=49 Placebo (95% CI)a Antibiotics (95% CI)a Difference (95% CI)a 
Pharmaceuticals  224 (121−420) 352 (126–624) -128 ((-)444–155) 
Transfusions/ 
testsb  240 (85–616) 190 (105–277) 50 ((-)137–418) 
TOTAL 465 (227–1008) 542 (284–867) -77  ((-)514–457) 
 Average Costs (Euro) for ’s-Hertogenbosch (NL)  Hospital Perspective 
n=33 Placebo (95% CI)a Antibiotics (95% CI)a Difference (95% CI)a 
Pharmaceuticals  394 (209−671) 134 (80–192) 260 (64–534) 
Transfusions 165 (88–232) 204 (77–319) -39 ((-)188–101) 
Testsb 272 (122−458) 95 (49–145) 177 (24−374) 
TOTAL 831 (410–1259) 432 (252−631) 399 ((-)44–878) 
 
a Bootstrapped 95% CI. Note: 1 Euro = 2.20ƒ= 1.96 DM; b cultures and diagnostic tests 
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From the Health Insurance Perspective, there was an average cost-saving of 35 Euro 
(95%CI: (-) 1713 - 2263) per patient in favour of giving prophylactic antibiotics in 
Heidelberg (GE) (not significant) (Table 6). The cost difference in ’s-Hertogenbosch 
(NL) was 2706 Euro (95%CI: 810 - 5948) per patient demonstrating savings in favour 
of prophylactic antibiotics of nearly 45% (Table 6). This correlated with cost savings in 
’s-Hertogenbosch (NL) of 605 Euro per cycle. 
From the Hospital Perspective there is a similar overall picture, with again a cost 
reduction of approximately 45% per patient in ’s-Hertogenbosch (NL) (Table 6), and 
cost-neutrality for Heidelberg (GE).  
In Heidelberg (GE), the average cost of treating an episode of FL was higher in patients 
in the antibiotics arm than in the placebo arm (Table 7), largely due to unexpected 
longer duration of FL and hospitalisation due to FL in the antibiotics arm (Table 4). In 
contrast, in ‘s-Hertogenbosch (NL) a cost-difference of 37% (1 - [2485 / 3970]) incurred 
per patient who experienced FL, in favour for the antibiotics arm (Table  7).  
 
 
Table 7 . Cost of treating FL for Heidelberg  (GE) and ‘s-Hertogenbosch (NL),  Health 
Insurance Perspective  
 
Heidelberg (GE) ’s-Hertogenbosch (NL) Average cost ± 
SD (Euro) for: Placebo Antibiotics Placebo Antibiotics 
Patients who 
experienced 
FL  
1789 ± 1407 
(n=8) 
3367 ± 1775  
(n=5) 
3970 ± 2452 
(n=6) 
2485 ± 964 
(n=4) 
All patients 551 ± 1124 
(n=26) 
732 ± 1609 
(n=23) 
1489 ± 2438 
(n=16) 
585 ± 1164 
(n=17) 
 
Note: 1 Euro = 2.20ƒ= 1.96 DM 
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Cost-effectiveness  
 
For the first cycle in Heidelberg (GE), prophylactic antibiotics reduced the absolute risk 
of FL by 6% (down from 15%). It also saved 274 Euro per patient. In ‘s-Hertogenbosch 
(NL), prophylactic antibiotics reduced the absolute risk of FL by 7% (down from 19%) 
in the first cycle. It is also saved 676 Euro per patient.  
 
In subsequent cycles: in Heidelberg (GE), prophylactic antibiotics did not reduce the 
risk of FL. With effectiveness the same, a cost minimisation analysis yields a saving of 
28 Euro per patient. In ‘s-Hertogenbosch (NL), prophylactic antibiotics reduced the 
absolute risk of FL by 21% (down from 38%). It is also saved 892 Euro per patient.  
In both cases  antibiotics is the dominant strategy as it results at the same time in a risk 
reduction and lower costs. 
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Threshold and sensitivity analysis 
 
In the sensitivity and threshold analyses, numbers refer to incidences per cycle. 
Prophylaxis is cost-saving for the situation in Heidelberg (GE), in case of baseline risk 
for FL of more than 20% per cycle, or in case of a relative reduction in risk of FL of 
more than 71%, or costs of hospitalisation due to FL of more than 377 Euro per day or a 
hospital stay longer than 8 days, or in case of reduced costs of prophylaxis due to a unit 
cost price of less than 13 Euro per day or a shorter need for prophylaxis of less than 7 
days (Table 8). The figures for ‘s-Hertogenbosch (NL) are 6%, 20%, 231 Euro, 2 days, 
30 Euro and 27 days, respectively (Table 8), with better threshold levels. 
 
Table  8. Threshold analysis for NL and GE, based on rates from main clinical trial  
 
 
Parameter 
Base Case 
GEa 
Thresholds 
GEa 
Base Case 
NLb 
Thresholds 
NLb 
Probability FL     
 Baseline risk hospitalisation 0.15 0.20 0.15 0.06 
 Relative reduction in FL 0.53 0.71 0.53 0.20 
     
Hospitalisation due to FL     
 Cost /day (Euro) 280 377 625 231 
 Average duration (days per 
cycle) 
6 8 6 2 
     
Prophylaxis     
 Cost /day (Euro)  18 13 11 30 
 Duration (days per cycle) 10 7 10 27 
 
Formula cost-neutrality: (FL baseline risk x relative reduction) x (unit cost x days hosp.) = (unit 
cost x days prophylaxis); a based on incidence/duration FL per cycle seen in the main clinical 
trial (in bold) (n=161), while costs are based on prices seen in Heidelberg (Euro); b based on 
incidence/duration FL per cycle seen in the main clinical trial (in bold) (n=161), while costs are 
based on prices seen in ‘s-Hertogenbosch (Euro) 
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In addition, a three-way sensitivity analysis was conducted for the baseline risk per 
cycle for hospitalisation due to FL, the average cost of hospitalisation for FL and the 
cost of prophylaxis (Figure 1). Any combination in the area above a given threshold line 
favours prophylaxis on a cost basis. For example, with an average hospitalisation cost 
for FL of 4000 Euro, prophylaxis at the cost of 100 Euro would be cost-saving for all 
baseline risks, whereas with prophylaxis at the cost of 1000 Euro cost-savings occurs 
only at a baseline risk for FL of more than 47%. 
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Figure 1. Three-way sensitivity analysis based on rates of main clinical trial. The 
effectiveness of prophylaxis in reducing FL is assumed to be 53% per cycle. 
Threshold lines are displayed for different costs of prophylaxis (100-1000 
Euro) 
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Discussion 
 
To our knowledge, this is the first economic evaluation on cost-savings of prophylactic 
antibiotics. 
 
This prospective economic evaluation was performed in two centres, in GE and NL, that 
accrued together 82 (51%) patients in the first part of a double-blind placebo-controlled 
phase III trial evaluating the efficacy of prophylactic antibiotics during CDE 
chemotherapy in SCLC patients. Determining resource utilization and the associated 
unit costs meant site visits, thus it was not feasible from either a practical or funding 
perspective to visit all centres in the trial. It was demonstrated that with prophylactic 
antibiotics the incidence of FL, the number of documented infections, the use of 
therapeutic antibiotics and hospitalisations due to FL were decreased by approximately 
50%, with a reduced number of infectious deaths (6% versus 0%) [1].  
 
In GE, the use of prophylactic antibiotics was cost-neutral, while in NL prophylactic 
antibiotics incurred cost-savings of 2706 Euro (95% CI: 810 - 5948) per patient, that is 
605 Euro per cycle, demonstrating savings in favour of prophylactic antibiotics of 
nearly 45% of average costs in the placebo arm (Table 6).  
 
The different outcome per centre indicates that differences in clinical parameters (more 
LD in GE) and differences in patient management on the one hand and on the other 
hand differences in the financing mechanisms of the health care systems influence cost 
results. The sample size per centre is relatively small and chance may play a role. In ’s-
Hertogenbosch (NL) the clinical outcome was similar to the main trial. However, in 
Heidelberg (GE), the incidence of FL was more or less the same for both treatment 
arms. The results demonstrate that, even within the confines of a randomised clinical 
trial, co-incidence and medical practice variation can occur and may influence the 
clinical outcomes at a particular centre. Consequently, no difference in costs was 
observed in GE.  
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For this reason, we used the clinical parameters (baseline risk for FL, proportional 
reduction in FL, duration hospitalisation due to FL and duration prophylactic treatment) 
of the main trial, and not of one particular subgroup, for the sensitivity analyses. The 
numbers of the main trial are considered to be more accurate and more representative 
for the real efficacy of prophylactic antibiotics. The same method was used for the 
pivotal ‘G-CSF versus placebo’ trial [2], with an economic evaluation in a subgroup of 
patients [7], but with (frequently quoted) sensitivity analyses based on the results of the 
main clinical trial [6,7].  
 
In our phase III trial, we looked at the efficacy and costs of prophylactic antibiotics per 
patient. It is important to realize, what the exact meaning is of an incidence of FL of 
24% of patients in the prophylaxis arm. In fact, this rate indicates that at least one 
episode of FL occurred in 24% of patients, with most patients having had only one 
event, but some up to four events. This explains the lower incidence of FL of 7% per 
cycle, in the prophylaxis arm. For the sensitivity analysis, it was considered more 
appropriate to use the costs and numbers per cycle. Such an approach also enables 
extrapolation to other situations. The risk for a second or third FL event may be 
different from our observation, in patients with other types of tumors or treated with 
other chemotherapy regimens.  
 
In the sensitivity analyses only hospitalisations for FL (i.e., hospitalisation with at least 
one day of hospitalisation and FL) were included, for the sake of simplicity [5]. We 
accept that the threshold values are hereby underestimated, which is also stressed by 
others [9].  
 
Recently, it was reported that (out-patient) treatment of FL by oral broad-spectrum 
antibiotics may be feasible [10,11]. However, for patients already receiving 
prophylactic antibiotics the optimal choice of antibiotic treatment in the case of FL has 
not yet been clarified. Therefore, we did not implement this variable in our sensitivity 
analyses.  
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From a Health Insurance Perspective, total cost-savings largely depends on costs of 
hospitalisation versus those of prophylaxis. In the threshold analysis it is demonstrated 
that for the two countries, with the same baseline assumptions, the thresholds reflecting 
cost-neutrality are quite different. In GE the unit cost price of prophylaxis is higher 
while the unit cost price of hospitalisation is lower compared to NL, making 
prophylaxis for NL more cost-saving. 
 
The three-way sensitivity analysis clearly demonstrates that for costs of antibiotic 
prophylaxis of 500 Euro or less, cost-savings will incur over a broad range of baseline 
risks for FL, that is a risk above 10% to 20% for FL per cycle. The costs of antibiotic 
prophylaxis and hospitalisations will be in this range in most countries.  
 
Importantly, these sensitivity analyses indicate that the strategy of antibiotic prophylaxis 
may be useful, from a clinical and from a cost-benefit view point, for other regimens 
and other tumour types with an increased risk of FL. 
 
Prophylactic G-CSF is an alternative way of preventing FL or febrile neutropenia (FN). 
The efficacy of G-CSF and antibiotic prophylaxis appears to be comparable [1-3,12,13], 
although for G-CSF a reduction in infectious mortality has never been reported [2,3]. 
The ASCO recommended that primary administration of CSFs should be reserved for 
patients with an expected incidence of FN of at least 40% [14]. In our trial the overall 
incidence of FL in the placebo arm was not that high (25% in the first cycle and 15% 
over all cycles). This lower incidence is in line with what is reported by others [15,16], 
implying that for the majority of (SCLC) patients treated by standard-dose 
chemotherapy primary G-CSF prophylaxis may not be cost-saving. 
 
In fact, this 40% threshold remains somewhat confusing, as it was not based on clinical 
grounds [17]. This threshold was based on a sensitivity analysis [6], which used as 
parameters a 50% efficacy of G-CSF in preventing FN in the first cycle, an average cost 
of $10000 (11628 Euro) per hospitalisation for FN and an average cost of $2000 (2326 
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Euro) per cycle for G-CSF prophylaxis. With a baseline FN risk of 40% for the first 
cycle, 20 hospitalisations per 100 patients will be avoided and prophylaxis will be cost-
neutral. In case of FN > 40% cost-savings will incur. 
 
This threshold of 40% only holds true for the above used cost prices. However, the 
actual cost prices may vary enormously. The Canadian Coordinating Office for Health 
Technology Assessment estimated the costs of treating an episode of FN at US $6000 
(6980 Euro) [18]. With this lower hospitalisation price the use of G-CSF would be cost-
neutral when the risk of FN is 50.9%. Other studies reported hospitalisation costs of 
$4000 (3440 Euro) [16] and $7464 (8680 Euro) for 6 days hospitalisation due to FL 
[15]. In our study, we demonstrated also that applying the cost of one country (1680 
Euro for 6 days hospitalisation in GE) to another (3750 Euro for NL) underestimates the 
complexity of what determines such thresholds. In the reported economic analyses of G-
CSF [6,7,8,13,15,16], the cost of G-CSF was more than 1000 Euro per cycle. In general, 
with cost of prophylaxis of more than 1000 Euro, cost-savings will not occur in the 
range of baseline risks for FL as seen during standard-dose chemotherapy (Figure 1).  
 
Another important issue is that the published economic and sensitivity analyses 
concerning prophylactic G-CSF are all based on the risk of FN in the first cycle only, 
while prophylaxis will generally be continued to the end of chemotherapy. In SCLC, the 
incidence of FN / FL during the first cycle is in fact much higher than in the subsequent 
cycles [1-3]. In our trial, the risk for FL in the placebo arm was 25% for the first cycle, 
but only 15% when taking all cycles, including the first one, into account [1]. This 
declining risk through later cycles may be due to improved performance status, patient 
selection and tumour response with less risk for post-obstructive pneumonia. This may 
indicate that primary G-CSF or antibiotic prophylaxis in certain circumstances and with 
certain unit cost prices may be cost-effective for the first cycle but not necessarily for 
subsequent cycles. One may also hypothesize, that for lung carcinoma with an increased 
risk for pneumonia in the first cycle, the use of prophylaxis may be indicated for the 
first cycle only, while in other tumours treated by other chemotherapy regimens 
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prophylaxis may only be cost-effective during later cycles due to cumulative 
myelotoxicity. 
 
In conclusion, this is the first economic evaluation concerning prophylactic antibiotics 
versus placebo during chemotherapy, prospectively conducted alongside a multi-
national phase III trial. We demonstrated that prophylactic antibiotics during 
chemotherapy is the dominant strategy in both GE and NL, demonstrating both cost-
savings and superior efficacy. Moreover, we showed that pooling of resource use in 
multi-centre multinational clinical trials can not be recommended. We demonstrated 
that a sensitivity analysis is a valuable tool to place results in a broader perspective, 
enabling extrapolation to other institutions or other reimbursement systems. Sensitivity 
analysis may also prevent misinterpretation of results of economic evaluations based on 
results of a subgroup analysis. In this trial, the sensitivity analyses demonstrate that, due 
to the efficacy of prophylactic antibiotics and their low unit cost, cost-savings will incur 
over a broad range of baseline risks for FL. 
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Abstract 
Purpose: Dose-intensity (DI) of the cyclophosphamide-doxorubicin-etoposide (CDE) 
regimen can almost be doubled by combining dose size increase and chemotherapy 
acceleration with the addition of G-CSF. The present multi-centre randomised study 
was designed to assess the impact of  such a DI increase on survival in SCLC patients.  
Patients and methods: SCLC patients with no prior treatment, ECOG performance 
status (PS) 0-1, 18-70 years were randomised to standard CDE (C 1000mg/m2 on day 1,  
D 45mg/m2 on day 1, E 100mg/m2  on days 1-3, q 3 weeks, 5 cycles) or intensified CDE 
(C 1250mg/m2 on day 1, D 55mg/m2 on day 1, E 125mg/m2  on days 1-3 with G-CSF 5 
µg/kg/day days 4-13, q 2 weeks, 4 cycles). Projected cumulative dose was almost 
identical in the two arms, whereas projected DI was nearly 90% higher in the intensified 
arm. In total, 244 pts were enrolled. The first 163 patients were also randomised (2x2 
factorial design) to prophylactic antibiotics or placebo to assess their impact on 
preventing febrile leukopenia (FL). This second randomisation was prematurely closed 
after an interim analysis showed a 50% reduction in incidence of FL by the use of 
antibiotic prophylaxis. Antibiotics were given to all patients for the remainder of the 
study. This report focuses on results concerning the impact of DI increase on survival.  
Results: With a median follow-up of 54 months, 216 deaths have occurred. Main 
patient characteristics were well-balanced in the two arms. Overall, median age was 59 
years, 57% had limited disease (LD) and 39% had PS 0. Actually delivered DI in the 
intensified arm was 70% higher than in the standard arm. Intensified CDE was 
associated with more grade 3-4 thrombocytopenia (70% versus 24%), anaemia (45% 
versus 21%) and mucositis (9% versus 2%). The incidence of FL and toxic deaths was 
similar in the two arms. Objective response rate was 79% for the standard arm and 84% 
for the intensified arm (P=0.315). Median survival was 54 weeks and 52 weeks, and 2-
year survival rate was 15% and 18%, respectively (P=0.885).  
Conclusion: A 70% increase of CDE actual DI, obtained by means of dose size and 
dose density increase with G-CSF support, does not translate into an improved outcome 
in SCLC patients. 
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Introduction 
 
Combination chemotherapy represents the mainstay of small cell lung cancer (SCLC) 
treatment [1]. Despite many years of intensive research, the role of chemotherapy dose-
intensification, as a way to improve the prognosis of SCLC, remains controversial. 
Classical high-dose chemotherapy plus autologous bone marrow transplant has been 
abandoned due to excessive toxicity and contradictory results [2], although recent 
developments in blood products have generated a renewed interest in this field [3,4]. 
Moderate chemotherapy dose increase has led to conflicting results [5-7] and maintaining 
standard full dose, by avoiding dose-reduction with prophylactic G-CSF, has not been 
shown to produce any significant survival benefit [8,9]. In 1984, Hryniuk & Bush [10] 
developed the concept of “dose-intensity (DI)”, defined as the amount of chemotherapy 
delivered per unit time, as a better instrument to correlate intensity of chemotherapy with 
the clinical outcome. A number of retrospective studies confirmed that chemotherapy DI 
correlates with objective response and survival in several solid tumours and 
haematological malignancies [11]. The concept of DI implies that chemotherapy 
intensification can be achieved either by increasing dose size, i.e., the dose of 
chemotherapy per cycle (high-dose chemotherapy) or by increasing dose density, i.e., 
shortening intervals between doses (dose-dense or accelerated chemotherapy). With the 
prophylactic use of myelopoeietic growth factors, chemotherapy intervals can be 
shortened by about 30%, thereby increasing DI by nearly 50%, in many tumour types and 
with different chemotherapy regimens [12-15]. 
In a retrospective study, chemotherapy DI has been shown to correlate with survival 
outcome in SCLC, particularly in extensive disease (ED) patients treated with 
cyclophosphamide-doxorubicin-etoposide (CDE) [16]. The CDE chemotherapy regimen 
is widely used in Europe to treat SCLC and has long been considered as the standard 
reference regimen by the EORTC Lung Cancer Group (LCG) [17]. 
In a pilot study of our group [18], it was feasible to deliver a 25% higher CDE dose 
every 2 weeks (instead of the usual CDE regimen every 3 weeks) with the support of 
prophylactic G-CSF, on an outpatient basis. The present multi-centre randomised study 
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was designed to assess the impact of such a DI increase on survival of previously 
untreated SCLC patients. 
 
Patients and methods 
 
Patient selection  
Patients had to meet all the following inclusion criteria: histological or cytological 
diagnosis of SCLC, presence of ED or limited disease (LD), measurable or assessable 
disease, no prior chemotherapy, ECOG performance status (PS) 0-1, age between 18-70 
years, ability to undergo protocol treatment, white blood cell counts (WBC) ≥ 4 x 109/l, 
platelets (PLT) ≥ 100 x 109/l, haemoglobin (Hgb) ≥ 6.0 mmol/l, creatinine ≤ 140 µmol/l 
and bilirubin < 35 µmol/l.  
Patients were excluded in case of symptomatic cerebral metastases, active infection or 
fever ≥ 38.3oC, uncontrolled hypertension, symptomatic cardiovascular disease within 3 
months prior to enrolment, previous malignancy, except for basal or squamous cell skin 
carcinoma or adequately treated carcinoma in situ of the cervix, any evidence or history 
of hypersensitivity or other contraindications for the drugs used in this trial. The 
investigational protocol was approved by the EORTC Protocol Review Committee and 
by the ethical committee of each participating institution. Written informed consent was 
obtained from each patient according to the national regulations.  
For each patient, baseline evaluation consisted of medical history, physical examination, 
laboratory investigations, chest X-ray, CT-thorax, CT-scan or ultrasound of upper 
abdomen, bronchoscopy and bone scan. As soon as a measurable or evaluable lesion 
was detected to diagnose ED, no further investigations were required by the protocol. In 
case of unexplained thrombocytopenia or leukopenia a bone marrow biopsy had to be 
performed to rule out bone marrow metastases. 
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Study design 
In this phase III trial, SCLC patients were randomised to standard or intensified 
chemotherapy to assess the impact of DI increase on survival. Secondary endpoints 
were response rate and risk of toxic deaths. Although not pre-defined as an endpoint by 
the protocol, the impact of DI increase on progression free survival, defined as the 
interval between randomisation and disease progression or death, was also assessed. 
The first 163 patients were also randomised, with a 2x2 factorial design, to prophylactic 
antibiotics (ciprofloxacin 750mg plus roxithromycin 150mg, bid, days 4-13) or placebo. 
The primary endpoint of this comparison was the incidence of febrile leukopenia (FL) 
in the first chemotherapy cycle. The antibiotic-placebo randomisation was prematurely 
stopped following the recommendation of an Independent Data-Monitoring Committee 
(IDMC), as an interim analysis showed a 50% reduction in the incidence of FL by the 
use of prophylactic antibiotics. Thereafter, all patients enrolled in both standard and 
intensified chemotherapy arm received prophylactic antibiotics (ciprofloxacin and 
roxithromycin). The results of the antibiotic comparison in this trial have been reported 
elsewhere [19].  
We report here the final results concerning the impact of DI increase on the clinical 
endpoints.  
 
Chemotherapy regimen  
Standard CDE chemotherapy consisted of cyclophosphamide 1000 mg/m2 on day 1, 
doxorubicin 45 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1-3, intravenously, 
every three weeks for five cycles. Intensified CDE chemotherapy consisted of 
cyclophosphamide 1250 mg/m2 on day 1, doxorubicin 55 mg/m2 on day 1 and etoposide 
125 mg/m2 on days 1-3, intravenously, every two weeks for four cycles [18].  The total 
dose of chemotherapy was approximately the same in both arms, but the planned DI 
was nearly 90% higher in the intensified arm. Chemotherapy was discontinued earlier in 
case of progressive disease, treatment failure, patient refusal or unacceptable toxicity.  
Blood counts were measured on days 8, 12, 15, 19, and 22 during standard CDE and on 
days 8, 12, and 15 during intensified CDE. Dose adjustments were based on day 1 blood 
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counts and on WBC and/or PLT nadir. Full dose chemotherapy was given in case of 
WBC counts > 3.0 x 109/l and PLT counts > 100 x 109/l at day 1 of every cycle.  
In the standard arm, the treatment was delayed for one week in case of WBC counts less 
than 2.0 x 109/l and/or PLT counts less than 75 x 109/l, and a 50% dose reduction was 
given in case of WBC counts between 2 - 3 x 109 /l and PLT counts between 75 - 100 x 
109/l on day one. For nadir WBC counts of less than 0.5 x 109/l and/or nadir PLT counts 
less than 25 x 109/l, the doses of all drugs had to be reduced to 75% in subsequent 
cycles.  
In the intensified arm, treatment was delayed in case of low day one blood counts. 
However, in case of reduced WBC counts (2 - 3 x 109/l) and/or PLT counts (75 - 100 x 
109/l) after one to two weeks delay, a 50% dose-reduction was applied. No dose-
reductions were allowed for nadir blood values, unless there was grade 4 
haematological toxicity for more than seven days or in case of serious complications 
like bleeding due to thrombocytopenia. In this case, a 25% dose reduction was 
prescribed. For nadir WBC counts of less than 1.0 x 109/l and/or nadir PLT counts of 
less than 25 x 109/l, lasting for over 14 days, protocol treatment was discontinued. 
G-CSF 
In the intensified arm, G-CSF (filgrastim) was given on days 4-13 at a dose of 300 
µg/day if body weight was ≤ 75 kg and at a dose of 5 µg/kg/day if body weight was > 
75 kg.  
 
 
Post-treatment procedures  
All abnormal pre-treatment investigations had to be repeated, except for bone scan, at 
the end of treatment. Repeated bronchoscopy was not required to confirm a radiological 
complete response (CR).  
Sequential thoracic radiation therapy in responding LD patients at the end of 
chemotherapy was allowed, provided that each institute had to follow one strategy 
throughout the study. Prophylactic cranial irradiation at the end of chemotherapy in case 
of CR in LD patients was also allowed according to institutional policy. 
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Patients were followed every 6 weeks by physical examination and chest X-ray. In case 
of progression, radiotherapy or second-line systemic therapy were allowed. In case of 
relapse more than 3 months after the last chemotherapy cycle, re-induction with 
standard-dose CDE was recommended. In case of relapse within 3 months, the use of 
second-line therapy was left to the discretion of the responsible physician.  
 
Statistical considerations   
For sample size estimation, it was calculated that a total of 192 deaths would permit the 
detection of an increase in median survival from 52 weeks in the standard CDE arm to 
78 weeks in the intensified CDE arm at a two-sided significance level of 5% and with a 
power of 80%. This corresponds to an increase in one-year survival from 50% to 63%. 
A total of 240 patients (60 in each strata) needed to be randomised to obtain this number 
of events. 
Randomisation was performed using the minimization technique, stratifying patients 
according to institution, age (≤ 60 years versus > 60 years) and stage of disease (LD 
versus ED) [20].  
The original protocol did not plan an interim analysis. However, after 163 patients were 
randomised and concerns were raised with respect to differences in the incidence of FL 
between the trial arms, the group decided to perform an unplanned interim analysis. 
This interim analysis investigated only the second question of the trial (impact of 
antibiotics versus placebo on the incidence of FL). The results were submitted to an 
IDMC, which recommended to prematurely close the antibiotic versus placebo part of 
the protocol on ethical grounds. Following this recommendation, the protocol was 
amended to become a two-arm study (intensified versus standard CDE) with all patients 
in both arms receiving prophylactic antibiotics. 
The trial was analysed as a 2 x 2 factorial design. Thus, for all statistical comparisons 
the effect of CDE DI was analysed after stratification for the type of prophylaxis (verum 
or placebo antibiotics). Based on the ‘intent-to-treat’ principle, all analyses included all 
patients according to the treatment arm they were allocated to by randomisation 
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irrespective of the treatment they actually received. All tests used in this report are two-
sided tests. 
DI was defined as the amount of drugs delivered per unit time (mg/m²/week) [10]. The 
actually delivered DI was calculated as the ratio of the total dose (mg) per m² actually 
received by the patient divided by the actual total treatment duration expressed in 
weeks. In this calculation, the end of treatment duration is considered to be 3 weeks 
(standard arm) or 2 weeks (intensified arm) after day 1 of the last cycle of 
chemotherapy received. The relative DI was calculated as the ratio of the actually 
delivered DI to the DI planned by the protocol. 
Overall survival and progression free survival analyses were performed by the Kaplan-
Meier technique [21]. Differences in survival between the two regimens (intensified 
versus standard) were tested for statistical significance using the two-sided log rank test 
at the 5% significance level. To adjust for any confounding variables, retrospective 
stratification and Cox’s regression analysis were performed in an exploratory spirit [22]. 
The Cox’s regression model was used with a two-sided test at the 5% significance level 
to test the prognostic value of each variable. A step-down variable selection procedure 
was used for building the multivariate model.  
Overall response rates (complete and partial), as secondary endpoint, have been 
compared between the two regimens (intensified versus standard) with the Cochran-
Mantel-Haenszel statistic. According to the protocol, incidence of toxic deaths should 
have been compared by using the log rank test. However, since only few toxic deaths 
occurred, comparisons by means of the Cochran-Mantel-Haenszel test have been 
performed instead.  
Although not foreseen in the protocol, the rates of grade 3-4 toxicity in the two 
treatment arms were compared, using a stratified exact Wilcoxon-Mann-Whitney test. 
However, for most of the toxicity items only a low rate of grade 3-4 toxicity was 
observed in this study and, therefore, no P-values could be computed for these items. 
Reported P-values, concerning differences in most frequent grade 3-4 toxicities, should 
be interpreted with caution in view of the multiple comparisons an the lack of sufficient 
power. 
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Results 
 
Patients 
From October 1994 to May 1999, a total of 244 patients were enrolled by 16 European 
institutions. Among these, 119 patients (49%) were randomised to receive standard dose 
CDE (80 patients receiving additional antibiotics and 39 patients receiving additional 
placebo), whereas 125 patients (51%) were randomised to receive intensified CDE (84 
patients receiving additional antibiotics and 41 patients receiving additional placebo). 
One patient in the standard arm was considered ineligible due to an incorrect diagnosis. 
According to the intent-to-treat principle, this patient was included in all analyses and in 
all tables. Another patient was randomised twice due to a program error and therefore 
the second randomisation was excluded from all analyses and tables. Main patient 
characteristics are shown in Table 1. The two arms were well-balanced in terms of 
baseline clinical characteristics and laboratory data (latter not shown). Briefly, most 
patients were males, median age was 59 years, 61% had PS 1 and 57% had LD. 
 
Table 1. Patient characteristics at baseline 
 Standard 
CDE 
n=119 (%) 
Intensified 
CDE 
n=125 (%) 
Age (years)   
median 
(range) 
59 
(33-69) 
59 
(35-70) 
Sex   
male 
female 
84 (71) 
35 (29) 
88 (70) 
37 (30) 
ECOG PS   
0 
1 
41 (35) 
78 (66) 
53 (42) 
72 (58) 
Disease Status   
LD 
ED 
70 (59) 
49 (41) 
70 (56) 
55 (44) 
Weight loss over last 3 months (%) 
≤ 5% 
>5% 
 
65 (66) 
33 (34) 
 
71 (72) 
28 (28) 
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Delivered chemotherapy 
Approximately 80% of patients in both arms completed the planned number of cycles, 
i.e., 5 cycles in the standard CDE chemotherapy arm and 4 cycles in the intensified 
CDE chemotherapy arm (Table 2). The median number of cycles received was 5 (range 
1-6) in the standard arm and 4 (range 1-6) in the intensified arm. Although the reasons 
for discontinuation of protocol treatment were largely comparable for both treatment 
arms, more patients stopped treatment for progressive disease in the standard arm (8% 
versus 2%), and more patients stopped protocol treatment because of toxicity (3% 
versus 6%) in the intensified arm. 
 
 
Table 2. Reasons for discontinuation of protocol treatment 
 Standard 
CDE 
n=119 (%) 
Intensified 
CDE 
n=125 (%) 
 
Completion of protocol 
Patient refusal 
Protocol violation 
Progressive disease 
Toxicity 
Early death, malignancya 
Early death, toxicitya 
Early death, othera 
Other 
 
94 (79) 
2 (2) 
3 (3) 
9 (8) 
4 (3) 
0 (0) 
3 (3) 
1 (1) 
3 (3) 
 
101 (81) 
4 (3) 
0 (0) 
3 (2) 
8 (6) 
1 (1) 
4 (3) 
0 (0) 
4 (3) 
 
a Early death is defined as death occurring within 6 weeks from randomisation 
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Dose reductions were used in approximately 10% of patients per cycle, in both arms 
(Table 3a), while treatment delay was more often applied in the intensified arm 
compared to the standard arm. The main reason for dose-modification was 
haematological toxicity, especially thrombocytopenia. 
 
Table 3a. Delivered chemotherapy 
 
 
Treatment modification 
Standard 
CDE 
n=119 (%) 
Intensified 
CDE 
n=125 (%) 
   
Cycle I   
 Reduction 
Delay 
Not given 
2 (2) 
1 (1) 
3 (2) 
1 (1) 
Cycle II   
 Reduction 
Delay 
Not given 
12 (10) 
20 (17) 
6 (5) 
13 (10) 
33 (26) 
8 (6) 
Cycle III   
 Reduction 
Delay 
Not given 
7 (6) 
13 (11) 
13 (11) 
10 (8) 
49 (39) 
17 (14) 
Cycle IV   
 Reduction 
Delay 
Not given 
6 (5) 
16 (13) 
14 (12) 
15 (12) 
56 (45) 
22 (18) 
Cycle V   
 Reduction 
Delay 
Not given 
11 (9) 
20 (17) 
23 (19) 
0 (0) 
1 (1) 
124 (99) 
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Table 3b. Delivered chemotherapy 
 
 
 
Standard 
CDE 
n=119  
Intensified 
CDE 
n=125 
Actually delivered DI (mg/m²/week) 
median (range) 
  
 
 
 
cyclophosphamide 
doxorubicin 
etoposide 
330 (178-556) 
15 (6-24) 
99 (53-167) 
568 (309-660) 
25 (13-30) 
169 (61-198) 
Planned DI (%) 
median (range) 
 
 
 
 
 
 
 
cyclophosphamide 
doxorubicin 
etoposide 
99 (53-167) 
99 (38-163) 
99 (53-167) 
91 (50-106) 
91 (48-110) 
90 (33-106) 
 
Delivered cumulative dose (mg/m²) 
median (range) 
  
 cyclophosphamide 
doxorubicin 
etoposide 
4974 (971-5750) 
222 (44-258) 
1492 (291-1725) 
4964 (1211-5848) 
217 (53-257) 
1489 (123-1754) 
 
 
The median relative DI for cycles actually delivered was 99% (range 53% - 167%) of 
planned for the standard CDE arm and 90% (range 50% - 106%) of planned for the 
intensified arm (Table 3b). For each drug, the actually delivered DI in the intensified 
arm was about 70% higher than that of the standard arm. For each drug, the median 
delivered cumulative dose in the intensified arm was comparable to that of the standard 
arm. 
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Toxicity 
The worst overall toxicity during all cycles is demonstrated in Tables 4a and 4b.  
Myelosuppression was more severe in patients treated with intensified chemotherapy 
(Table 4a). While overall incidence of grade 3-4 leukopenia was similar (over 90%) in 
the two arms, grade 4 toxicity (WBC < 1.0 x 109/l) occurred in 50% of patients in the 
standard-dose arm compared to 79% of patients in the intensified arm, despite the use of 
prophylactic G-CSF in this arm. The incidence of grade 3-4 thrombocytopenia and 
anaemia was also higher for the intensified arm: 70% versus 24% (P<0.001) and 45% 
versus 21% (P<0.001), respectively. The median WBC nadir over all cycles was 1.0 x 
109/l (range 0.1-4.2 x 109/l) in the standard arm versus 0.5 x 109/l (range 0-13.5 x 109/l) 
in the intensified arm, with a median duration of grade 4 leukopenia episodes of 3 days 
in both arms. Thrombocyte nadirs were 84 x 109/l (range 1-280 x 109/l) in the standard 
arm versus 27 x 109/l (range 0-273 x 109/l) in the intensified arm. Hgb nadir was 5.7 
mmol/l (range 1.8 - 8.9 mmol/l) in the standard arm versus 4.9 mmol/l (range 2.9 - 9.2 
mmol/l) in the intensified arm. Forty-one patients (34%) in the standard arm and 89 
patients (71%) in the intensified arm received at least one transfusion (red cell or 
platelet or whole blood) during chemotherapy treatment. 
FL occurred at least once in 24% of patients treated with standard-dose CDE 
chemotherapy versus 34% of patients treated with intensified CDE chemotherapy 
(P=0.102). 
Non-haematological toxicities were generally mild and similar in the two arms (Table 
4b). However, more patients in the intensified arm suffered from severe stomatitis / 
mucositis (P=0.024). 
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Table 4a. Worst haematological toxicity (NCIC-CTC grade 3-4, per patient) 
 Standard 
CDE 
n=119 (%) 
Intensified 
CDE 
n=125 (%) 
 
White Blood Cell a 
3 
4 
 
 
50 (42) 
59 (50) 
 
 
20 (16) 
99 (79) 
 
Platelet b 
3 
4 
 
 
16 (13) 
13 (11) 
 
 
33 (26) 
55 (44) 
 
Haemoglobin c 
3 
4 
 
 
19 (16)  
6 (5) 
 
 
51 (41) 
5 (4) 
 
Note: P-values in comparisons of grade 3-4 toxicity of standard versus intensified CDE:  
a P=0.380;  b P<0.001; c P<0.001 
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Table 4b. Worst non-haematological toxicity (NCIC-CTC grade 3-4, per patient) 
 Standard 
CDE 
n=119 (%) 
Intensified 
CDE 
n=125 (%) 
Febrile leukopenia a 
yes 
 
28 (24) 
 
42 (34) 
Haemorrhage   
3 
4 
0 (0) 
0 (0) 
1 (1) 
2 (2) 
Flu-like symptoms 
3 
 
0 (0) 
 
2 (2) 
Renal and Bladder 
3 
 
0 (0) 
 
2 (2) 
Anorexia 
3 
 
0 (0) 
 
4 (3) 
Nausea b 
3 
 
2 (2) 
 
7 (6) 
Vomiting c 
3  
4 
 
1 (1) 
1 (1) 
 
8 (6) 
0 (0) 
Stomatitis-mucositis d 
3 
 
2 (2) 
 
11 (9) 
Diarrhoea 
3 
 
0 (0) 
 
3 (2) 
Liver 
3 
 
2 (2) 
 
2 (2) 
Cardiac 
3 
4 
 
0 (0) 
1 (1) 
 
1 (1) 
2 (2) 
Pulmonary 
3 
4 
 
2 (2) 
1 (1) 
 
0 (0) 
3 (2) 
Neurological 
3 
 
2 (2) 
 
1 (1) 
Others 
3 
4 
 
2 (2) 
1 (1) 
 
7 (6) 
2 (2) 
 
Note: P-values in comparisons of grade 3-4 toxicity of standard versus intensified CDE:  
a P=0.102;  b P<0.195; c P<0.119; d P<0.024 
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Other therapies after protocol treatment 
After first-line CDE chemotherapy, further anticancer therapy was reported for 84% of 
patients in the standard-dose arm and for 86% of patients in the intensified arm. 
However, detailed information about type and compliance of further treatment was not 
prospectively collected. Chest radiotherapy was given in 54% and 52% of patients, 
respectively. Prophylactic brain radiotherapy in 19% and 20% of patients, respectively. 
Radiotherapy for progressive disease was given in 51% and 43% of patients, 
respectively. Maintenance therapies were given in 8% and 7% of patients. 
 
Efficacy  
Table 5 summarizes responses by treatment arm. There was no significant difference 
between the 2 arms. After a median follow-up of 49 months for the patients in the 
standard arm and 57 months for the patients in the intensified arm, 107 (90%) and 109 
(87%) patients have died, respectively. Ninety-five (89%) versus 96 (88%) patients died 
from progressive disease. At the time of the analysis, 102 patients (86%) in the standard 
arm and 103 (82%) in the intensified arm had progressed. Toxic death was observed in 
three (3%) patients in the standard CDE arm, and in six (5%) patients in the intensified 
arm (P=0.346). Seven of these nine patients died from an infectious cause, three in the 
standard and four in the intensified arm, with five being randomised to placebo 
antibiotics and two to verum antibiotics. In addition, three patients in the standard arm 
and one patient in the intensified arm died from cardiovascular disease. In both arms, 
six other patients died from various causes. 
The median survival time was 54 weeks (95% CI: 47 - 63 weeks) in the standard arm 
versus 52 weeks (95% CI: 45 - 61 weeks) in the intensified arm (P=0.885), with a two-
year survival rate of 15% and 18%, respectively (Figure 1). 
The median progression free survival was 34 weeks (95% CI: 30-38 weeks) in the 
standard arm versus 31 weeks (95% CI: 27-34 weeks) in the intensified (P=0.680). One 
and 2-year progression free survival were, respectively, 24% (95% CI:17-32%) and 9% 
(95% CI: 4-14%) in the standard arm and 22% (95% CI: 15-29%) and 12% (95% CI: 6-
18%) in the intensified arm. 
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Table 5.  Efficacy of chemotherapy 
 
Standard 
CDE 
n=119  
Intensified 
CDE 
n=125  
P-value 
Response    
Number complete response (%) 30 (25) 26 (21)  
Number partial response (%) 64 (54) 79 (63)  
Number no change (%) 14 (12) 9 (7)  
Number overall response (%) 94 (79) 105 (84) 0.315b 
 (95% CI) (72 – 86) (78 – 90)  
    
Survival    
Number of toxic deaths (%) 3 (3) 6 (5) 0.346b 
Number of deathsa (%) 107 (90) 109 (87)  
Median survival (weeks) 54 52 0.885c 
 (95% CI) (47-63) (45-61)  
Two-years survival (%) 15 18  
 (95% CI) (8-22) (11-26)  
 
a Median follow-up: 49 months and 57 months for standard and intensified arm, respectively; b 
Stratified Cochran-Mantel-Haenszel test; c Stratified log rank test 
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Figure 2.  Overall survival by chemotherapy regimen 
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Prognostic factors for survival 
Factors included in the multivariate Cox proportional hazards model for overall survival 
were age (≤ 60 versus > 60 years), weight loss (≤ 5% versus > 5%), disease status (LD 
versus ED), PS (0 versus 1), antibiotics (placebo versus verum), chemotherapy regimen 
(standard versus intensified) and a term for interaction between chemotherapy and 
antibiotics treatment (Table 6). The step-down variable selection procedure removed 
from this model the antibiotics (P=0.627), the interaction term (P=0.467), PS 
(P=0.550), the chemotherapy regimen (P=0.539), age (P=0.311) and weight loss 
(P=0.068).  
The final multivariate model indicated that having ED is the only prognostic factor for a 
worse survival (hazard ratio 2.083 (95%CI: 1.583-2.741); P<0.0001). The median 
survival time in LD patients was 63 weeks (95% CI: 60 – 77 weeks), and about 4 
months shorter in ED (median 46 weeks, 95% CI: 38-46 weeks). The two and three year 
survival rate were respectively 26% (95% CI: 18 – 33%) and 19% (95% CI: 12 – 26%) 
in the LD and 5% (95% CI: 1 – 10%) and 3% (95% CI: 0 – 7%) in the ED. After 
adjustment for extent of disease (LD versus ED), the effect of dose intensification on 
survival remained non-significant. 
In fact, in patients with LD median survival was 62 weeks (95% CI: 50-67 weeks) for 
those treated with standard chemotherapy (59 deaths per 70 patients) versus 77 weeks 
(95% CI: 61-87 weeks) for those treated with intensified chemotherapy (55 deaths per 
70 patients). In patients with ED the corresponding figures were 51 weeks (95% CI: 36-
57 weeks) for those treated with standard chemotherapy (48 deaths per 49 patients) 
versus 40 weeks (95% CI: 36-50 weeks) for those treated with intensified chemotherapy 
(54 deaths per 55 patients). 
The fact that the interaction between chemotherapy and antibiotics treatment has not 
been found to be significant was expected due to the insufficient power to test this 
interaction. These results seems to confirm that the chemotherapy DI is not a prognostic 
factor for overall survival.  
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Table 6. Baseline prognostic factors for survival, all included in the Cox PH model 
 
Prognostic factor 
Deaths /  
No. pts 
(%) HR 95% CI P-value 
Age      
≤ 60 yearsa 
> 60 years 
117/134 
99/110 
(87) 
(90) 
1 
1.181 
 
(0.873-1.600) 
 
0.2807 
Weight loss      
≤ 5%a 
>5% 
116/136 
57/61 
(85) 
(93) 
1 
1.407 
 
(1.015-1.950) 
 
0.0406 
Disease status      
LDa 
ED 
114/140 
102/104 
(81) 
(98) 
1 
2.173 
 
(1.588-2.976)  
 
<0.0001 
Performance status      
0a 
1 
86/94 
130/150 
(92) 
(87) 
1 
0.884 
 
(0.641-1.220) 
 
0.4546 
Antibiotics      
Placeboa 
Verum 
76/80 
140/164 
(95) 
(85) 
1 
0.894 
 
(0.568-1.406) 
 
0.6274 
Chemotherapy      
Standarda 
Intensified 
107/119 
109/125 
(90) 
(87) 
1 
0.740 
 
(0.431-1.271) 
 
0.2794 
Interaction     0.3883 
a Reference category; HR: Hazard Ratio 
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Discussion 
 
This is the first prospective randomised trial assessing the impact of chemotherapy 
dose-intensification obtained by means of both dose size and dose density increase in 
patients with SCLC. In the experimental arm of this study, planned CDE chemotherapy 
dose size was 25% higher and chemotherapy dose density was 33% higher, resulting in 
an overall planned DI increase of nearly 90% compared to standard CDE chemotherapy 
arm. Due to more frequent dose reductions, delays and omissions in the intensified 
chemotherapy arm, delivered CDE DI turned out to be actually only 70% higher in this 
arm as compared to standard CDE arm. Increasing delivered CDE DI by augmenting 
both dose size and dose density, with the support of prophylactic G-CSF and antibiotics, 
proved to be feasible in the context of this multi-centre European trial. However, in our 
study, such a chemotherapy dose intensification did not lead to a significant 
improvement in either response rate or survival, but only led to an increased 
haematological and non-haematological toxicity.  
 
The sample size of this trial allowed us to detect a 50% difference in median survival 
with a 80% power. Although a 50% increase in median survival could be regarded as a 
too optimistic expectation, the level of planned dose intensification (almost double 
compared to standard chemotherapy) and the significant increase of toxicity and costs 
related to growth factors and antibiotics prophylaxis, led us to conclude that only a 
major improvement in survival would have justified the introduction into clinical 
practice of this experimental regimen. 
 
The role of chemotherapy dose intensification in SCLC has been so far controversial. In 
fact,  although retrospective data support a correlation between DI and survival, at least 
in patients with ED treated with CDE [16], results of most important prospective 
randomised trials are conflicting.  
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Studies assessing the impact of moderate dose size increase have been largely negative. 
Ihde et al. [5] compared standard cisplatin/etoposide (PE) versus dose intensified PE 
with a planned dose size increase of nearly 70% in 90 patients with previously untreated 
ED SCLC. PE dose size intensification did not translate into a significant clinical 
benefit in that study. Similarly, negative results were also obtained in a Southeastern 
Cancer Study Group trial of 298 ED SCLC patients assessing the impact of a 20% and a 
75% dose size increase of cyclophosphamide and doxorubicin, respectively, within the 
CAV regimen [6]. Pujol et al. [23], sought to assess the impact of a 50% dose size 
increase of a four-drug chemotherapy regimen including cyclophosphamide, 
epidoxorubicin, etoposide and cisplatin in 125 patients with ED SCLC. Surprisingly, 
patients in the intensified arm had a worse outcome than patients in the standard-dose 
arm. However, in this study, the role of dose intensification could not be properly 
assessed since GM-CSF failed to allow the delivery of the planned total dose and dose 
intensification. The only study showing a significant benefit associated with dose size 
increase in SCLC is a French trial including 105 patients with LD SCLC where, 
surprisingly, a 25% increase in chemotherapy dose during the first cycle only led to a 
statistically significant survival improvement [7]. 
 
The other approach to increase DI, i.e., chemotherapy acceleration also referred to as 
‘dose dense’ chemotherapy, has been more successful. Steward et al. assessed the 
impact of a 25% increase of V-ICE chemotherapy planned DI by reducing the interval 
between cycles from 4 to 3 weeks, with or without GM-CSF support [24]. Accelerated 
V-ICE was found to be associated with a statistically significant 25% improvement in 
median survival. A similar study conducted by the British MRC yielded the same 
outcome [25]. In this trial 403 SCLC patients were randomised between CDE recycled 
at standard 3-week intervals and accelerated CDE recycled every 2 weeks, 
corresponding to a planned DI increase over the standard of 33%. Also in this study, 
chemotherapy acceleration was associated with a statistically significant survival 
improvement. However, the relative gain in 1-year survival with the intensified 
treatment was only 5%. Conversely, a recently published 3-arm study from the 
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European Lung Cancer Working Party, assessing the role of an accelerated epirubicin-
vindesine-ifosfamide regimen with GM-CSF or co-trimoxazole in 233 ED-SCLC 
patients, failed to show any survival improvement associated with dose-dense 
chemotherapy [26]. 
 
The reason for these contradictory results among studies with a similar design is 
unclear. A possible confounding factor in our trial, which is the only one using a 
combination of dose size and dose density increase to achieve maximum chemotherapy 
DI, might be the use of a 2x2 factorial design in the attempt to answer two different 
questions at once (impact of DI on survival and impact of antibiotic prophylaxis on FL). 
The antibiotic part of our study showed a clear benefit in favour of antibiotic 
prophylaxis in reducing not only FL, but also associated complications such as 
documented infections, hospital admissions and septic deaths. The benefit of antibiotic 
prophylaxis was particularly evident in patients receiving dose-intensified 
chemotherapy [19]. This result suggests a possible interaction between dose 
intensification and antibiotic prophylaxis, which might have compromised the validity 
of results achieved in this second part of the trial. However, we have no power to test 
this possible interaction and the multivariate analysis performed to assess factors 
associated with survival outcome indicated a non-significant effect of antibiotic 
prophylaxis as an interaction factor. 
In conclusion, increasing CDE DI by nearly 70%, by means of a combination of dose 
size and dose density increase, did not produce any significant survival benefit 
compared to conventional dose and schedule. The results of the present study do not 
allow us to replace full-dose 3-weekly CDE chemotherapy with intensified CDE 
chemotherapy, as standard regimen for the treatment of SCLC. Given the discrepancy in 
results from similar studies investigating chemotherapy dose-intensification for SCLC, 
a meta-analysis of all studies so far conducted would be helpful in further clarifying this 
issue and in excluding a possible small benefit associated with chemotherapy dose-
intensification which might be undetectable in the context of a single average size 
prospective trial. 
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Abstract 
 
Background: The survival in untreated small cell lung cancer (SCLC) is less than 3 
months. Prognosis has improved with chemotherapy, but remains poor. One of the 
issues concerning current chemotherapy is whether there is any benefit of increasing 
chemotherapy dose or dose-intensity (DI).  
Design: In the present review, 20 randomised studies published in the period 1980-
2001, in which dose or DI of chemotherapy in SCLC were the only variables tested, are 
analysed. The studies were categorised as follows: 1. number of cycles (treatment 
duration), 2. dose per cycle, 3. interval between cycles (dose-densification), and 4. a 
combination of these variables.  
Results: 1. With reduced treatment duration to 3-6 cycles, median survival time (MST) 
was two months shorter, most evident in patients showing a (complete) response to 
initial chemotherapy. 2. An improved survival was observed in two out of five high-
dose studies. 3. Survival was increased with 0.6 to 6.2 months in all four densification 
studies. 4. Survival was not improved in studies that used dose-escalation and/or –
densification in combination with a reduced number of cycles. The sample sizes were 
too small in most of the individual trials to be conclusive. The median of the MST of 
the patients in the 20 trials taken together was 9.8 months for the standard arms and 
11.5 months for the intensified arms (i.e., more cycles, higher dose per cycle and/or 
shorter intervals). After omitting the two trials with reduced number of cycles in the so-
called ‘high-dose’ arm, the median of MSTs was 8.7 and 11.5 months, respectively. 
There was only a slight improvement in 2-year survival of 1% for all trials taken 
together. However, when only taking high-dose and dose-densified chemotherapy trials 
into account, the difference in median 2-year survival became 19% (12% versus 31%). 
Conclusions: The above used classification facilitates our understanding about doses of 
chemotherapy and it makes us appreciate the relevance of the individual determinants. It 
appears that the number of cycles, dose level, dose-density, cumulative dose and DI are 
all important factors for improving survival. Intensification of chemotherapy still 
deserves further research in SCLC. 
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Introduction  
 
Survival in small cell lung cancer (SCLC) is only 5-12 weeks without treatment. 
Prognosis has clearly improved to a median survival time (MST) ranging from 7-18 
months with combination chemotherapy, though long-term survival remains poor with 
less than 5% of patients being alive at 5 years [1]. Currently, the most frequently used 
chemotherapy combinations are CAV (cyclophosphamide, adriamycin, vincristine), 
CAE or CDE (cyclophosphamide, doxorubicin, etoposide), (V)-ICE (vincristine, 
ifosfamide, carboplatin, etoposide), and EP (etoposide, cisplatin). New active drugs 
against SCLC include the taxanes and topo-isomerase I inhibitors. Studies with these 
new drugs are running.  
 
In fact, little progress has been made since the introduction of combination 
chemotherapy. The only clear improvement of treatment outcome in terms of survival 
benefit, which has been achieved since, is by the introduction of prophylactic cranial 
irradiation and consolidation chest irradiation which increased long-term survival by 5-
10% for patients with a complete response (CR) or partial response (PR), especially in 
those with limited disease (LD) [2,3]. For both a meta-analysis was needed to 
demonstrate the beneficial role of local treatment added to systemic treatment. 
 
One of the continuing debates concerning combination chemotherapy for SCLC is its 
optimal dose. The importance of dose-intensity (DI) was first demonstrated by Hryniuk 
for chemotherapy in breast cancer [4], and since then this concept has been applied to 
many other tumours. DI is defined as the chemotherapy dose per unit time and is 
expressed as mg/m2/week. DI is generally used as a relative DI, e.g. the ratio of the DI 
of an experimental versus a standard regimen or the delivered versus planned DI of a 
specific regimen. Importantly, the reported DI does not take into account 
discontinuation of chemotherapy as it is calculated for only those cycles that are 
actually delivered. In addition to DI, the cumulative dose may contain valuable 
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information. The cumulative dose is the product of dose per cycle and number of cycles 
of chemotherapy. 
The continuing confusion about the relevance of chemotherapy dose and DI in SCLC is 
partly due to the fact, that the above mentioned distinction between dose and DI has not 
always explicitly been considered. This may abusively lead to comparisons of high-dose 
studies with dose-dense studies [5]. In this review, it will be analysed whether a higher 
than standard dose (cumulative or per cycle) and/or higher than standard DI improves 
survival.  
 
 
Methods 
 
Studies were searched for by Medline. All publications in the English language between 
1980 and September 2001 were examined by the hits ‘small cell’, ‘lung cancer’, 
‘chemotherapy’ and ‘randomised’. In addition, references of relevant articles were 
reviewed. All studies in which dose or DI of chemotherapy in SCLC were the only 
variables tested were included. Studies that performed comparisons between different 
drugs [6] were excluded from this review. Further, studies only evaluating the impact of 
prophylactic growth factors on febrile complications were excluded.  
 
 
Studies concerning dose and DI were categorised by (Table 1): 
1. number of cycles (treatment duration),  
2. dose per cycle,  
3. interval between cycles (dose-density), and  
4. a combination of these variables. 
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Table 1. Variations in dose and dose-intensity (DI) 
Variable : standard versus experimental    
Cumulative 
dose 
DI 
1. Number of cycles   
    
         
⇑ = 
2. Dose per cycle 
 
 
⇑ ⇑ 
3. Interval between cycles 
 
 
= ⇑ 
 
 
When the number of cycles increases the cumulative dose increases, whereas the DI 
remains the same; when the dose per cycle increases the cumulative dose and DI 
increase; when the interval between cycles is shortened, cumulative dose remains the 
same, whereas the DI increases. 
 
 
Results  
 
Category 1. Number of cycles: different treatment durations 
Several investigators have attempted to determine the optimal number of cycles of 
chemotherapy to be delivered in the first-line, with respect to survival [7-14]. Herein, 
the same drugs were delivered at the same dose per cycle (apart from one, in which the 
dose in the maintenance phase was slightly lower [9]) and the same interval between 
cycles, but for a different number of cycles (Table 2).  
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In the different trials, various regimens were used, mainly based on cyclophosphamide, 
vincristine, adriamycin and/or etoposide. The trials are categorised by a declining 
number of chemotherapy cycles.  
 
The trial of the CALGB is difficult to interpret, because three separate randomisations 
were involved: the first, for the type of chemotherapy, including cyclophosphamide, 
methotrexate, and/or vincristine (CMV); the second for plus or minus cranial 
irradiation; and the third, for maintenance chemotherapy until relapse or observation 
[7]. In 46 LD patients with a CR, survival was significantly improved with 10 months 
by maintenance chemotherapy (P=0.01).  
 
In the trial of the ECOG, 577 extensive disease (ED) patients were randomised in a 2x2 
factorial fashion to assess the impact on survival of standard CAV compared with 
alternating CAV-HEM chemotherapy (CAV - hexamethylmelamine, etoposide, 
methotrexate) [8]. In addition, 86 patients with a CR after 6 to 8 initial cycles of 
chemotherapy were randomised to maintenance chemotherapy (total treatment duration 
of 28 cycles) or to observation until progression. Patients without CAV maintenance 
therapy had a shorter time to progression (TTP), whereas patients on CAV-HEM no 
maintenance therapy survived longer than those on CAV-HEM maintenance therapy. 
 
In four studies, it was shown that 5 or 6 cycles was not worse than 12 or 14 cycles, at 
least not when considering overall and long-term survival [9-12]. However, TTP and 
MST appeared to be reduced for the short treatment arm [10,12]. This latter should be 
offset against a documented worse quality of life with prolonged treatment [10]. 
Importantly, in one study it was noted that in the short-treatment arm there was a longer 
total off-chemotherapy time, taking 2nd line chemotherapy into account [12]. The 
Medical Research Council (MRC) reported that for the subgroup who were in CR after 
initial chemotherapy there was a suggestion of longer survival with 12 cycles of 
chemotherapy (MST 6.9 versus 9.7 months, P<0.05, log rank test) [10].   
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Table 2. Number of cycles: randomised trials testing treatment duration of 
chemotherapy in SCLC 
 
Results 
Short versus Longb 
Ref. Total no. pts Regimen
a 
No. cycles 
(no. pts 
randomised) 
TTP 
(months) 
P-valuec MST 
(months) 
2-yrs OS 
(%) 
P 
log- 
rankc,d 
         
[7] 258 CMV 6 vs. till relapse 3.7 vs. 5.0 >0.05 6.8 vs. 16.8  0.01 
   (46: with CR)      
         
         
[8] 577 
ED 
CAV-HEM 
or CAV 
6-8 vs. 28 
(86: with CR) 
4.4 vs. 5.2 
2.8 vs. 5.6 
0.96 
0.015 
14.1 vs. 11.3 
6.8 vs. 9.5 
24 vs. 4 
6 vs. 6 
0.13 
0.09 
         
         
[9] 309 CAV 6 vs. 14e    
 LD/ED  (93:with CR)   
8.5 vs. 12.5f 
18 vs. 12g  
0.006e 
0.13f 
         
         
[10] 497 ECMV 6 vs. 12 5.3 vs. 7.2 <0.001 6.7 vs. 8.1 5 vs. 6 0.27 
 LD/ED  (265: with OR)      
         
         
[11] 320 LCAE 6 vs. 12 9.2 vs 12.5 >0.05 8.1 vs. 10.9 22 vs. 28 0.41 
 LD/ED  (79: with CR)      
         
         
[12] 654 CAE 5 vs. 12 3.7 vs. 5.8 0.0004 9.3 vs. 9.3 10 vs. 12 0.7 
 LD /ED  (434: no-PD)      
         
         
[13] 610 CVE 4 vs. 8 5.3 vs. 7.2 <0.001 7.4 vs. 9.0h 5 vs. 5 0.085g 
 LD/ED  (610: all)      
         
     
309 3 vs. 6 5.8 vs. 7.0 0.09 7.4 vs. 8.6 7 vs. 8 
 (309: all)  
  
    
[14] ECMV 0.6 
 LD/ED     
       
 
 
a see text, ECMV: etoposide, cyclophosphamide, methotrexate, vincristine; LCAE: lomustine, 
cyclophosphamide, adriamycin, etoposide; b from randomisation, c significant P-value: <0.05, d 
P log rank for overall survival, e maintenance: lower dose of CAV at 4-week intervals, f for 
ED(n=61) P=0.006, with P=0.05 in the multivariate analysis, g for LD(n=32), h P=0.085 log 
rank-test, but P=0.007 for MST  
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The trial reported by Spiro et al. for the Cancer Research Campaign is of particular 
importance as it addressed the role of 2 otherapy in advance [13]. In this 
study with a 2x2 factorial design, patients were at registration assigned to 4 or 8 cycles 
and to 2 otherapy or symptomatic therapy in case of progression. Based on 
the initial randomisation, the overall survival was not significant different (P=0.085). 
However, 4 cycles of chemotherapy alone - without 2 otherapy at relapse - 
gave inferior survival compared to the other three arms, which were equivalent in 
outcome (MST 6.9 versus 9.0 months, P<0.01). Importantly, the policy of 2
chemotherapy was difficult to achieve because patients and physicians were reluctant to 
restart chemotherapy.  
 
nd line chem
nd line chem
nd line chem
nd line 
 
In another trial of the MRC, patients were randomised to 3 or 6 cycles [14]. Again, TTP 
was shorter with the reduced number of cycles, and now, as toxicity and quality of life 
were similar for both arms, the investigators recommended 6 cycles of chemotherapy as 
the optimal standard. Furthermore, in the light of the comparison of 3 versus 6 cycles, 
the authors emphasized that with current chemotherapy regimens almost all of their 
potential action is being achieved during the first three cycles, indicating that these three 
cycles should be given without interruption or modification.  
In conclusion, most of these ‘maintenance’ trials didn’t reveal significant survival 
differences [7-14], reason for a generally rather sceptic view concerning prolonged 
treatment. However, some studies did show a trend for improved overall survival or did 
show a significant improved MST and/or TTP for the maintenance arm. In fact, a 
significant increase in TTP was observed in all but one of the studies in which more 
than 100 patients were randomised. When putting the data of the various trials together 
in one graph, it becomes even more obvious that the direction of outcome is quite 
comparable for all studies. That is, both the TTP and the MST are about 2 months 
longer with prolonged treatment (Figure 1). In other words, more drugs apparently 
increases efficacy, even despite the use of 2nd line chemotherapy.  
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Figure 1. Effect of maintenance chemotherapy on TTP and on MST in months. Each 
mark indicates the TTP (upper figure) and MST (lower figure) of one 
randomised ‘maintenance versus no-maintenance’ trial (Table 2). Marks 
located upon the line represent equivalent results. In case the TTP (upper) or 
MST (lower) are improved by maintenance chemotherapy the marks are 
located above (to the left of) the equivalence line. 
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Category 2. Dose per cycle: increased chemotherapy dose for one or more cycles  
 
 
In 5 randomised trials the impact of chemotherapy dosage on survival was evaluated 
[15-19] (Table 3). The same drugs were delivered at the same interval and for the same 
number of cycles with the only variable being the dose in one or more cycles, resulting 
in increased cumulative dose and DI. 
 
 
Table 3. Dose per cycle: randomised trials testing dose-escalation of chemotherapy in 
SCLC 
Results  
Standard versus Experimental 
Ref Total no. pts Regimen
 a 
High- 
dose/ 
total no. 
cycles b 
Relative  
increase 
in dose  
(%)d 
MST 
(months)  
2-yrs OS 
(%) 
P 
log 
rankf 
[15] 103 
 LD/ED CAV 4/4 C+56; A+18 
    
ED 3/6
[17] 90 
    
LD CAEP   
10 vs. 30 
bc 12 vs. 13 – 0.36 
    
[16] 247 
 CAV 
b C+16; A+68 8.0 vs. 6.8 2 vs. 2 >0.05 
        
 ED EP 2/4
bc EP+68 10.7 vs. 11.4 13 vs. 10 0.68 
    
[18] 105 
 1/6
b C+33; P+25e 14 vs. 18 26 vs. 43 0.02 
        
[19] (101) 
 45 CEB 1/6 C800; E67; B5000 12.7 vs. 15.7 0.13 
 LD/ED       
 
a See text; b Number of high-dose cycles / total number of cycles (other cycles at standard-dose); 
c After the initial chemotherapy period, more cycles may have been administered depending on 
response; d Actually delivered increase in dose in high-dose cycles, when compared to standard-
dose cycles; e Planned increase in dose; f Significant P-log rank value for overall survival: <0.05 
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In two of these studies, the impact of high-dose cyclophosphamide and adriamycin as 
part of a 3-weekly CAV regimen was assessed [15,16]. Although the CR rate was 
significantly increased in one (22% versus 12%, P=0.045), dose-escalation did not 
provide a survival benefit and was associated with substantial more toxicity [16].   
 
Ihde et al. evaluated the efficacy of higher doses of etoposide and cisplatin [17]. 
Patients received the higher doses in the first two cycles, while in the third and fourth 
cycle all patients received standard dose EP, at 3-weekly intervals. Patients with a CR 
after 4 cycles continued on EP, while the remaining received in most instances CAV in 
cycles 5-8. Considerable excess toxicities were manifested in patients who received 
high-dose EP, and again no survival difference was seen.  
 
Arriagada and colleagues reported on a prospective study in 105 LD patients, 
randomised to higher versus lower doses of cisplatin and cyclophosphamide in the first 
cycle only [18]. All patients received the lower doses of cisplatin and 
cyclophosphamide and the same doses of adriamycin and etoposide from the second 
through the sixth cycle of chemotherapy at 4-weekly intervals. Enrolment was 
prematurely closed after a planned interim-analysis due to the favourable outcome in the 
intensified arm: 2-year survival rate 26% versus 43% (P=0.02).  
 
There is only one randomised trial in which the benefit of high-dose chemotherapy 
requiring bone marrow transplantation was evaluated [19]. In contrast to the studies 
mentioned above, this concerns a ‘late intensification’ study. First, 3 cycles of standard-
dose methotrexate plus CAV were given followed by 2 cycles of standard-dose EP. 
Then, 45 responding fit patients were randomised to a last cycle of cyclophosphamide, 
etoposide and BCNU at conventional or intensified dose. In the intensified arm the CR 
rate increased from 39% before to 79% after the high-dose cycle, while in the standard 
arm the last conventional-dose cycle did not modify the response rate. Despite the clear-
cut dose-response relationship and an improved relapse-free survival (2.3 versus 6.5 
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months, P=0.002), median overall survival showed only a trend for improvement (12.7 
versus 15.7 months, P=0.13).  
 
Several limitations of the 4 ‘early intensification’ studies are the small number of 
patients included, and the relative moderate dose increment, ranging from 16% to 68% 
per cycle for a few number of cycles only. In the light of the 3 negative studies, the 
results of the French’ are both impressive and surprising. Some have hypothesized, that 
the benefits of high-dose chemotherapy may be restricted to LD patients. The lack of 
significance of the ‘late intensification’ trial may be due to the low number of patients 
randomised, an imbalance at the time of randomisation with more patients in the 
conventional arm having CR (55% versus 39%), and a high number of toxic deaths in 
the intensified arm compared to the standard arm (17% versus 0%). Importantly, these 
studies were all performed before the haematopoietic growth factor era. Despite these 
drawbacks, an improved overall or relapse free survival was observed in two out of five 
high-dose studies, demonstrating the correctness of the concept of dose-escalation.  
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Category 3. Interval between cycles: densification of chemotherapy 
 
The impact of shortening chemotherapy intervals on survival has also been tested 
[20,21,23,24] (Table 4). In these trials the same drugs were delivered at the same dose 
per cycle and the same number of cycles, with the only variable being the interval 
between cycles. Cumulative doses were planned to remain the same, while DI was 
increased in the experimental arm due to the shorter treatment duration.  
 
In three small trials, the primary study objective was to determine whether the addition 
of granulocyte colony-stimulating factor (G-CSF) would enable dose-densification, with 
survival being a secondary endpoint in two of these [20-22].  
 
In the first trial, 65 patients were randomised to 6 cycles of V-ICE (vincristine, 
ifosfamide, carboplatin, etoposide) alone or with G-CSF [20]. Prophylactic cranial 
irradiation was given after cycle 1 and thoracic irradiation after cycle 3. There was no 
fixed dose interval: in both arms re-treatment was given as soon as blood counts had 
recovered. Thus, in both arms the chemotherapy had to be administered at the shortest 
possible interval to ensure that the difference in DI would be attributable to G-CSF 
only. Dose reductions were not permitted. DI was expressed relative to standard 4-
weekly V-ICE. The G-CSF arm received a small but significantly higher DI than the 
control group  (1.18 versus 1.25 over all cycles, P=0.03). Despite the small difference in 
DI, i.e., a relative increase of 6%, the 2-year survival was increased for the G-CSF arm 
(15% versus 32%, P<0.05).  
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Table 4. Interval between cycles: randomised trials testing densification of 
chemotherapy in SCLC 
Results 
Standard versus Experimental Ref Total no. pts 
Regimen 
(no. 
cycles)a 
Interval  
 (weeks) MST  
(months)  
2-years OS 
(%)  
P  
log rank b 
LD/ED 
V-ICE 
6x not fixed 15 vs. 15.9 <0.05
c 
     
63 [21] ED 
CODE 
9x 1 7.4 vs. 13.6  7 vs. 31  0.0004 
     
299 
LD/ED 
V-ICE 
6x 4 vs. 3 11.5 vs. 14.2  18 vs. 33 0.0014 
      
[24] LD/ED 
CDE 
6x 3 vs. 2 10.9 vs. 11.5 8 vs. 13 0.04 
65 [20] 15 vs. 32 
  
  
[23] 
 
403  
 
 
 
a see text; b Significant P log rank value for overall survival: <0.05; c Not log rank: not 
significant for MST, but significant for 2-years OS 
 
In a trial using weekly chemotherapy, 63 patients with ED SCLC were randomised to 
CODE (cyclophosphamide, vincristine, adriamycin and etoposide) alone or with G-CSF 
[21]. Treatment was delayed for one week or more if white blood cell counts were less 
than 1.0 x 109/l or if platelet counts were less than 30 x 109/l. Dose-reductions were not 
allowed. With G-CSF, chemotherapy could be delivered more at the time the next cycle 
was planned, resulting in an increased delivered DI over all cycles (72% versus 84% of 
planned DI, P=0.03) with a significant improvement in 2-year survival of 7% versus 
31% (P=0.0004), also in the multivariate analysis (P=0.03).  
 
In sharp contrast, in another trial with a comparable design, but using a different 
chemotherapy regimen, the addition of G-CSF did not result in an increase in delivered 
DI [22]. For this reason, this trial is not included in Table 4. 
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In the trial of Steward et al., patients were randomised to 6 cycles of V-ICE (vincristine, 
ifosfamide, carboplatin, etoposide) at fixed intervals, either every 3 weeks or every 4 
weeks [23]. A second randomisation (2x2 factorial) was made to granulocyte-
macrophage colony-stimulating factor (GM-CSF, d4-17) or placebo. The primary 
objective was to determine whether GM-CSF could reduce the incidence of febrile 
neutropenia. Survival was a secondary endpoint. Patients in CR were offered 
prophylactic cranial and/or thoracic radiotherapy at the end of chemotherapy. In total, 
299 patients were assessable. Importantly, the feasibility of 3-weekly chemotherapy was 
not dependent on the use of GM-CSF. The change in policy to deliver 3-weekly instead 
of 4-weekly chemotherapy caused an increase in actually delivered DI of 26%. There 
was no significant difference in total dose of chemotherapy delivered in the two arms. 
The densified treatment resulted in an improvement of 15% in 2-year survival rate and 
of 3 months in median survival (P=0.0014). This difference remained significant after 
adjusting for additional prognostic variables in a Cox regression analysis, and the 
magnitude of the difference was comparable for LD and ED patients.  
 
The MRC has recently also reported a large randomised trial in which the impact of 
shortened therapy interval on survival was assessed [24]. In total, 403 patients were 
randomised to 6 cycles of CDE chemotherapy given over 3 days at 2-week intervals 
with the addition of G-CSF, or to the same chemotherapy but at the standard 3-week 
intervals and without G-CSF. Patients with LD were offered thoracic radiotherapy after 
chemotherapy. The actually received DI was 34% higher in the intensified arm, while 
the total amount of chemotherapy delivered was similar in the two arms. CR rates were 
40% versus 28%, in favour for the densified arm (P=0.02). There was a survival benefit 
for the densified arm with an increase in survival at 1-year of 8%, at 2-year of 5%, and 
in median survival of 0.6 months (P=0.04). Subgroup analysis showed that the survival 
advantage for ED patients was as large as for LD patients. 
In conclusion, median and two-year survival was improved in all studies that used 
densification as the only variable [20,21,23,24]. 
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Category 4. Combination of variables: chemotherapy for different number of cycles at 
different dosages and/or at different treatment intervals  
 
There have been 3 trials reported fitting into this category 4, all with a different study 
design (Table 5). 
 
 
 
Table 5. Combination of variables: randomised trials testing chemotherapy at different 
number of cycles, a different dose per cycle and/or at different intervals 
between cycles in SCLC   
 
Results 
Standard versus Experimental Ref Total no. pts 
Dose  
per regimena No. cycles 
Interval 
(weeks) MST 
(months) 
2-year OS 
(%) 
P 
logrankb 
[25] 167 PE/CAV  
 ED 100% vs. 50% 6 vs. 12 3 vs. 1½ 
 
100% vs. 150% 
  
LD/ED 5 vs. 4 
5.8 vs. 6.4 3 vs. 4 NS 
       
[26] 125 CEEP  
 ED 6 vs. 4 4 vs. 4 11 vs. 8.9 13 vs. 3 0.0005 
      
[27] 244 CDE  
  100% vs. 125% 3 vs. 2 12.5 vs. 12 15 vs. 18 0.9113 
 
a See text, dose of experimental arm in comparison to standard arm, which is considered to be 
100% dose; b Significant P-log rank value for overall survival: <0.05, NS=not significant, P-
value not reported 
 
 
James et al. reported a randomised trial in 167 patients treated by alternating PE/CAV 
(cisplatin, etoposide / cyclophosphamide, adriamycin, vincristine) chemotherapy [25]. 
In the control arm patients received standard-dose chemotherapy for 6 cycles at 3-
weekly intervals, while in the experimental arm the dose was reduced to 50%, the 
number of cycles was doubled and delivered at 10/11 days interval. The delivered dose 
and DI were similar for both arms. There was no significant survival difference. 
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In the randomised trial of Pujol et al., the impact of an increased dose per cycle for a 
reduced total number of cycles delivered at the same interval was evaluated [26]. High-
dose chemotherapy of CEEP (cyclophosphamide, epidoxorubicin, etoposide and 
cisplatin) with GM-CSF support for 4 cycles was compared with a standard-dose 
regimen with the same drugs given for 6 cycles, both at 4-weekly intervals. Planned 
cumulative doses of the drugs were the same in both arms (except for cisplatin: 80% in 
the high-dose arm), but DI was planned to be increased by 50% due to the shorter 
treatment duration (4 cycles only). At a planned interim-analysis 125 patients were 
included, after which it was decided to close the accrual. The cumulative doses of 
actually delivered chemotherapy were significantly lower in the high-dose arm (84% of 
planned in standard-dose arm versus 75% in ‘high-dose’ arm, P<0.05). The actually 
delivered DI was not reported. The CR rate was 38% for the standard-dose arm and 
22% for the ‘high-dose’ arm (P=0.05). Patients in the ‘high-dose’ arm had a significant 
reduced TTP with a shorter MST of 2 months and reduced 2-years survival of 10% 
(P=0.0005).  
 
The EORTC has recently performed a trial, in which patients were randomised to 
standard-dose CDE (cyclophosphamide, doxorubicin, etoposide) chemotherapy given at 
3-week intervals for 5 cycles or to intensified CDE chemotherapy given at 125% dose 
of standard-dose at 2-week intervals for 4 cycles with support of G-CSF [27]. By the 
design of the study the planned cumulative dose was intended to be the same for both 
treatment arms, with an increase in DI of nearly 90% in the intensified arm. The 
actually delivered increase in DI was about 70%, while delivered cumulative dose was 
comparable for both arms. However, dose-intensification of CDE chemotherapy by 
dose-escalation and treatment-densification did not result into improved survival, with a 
MST of 12.5 months for the standard arm and 12.0 months for the intensified arm (not 
significant), possibly due to the lower number of cycles in the intensified arm. 
In conclusion, it may be hypothesized that the small benefit from dose-escalation and/or 
densified chemotherapy seems not to weight up against the negative impact of the 
reduced number of cycles.  
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Median of the median survival times 
 
In Figure 2a. the MSTs of the intensified arms are plotted against the MSTs of standard-
dose arms. For the categories 1-3, the black squares (the MST of the intensified arms) 
are generally located above the open round marks (the MST of the standard-dose arms). 
 
In category 1, comprising the randomised trials testing treatment duration, the median 
of MSTs is 8.0 months (range 6.7 – 14.1 months) in the short arm versus 10.2 months 
(range 8.1 – 16.8 months) in the maintenance arm (Table 2).  
In category 2, of randomised trials testing chemotherapy dose-escalation, the median of 
MSTs is 12.0 months (range 8.0 – 14.0 months) in the standard-dose arm versus 13.0 
months (range 6.8 – 18.0 months) in the high-dose arm (Table 3).  
In category 3, testing densification of chemotherapy, the median of MSTs is 11.2 
months (range 7.4 – 15.0 months) in the standard arm versus 13.9 months (range 11.5 – 
15.9 months) in the densified arm (Table 4). 
 
 
Figure 2a.  MST from randomized trials comparing intensified with 
standard chemotherapy
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The median of the MSTs of all twenty randomised trials is 9.8 months (range 5.8 – 15.0 
months) for the standard arms and 11.5 months (range 6.4 – 18.0 months) for the 
intensified arms. The difference becomes even more striking, when omitting the data of 
the two trials in which the so-called ‘high-dose’ arms in fact used a reduced number of 
chemotherapy cycles [26,27], with a median of MSTs of the remaining eighteen trials of 
8.7 months (range 6.7 – 15.0 months) and 11.5 months (range 6.8 – 18.0 months), 
respectively.  
 
 
Median of the 2-year survival rates 
 
The 2-year survival rates were available for 17 trials. In Figure 2b. the 2-year survival 
rates of the intensified arms are plotted against the 2-year survival rates of standard-
dose arms, which were improved by intensified chemotherapy in 12 of 17 trials. 
 
 
Figure 2b.  Two-year survival rates from randomized trials comparing 
intensified with standard chemotherapy
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In category 1, the median of 2-year survival rates is 7% (range 5 – 24%) in the short 
arm versus 6% (4 – 28%) in the maintenance arm (Table 2).  
In category 2, 12% (2 – 26%) in the standard-dose arm versus 20% (2 – 43%) in the 
high-dose arm (Table 3).  
In category 3, 12% (7 – 18%) in the standard arm versus 32% (13 – 33%) in the 
densified arm (Table 4). 
 
The median of the 2-year survival rates of the available 17 randomised trials is 10% (2 – 
26%) for the standard arms and 11% (2 – 43%) for the intensified arms. When omitting 
the data of the two trials in which the so-called ‘high-dose’ arms in fact used a reduced 
number of chemotherapy cycles [26,27], the median of 2-year survival rates is 9% (2 –
26%) and 11% (2 – 43%), respectively. Importantly, for category 2 plus 3, the 
difference in median survival rates is 19% (12% versus 31%). 
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Discussion 
 
Despite the conduct of clinical trials in SCLC over more than 20 years, doubt about the 
relevance of chemotherapy-intensification continuous to exist. Cohen was the first to 
report a benefit of increased chemotherapy dose, but in this study a comparison between 
low and standard dose was made [28]. Currently, the more critical issue is whether 
further chemotherapy intensification - beyond the standard - will improve efficacy.  
 
Variations in cumulative dose and DI can be achieved by differences in the dose per 
cycle, the number of cycles and/or the intervals between cycles. The impact of dose-
escalation may not necessarily be the same as that of dose-densification. At present, in 
total 20 randomised trials have been published in SCLC in which the number of cycles, 
dose per cycle, interval between cycles, cumulative dose and/or DI were changed, while 
the chemotherapy regimens were kept the same. A classification based on each of these 
5 variables may give more insight, and may be helpful for making future directions 
(Table 1 and 6).  
 
As discussed above, the ‘maintenance’ trials demonstrate, that the TTP and MST is 
approximately 2 months longer with prolonged treatment, most evident in patients 
showing a (complete) response to initial chemotherapy (Table 2, Figure 1) [7-14]. This 
is not really surprising, considering the efficacy of second-line chemotherapy in chemo-
sensitive tumours [29], indicative for the presence of chemo-sensitive minimal residual 
disease after first-line chemotherapy. However, whether maintenance chemotherapy 
may also improve long-term survival may be questioned. As prolonged treatment is not 
always possible due to cumulative toxicity, other ways of chemotherapy intensification, 
e.g. by giving a higher dose per cycle, may be more feasible and may be equally 
effective. 
 
The delivery of higher initial doses could prevent the emergence of chemo-resistant 
tumour cells, while late intensification may be attractive because patients may be 
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selected by their response on the induction regimen. Indeed, in two out of five dose-
escalation studies, an improved overall survival or relapse free survival rate was 
observed. Trials with more patients are warranted. 
 
 
Table 6. Increase in delivered dose and/or dose-intensity versus TTP and Survival 
 
cycle 
No. 
cycles First author 
Dose/ Interval Dose- Intensity 
Cumulative 
dose TTP Survival 
1. More cycles 
7 = ⇑ = = ⇑ ⇑ 
Ettinger8 = ⇑ = = ⇑ =/⇑ =/⇑ 
Cullen9 = ⇑ ⇑  =/⇑ 
Bleehen10 = = = ⇑ ⇑ = 
Lebeau11 = ⇑ = = ⇑ = = 
Giaccone12 = ⇑ = = ⇑ = 
Spiro13 = ⇑ = = ⇑ ⇑ =/⇑ 
Bleehen14 = ⇑ = = ⇑ = 
      
2. High-dose  
Figueredo15 ⇑ = = ⇑ ⇑  = 
Johnson16 = = ⇑ ⇑  = 
Ihde17 ⇑ = ⇑ ⇑  = 
Arriagada18 ⇑ = = ⇑ ⇑  ⇑ 
Humblet19 ⇑ = = ⇑ ⇑  =/⇑ 
 
3. Densified  
Woll20 = = ⇓ ⇑ =  ⇑ 
Fukuoka21 = = ⇓ ⇑ =  ⇑ 
Steward23 = = ⇓ ⇑ =  ⇑ 
Thatcher24 = = ⇓ ⇑ =  ⇑ 
 
4. Combinations 
James25 ⇓ ⇑ ⇓ = =  = 
Pujol26 ⇑ ⇓ = ⇑ ⇓ ⇓ ⇓ 
Tjan-Heijnen27 ⇑ ⇓ ⇓ ⇑ =  = 
Maurer = 
= = 
⇑ 
⇑ 
=/⇑ 
  
⇑ 
= 
 
Compared to what is currently considered as standard: ⇑ higher; ⇓ lower/shorter; = similar; =/⇑ 
trend for significant difference or significant different in subgroup analysis 
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Especially for a rapidly dividing tumour like SCLC the administration of chemotherapy 
at shortened intervals may also be a rational approach. In all studies that used 
densification as the only variable, survival was clearly improved with an increase in 
median of MSTs of 2.7 months [20,21,23,24]. The maintained survival difference at 2-
years indicates that dose-densification also increased the curative potential of the 
densified regimens. This implies that research should continue on maximizing dose-
densification.  
 
When appreciating the impact on survival of each of the five discussed variables, the 
outcome of the remaining three trials may even become predictable [25-27] (Table 6). 
In one trial, more cycles were given at a reduced interval but at a lower dose in the 
experimental arm, leading to an equivalent cumulative dose and DI for both arms and 
also to an equivalent survival [25]. Pujol et al. gave a higher dose per cycle for a 
reduced number of cycles in the experimental arm, while keeping the interval the same 
[26]. The delivered DI was increased, but the cumulative dose was reduced in the so-
called ‘high-dose’ arm. In concordance with the lower number of cycles and the reduced 
cumulative dose, survival was worse in the ‘high-dose’ arm. Recently, Tjan-Heijnen et 
al. reported on the results of a randomised EORTC trial in which high-dose 
chemotherapy was given at shorter intervals for a fewer number of cycles in comparison 
with the conventional-dose arm [27]. The survival curves were completely overlapping. 
By extrapolating from the discussed trials, it may be hypothesized that the small benefit 
from dose-escalation and/or densified chemotherapy do not weight up against the 
negative impact of the reduced number of cycles.  
 
Although the trials are rather different in design, we also combined all data for the sake 
of simplicity. For all trials together, the MST was improved by 1.7 months, and after 
omitting the two ‘high-dose’ trials with a reduced number of cycles in the ‘high-dose’ 
arm, the MST was improved by 2.8 months. There was only a slight improvement in 2-
year survival of 1% for all trials taken together. However, when only considering high-
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dose and dose-densified chemotherapy trials, the difference in median 2-year survival 
became 19%. 
Table 7. Sample size calculation for randomised trials with survival as endpoint 
 
 
 
MST control (months) Increase in MST (months) 
Required sample size per arm 
α  2-sided /1-sided 
15 2 1221 / 962 
15 1 4541 / 3577 
9 
(months) 
12 2 754 / 594 
12 1 2767 / 2180 
2 419 / 330 
9 1 1507 / 1187 
6 2 195 / 153 
6 1 674 / 531 
MST control Sample size per arm Detectable experimental MST (months) α  2-sided /1-sided 
15 100 24 / 22 
12 100 19 / 18 
9 100 14 / 13 
6 100 9 / 9 
 
Assumption: power 80%, alpha 5%, 3 years accrual, at least 2 years follow-up 
 
 
How can we then explain the lack of significance in the majority of the trials? The low 
number of patients randomised certainly plays a role. To find a 2-month improvement 
in MST for a MST of 9 months in the control arm the required sample size is 419 
patients per arm, taking 3 years accrual and 2 years of follow-up into account (Table 7). 
In 12 of 20 included trials less than 200 patients were randomised. In case of 200 
patients being randomised (100 per arm), an increase in MST from 9 to 14 months is 
detectable. In this situation, the power to detect a difference smaller than 5 months is 
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less than 80%, and the power to detect a difference of 2 months is only 18%. However, 
such a huge difference (5 months) is totally unrealistic to be expected. Chute et al. 
reported that in twenty years of North American phase III trials, the MST in ED-SCLC 
had improved by 2 months, as was also seen in the population-based Surveillance, 
Epidemiology, and End Results (SEER) database [30]. 
 
For future research, it is important to discuss what the best way of dose-intensification 
is. At first glance, it may be concluded that only chemotherapy densification is really 
effective considering the significant P-values in the four trials. However, these trials 
were all performed with the support of haematopoietic growth factors, making dose-
intensification more feasible in comparison to the older ‘maintenance’ and ‘high-dose’ 
trials. Looking at Table 6 and Figure 2, it appears that the number of cycles, the dose 
per cycle, the interval between cycles, the cumulative dose and the DI all matter for the 
survival. To improve not only the MST but also the curative potential it can be argued 
that further research should preferably focus on densification and dose-escalation at 
later cycles with stem cell support in a selected group of patients.  
 
As both a shorter interval and a higher dose may be relevant, an additional question 
emerges: do haematopoietic growth factors during standard-dose chemotherapy improve 
survival, by preventing dose-reductions and delays? In none of the reported trials 
evaluating the use of haematopoietic growth factors, an increase in survival was 
reported [21-23, 31-35]. But again, as survival was seldom an endpoint, the included 
number of patients may have been too low to detect a small survival difference. A meta-
analysis would be needed to adequately address the role of haematopoietic growth 
factors during standard-dose chemotherapy. Importantly, non-haematological toxicities 
such as increased creatinine concentration also prevented an increase in the relative DI 
(and thus of survival) in the G-CSF arm in one study [22], stressing that not all 
chemotherapy regimens are suitable for achieving dose-intensification. 
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In conclusion, the above used classification facilitates our understanding. From these 
randomised studies it can be learned that apparently the number of cycles, the dose per 
cycle, the interval between cycles, the cumulative dose and the DI are all relevant for 
improving survival. However, as dose-densification and escalation seems to improve 
survival only modestly, research should also focus on alternative approaches in the 
treatment of SCLC. 
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Chapter 8 
Summary 
 
Without treatment, survival of patients with small cell lung cancer (SCLC) is less than 3 
months. Although combination chemotherapy has improved the prognosis (median 
survival time (MST) ranging from 7 to 18 months), long-term survival remains poor. 
Obviously, more effective chemotherapy is needed for SCLC. One approach that may 
improve outcome is to administer chemotherapy at increased dose-intensity (DI). Dose-
intensification can be achieved by adding granulocyte colony-stimulating factor (G-
CSF) to CDE (cyclophosphamide, doxorubicin, etoposide) chemotherapy. Furthermore, 
G-CSF was found to reduce the number of febrile complications when added to 
conventionally dosed CDE. Alternatively, febrile leukopenia (FL) might be prevented by 
the prophylactic use of antibiotics.  
 
In chapter 1 a general introduction and the outline of the thesis is presented. 
The aims of the studies described in this thesis were: 
1. to review studies in SCLC that used different ways of intensification of 
chemotherapy, dose-escalation versus densification, and the role of G-CSF in 
supporting such intensification, 
2. to determine the impact of G-CSF priming on recovery of peripheral blood cell 
counts,  
3. to assess the impact of prophylactic antibiotics on preventing FL, 
4. to evaluate the costs of prophylactic antibiotics in relation to cost-savings produced 
by the expected reduced number of hospitalisations for FL, 
5. to investigate the impact of CDE dose-intensification (with G-CSF support) on 
survival in SCLC, 
6. to analyse reported randomised studies that assessed the impact of chemotherapy 
dose-intensification on survival in SCLC. 
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The different ways of achieving intensification of chemotherapy, dose-escalation versus  
treatment densification, are highlighted in chapter 2.  
The chapter is divided into two parts. The first part concerns studies performed before the 
growth factor era. The dose-response relationship for single agents in SCLC is discussed. 
To address this question further, five randomised studies are reviewed that have assessed 
the impact of early or late dose-escalation of commonly used agents. Two of five trials 
showed an improved (relapse-free) survival. In that period, there were no randomised 
densification studies reported in which the only difference was the interval between cycles.  
In the second part, the role of growth factors as adjunct to chemotherapy in SCLC is 
reviewed. Colony stimulating factors are physiologically occurring glycoproteins that 
control proliferation and differentiation of multipotent and lineage-restricted 
haematopoietic progenitor cells and, furthermore, promote the functional activation of 
mature cells.  
The addition of growth factors to dose-escalated or densified schedules seems to result 
in a relative DI of no more than 150% when compared to optimally delivered 
conventional regimens. It should be noted, that densification of treatment (increased DI) 
seems only feasible for the first four cycles due to cumulative thrombocytopenia and 
anaemia. As a consequence the total dose in a densified regimen may even be lower than 
in a conventional regimen. We concluded in 1997, that it had to be awaited from 
randomised phase III trials whether such a moderate degree of dose intensification 
would improve survival rates.  
In view of the influence of G-CSF and granulocyte-macrophage colony-stimulating factors 
(GM-CSF) on neutropenia its impact on febrile neutropenia has been evaluated: in three 
out of four G-CSF studies the incidence of febrile neutropenia was reduced by almost 50% 
when compared to no support, while conflicting results were reported with GM-CSF.  
 
From this review it became clear that, although it has become easier after the 
introduction of haematopoietic growth factors, several myelotoxicity related problems 
make densification or acceleration difficult. Therefore, we evaluated the impact of G-
CSF priming on peripheral blood cell counts during standard-dose second-line 
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chemotherapy in twelve patients with relapsed SCLC, each treated with two 
chemotherapy cycles (chapter 3). Six patients received G-CSF priming only before the 
first cycle (group A) and the other six patients only before the second cycle (group B). 
Each patient served as his own control. Patients were treated with cyclophosphamide, 
epirubicin, and etoposide (CEE), or with vincristine, ifosfamide, mesna and carboplatin 
(VIMP) every 4 weeks. G-CSF was administered subcutaneous 5 µg/kg/day for 6 days 
until 48 hours before the first or second chemotherapy cycle.   
Priming caused a lowering of white blood cell counts and absolute neutrophils nadir. 
There was a trend for a lower platelet nadir. G-CSF priming resulted in a prolonged 
duration of leukopenia and thrombocytopenia.  
In conclusion, G-CSF administration until 48 hours before the next chemotherapy cycle 
increased chemotherapy-associated leukopenia and thrombocytopenia. 
 
The impact of prophylactic antibiotics on the incidence of FL during chemotherapy for 
SCLC was reported in chapter 4. Patients with chemo-naive SCLC were randomised to 
prophylactic antibiotics (ciprofloxacin 750 mg plus roxithromycin 150 mg, b.i.d., days 
4-13) or to placebo, with half of the patients being treated with standard 3-weekly CDE 
and half of the patients being treated with intensified 2-weekly CDE (2x2 factorial 
design). The randomisation between prophylactic antibiotics versus placebo was 
prematurely stopped (n=163 patients), as recommended by an Independent Data 
Monitoring Committee.  
Prophylactic ciprofloxacin plus roxithromycin during CDE chemotherapy reduced the 
incidence of FL, the number of infections, the use of therapeutic antibiotics and 
hospitalisations due to FL by approximately 50%, with reduced number of infectious 
deaths. It was concluded that for patients with similar risk for FL, the prophylactic use 
of antibiotics should be considered. 
 
To determine whether the cost of prophylactic antibiotics during chemotherapy is offset 
by cost savings due to a decreased incidence of FL, an economic evaluation was 
performed examining the costs and effects of patients taking antibiotics versus placebo 
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(chapter 5). Medical resource utilization was documented prospectively, including 33 
patients from 1 centre in the Netherlands and 49 patients from 1 centre in Germany. The 
evaluation took the perspective of the health insurance systems and of the hospitals.  
In contrast to the findings in the main trial, the incidence of FL was not reduced by 
prophylaxis in Germany. This resulted in an average cost-difference of only 35 Euros in 
favour of prophylaxis (not significant). In the Netherlands, prophylaxis reduced the 
incidence of FL by nearly 50%, comparable to the results of the main trial, resulting in a 
cost difference of 2706 Euro, demonstrating savings in favour of prophylactic 
antibiotics of nearly 45%. It can be concluded that giving oral prophylactic antibiotics 
to SCLC patients undergoing chemotherapy is the dominant strategy in both Germany 
and the Netherlands, demonstrating both cost-savings and superior efficacy. Sensitivity 
analyses indicate that, with an efficacy of prophylaxis of 50%, and with expected costs 
of antibiotic prophylaxis of 500 Euro or less, cost-savings will incur over a broad range 
of baseline risks for FL, that is a risk above 10% to 20% for FL per cycle.  
 
Doubling DI of CDE chemotherapy, by combining dose-escalation and chemotherapy 
densification with the addition of G-CSF, has been to shown to be feasible. To assess 
the impact of dose intensification on survival, 244 SCLC patients with no prior 
treatment, ECOG PS 0-1 and 18-70 years old were randomised to standard CDE (C 
1000mg/m2 day 1, D 45mg/m2 day 1, E 100mg/m2 days 1-3, every 3 weeks for 5 cycles) 
or intensified CDE (C 1250mg/m2, D 55mg/m2, E 125mg/m2 days 1-3 with G-CSF 5 
µg/kg/day days 4-13, every 2 weeks for 4 cycles). The projected total dose was almost 
identical, while projected DI was nearly 90% higher in the intensified arm. The first 163 
pts were also randomised (2x2 factorial design) to prophylactic antibiotics or placebo to 
assess their impact on FL. The remaining patients all received prophylactic antibiotics. 
The results of this multi-centre randomised study concerning impact of chemotherapy 
DI on survival are reported in chapter 6. 
On September 5, 2001, 216 fatal events had occurred after a median follow-up of 49 
months in the standard arm and 57 months in the intensified arm. The arms were well-
balanced. Median actually delivered chemotherapy DI was 170% in the intensified arm 
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compared to the standard arm. Thrombocytopenia was more severe in the intensified 
arm: thrombocytopenia grade 4 occurred in 11% of patients in the standard arm 
compared to 44% in the intensified arm. Median survival was 54 weeks in the standard 
arm and 52 weeks in the intensified arm with 2-year survival rates of 15% and 18%, 
respectively (P=0.885).  
In conclusion, a 70% increase in DI with a comparable total dose of CDE chemotherapy 
did not translate into a survival difference in SCLC patients.  
 
In chapter 7, 20 randomised studies in which the dose or DI of chemotherapy in SCLC 
were the only variables tested and which were published in the period 1980-2001 were 
analysed.  
The analysis showed the following results: 1. With reduced treatment duration to three 
to six cycles, median survival time (MST) was approximately two months shorter. 2. An 
improved overall or relapse free survival was observed in two out of five high-dose 
studies. 3. Survival was increased with 0.6 to 6.2 months in all four densification 
studies. 4. Survival was not improved in studies that used chemotherapy dose-escalation 
and/or –densification in combination with a reduced number of cycles. The median of 
the MST of the patients in the 20 analysed trials taken together was 9.8 months for the 
standard arms and 11.5 months for the intensified arms. After omitting the two trials 
with reduced number of cycles in the so-called ‘high-dose’ arm, the median of MSTs 
was 8.7 and 11.5 months, respectively. There was only a slight improvement in 2-year 
survival of 1% for all trials taken together. However, when only taking high-dose and 
dose-densified chemotherapy trials into account, the difference in median 2-year 
survival became 19% (12% versus 31%). 
In conclusion, it appears that the number of cycles, dose level, dose-density and  
cumulative dose are all important factors for improving survival.  
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Final conclusions and future perspectives 
 
We observed that G-CSF administration until 48 hours before the next chemotherapy 
cycle increased chemotherapy-associated leukopenia and thrombocytopenia. Other 
investigators have observed that 2 to 4 days after cessation of G-CSF treatment, in 
contrast to GM-CSF, the progenitor cells are still rapidly proliferating, the period in 
which the chemotherapy is being administered. This probably explains the detrimental 
effect on peripheral blood counts of the aforementioned G-CSF priming schedule. This 
may be of special concern for chemotherapy regimens prescribed at shortened intervals, 
because in these regimens, G-CSF is often discontinued only shortly before the next 
chemotherapy cycle. Note, that patients in the intensified CDE arm of the EORTC 
08923 trial received G-CSF on days 4-13, while the next chemotherapy cycle started at 
day 15, that is 48 hours after the last G-CSF administration. A major implication of our 
observation in the side-study might be that the myeloprotective effect of post-chemothe-
rapy G-CSF in the intensified arm of the EORTC 08923 trial may have been reduced by 
the negative effect of G-CSF priming.  
To test this hypothesis, we are currently performing a trial in breast cancer patients 
(WKR-15) in which 2-weekly chemotherapy (days 1 and 2) is given with G-CSF 
support. The patients serve as their own control. They receive G-CSF either on days 3-
10 in cycle one, on days 3-13 in cycles two and three, and on days 3-10 in cycles four 
and five (group A) or G-CSF on days 3-13 in cycle one, on days 3-10 in cycles two and 
three, and on days 3-13 in cycles four and five (group B). Myelotoxicity of cycles two 
versus three and of cycles four versus five will be compared. 
 
We have demonstrated that prophylactic use of the antibiotics ciprofloxacin and 
roxithromycin are well tolerated and effective in reducing FL and infections in SCLC 
patients receiving CDE chemotherapy. The protective effect of antibiotics was 
especially seen in patients who were treated with intensified chemotherapy. In this 
patient population with an excellent PS, patients with an ED and elderly age had an 
increased risk for FL. Similarly to G-CSF, ciprofloxacin-roxithromycin antibiotic 
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prophylaxis is recommended to prevent infectious complications in patients with an 
increased risk for FL during chemotherapy.  
From the economic evaluation, it can be concluded that giving oral prophylactic 
antibiotics to SCLC patients undergoing chemotherapy is the dominant strategy in both 
Germany and the Netherlands, demonstrating both cost-savings and superior efficacy. 
Sensitivity analyses indicate that, with an efficacy of prophylaxis of 50%, and with 
expected costs of antibiotic prophylaxis of 500 Euro or less, cost-savings will incur over 
a broad range of baseline risks for FL, that is a risk above 10% to 20% for FL per cycle.  
It can be hypothesized that antibiotics can be an alternative to G-CSF for the prevention 
of FL. Some support that G-CSF and antibiotics give similar results can be found in the 
literature. It has been reported by others that prophylaxis with G-CSF generally 
produces cost-savings only in case of a risk above 40% for FL per cycle. 
We have implemented the results of the abovementioned trial in the Guidelines ‘Small 
Cell Lung Cancer 2001’ of the Working Group on Lung Cancer of the Comprehensive 
Cancer Centre East in the Netherlands, with the recommendation to use prophylactic 
antibiotics in case of increased risk for FL during CDE chemotherapy (age ≥ 60 years, 
ED, PS ≥ 2 or second-line chemotherapy).  
It is not known whether the addition of G-CSF to prophylactic antibiotics in patients 
with increased risk for FL is of any value. For this reason, we launched in December 
2000 a phase III trial (“Ontwikkelingsgeneeskunde project 99053”) in the Netherlands, 
in which SCLC patients with at least one risk factor for FL are randomised between 
prophylactic antibiotics alone versus prophylactic antibiotics plus G-CSF during CDE 
chemotherapy.  
 
We have shown that standard CDE given for 5 cycles compared with densified CDE 
given for only four cycles at an approximately 25% higher dose per cycle with the 
support of G-CSF resulted in a median increase in actually delivered chemotherapy DI 
of 70% in the intensified arm. This 70% increase in DI with a comparable total dose, 
but with a lower number of cycles, did not translate into a survival difference.  
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To understand this outcome, we critically reviewed the literature. The median of the 
MST of the patients in the 20 analysed trials taken together was 9.8 months for the 
standard arms and 11.5 months for the intensified arms. After omitting the two trials 
with reduced number of cycles in the so-called ‘high-dose’ arm, the median of MSTs 
was 8.7 and 11.5 months, respectively. From these randomised studies it can be learned 
that apparently the number of cycles is also relevant for improving survival.  
It may be concluded that in the EORTC 08923 trial, the expected benefit from the 
planned chemotherapy densification and dose-escalation may have been counteracted 
by the reduced number of cycles in the ‘intensified’ arm, with a possibly lower than 
expected increase in DI due to the wrong timing of the G-CSF.  
An interesting question yet to consider is, whether the use of (primary) G(M)-CSF 
prophylaxis during standard-dose chemotherapy is indicated, not only to prevent febrile 
complications, but, more importantly, to improve survival by preventing dose-reduction 
or delay of chemotherapy. We have recently taken the initiative for planning a meta-
analysis with the primary objective being the impact of G(M)-CSF during standard-dose 
(and intensified) chemotherapy on survival in SCLC patients.  
Finally, it is stressed, that as dose-densification and escalation seems to improve 
survival only modestly, research should also focus on alternative approaches in the 
treatment of SCLC. 
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Samenvatting 
De prognose van het kleincellig longkanker is slecht. Zonder behandeling is de 
overlevingstijd minder dan 3 maanden. Met chemotherapie is de prognose duidelijk 
verbeterd tot een gemiddelde overlevingstijd variërend van 7 tot 18 maanden, alhoewel 
overleving op lange termijn teleurstellend blijft. Het is duidelijk dat we voor deze 
kanker betere chemotherapie nodig hebben. Een aanpak om de resultaten mogelijk te 
verbeteren zou de toediening van chemotherapie met een verhoogde dosisintensiteit (DI) 
kunnen zijn. Door toevoeging van granulocyt-koloniestimulerende factoren (G-CSF) 
wordt de intensivering van CDE chemotherapie (cyclofosfamide, doxorubicine, 
etoposide) vergemakkelijkt. Bovendien heeft G-CSF bewezen de kans op koorts tijdens 
leukopenie bij standaard-dosis CDE chemotherapie te verminderen. Een alternatief voor 
het voorkomen van febriele leukopenie (FL) kan het profylactisch gebruik van antibiotica 
zijn.  
 
1. het bestuderen van onderzoeken bij kleincellig longkanker die verschillende 
manieren gebruikten om chemotherapie te intensiveren, te weten dosisescalatie 
tegenover dosisdensificatie (dezelfde dosis gegeven in kortere tijd), en de rol van G-
CSF bij de ondersteuning van een dergelijke intensivering, 
2. vaststellen van effect van G-CSF priming op herstel van perifere bloedcelwaarden,  
5. onderzoeken van het effect van intensivering van CDE chemotherapie (met 
ondersteuning van G-CSF) op de overleving bij kleincellig longkanker, 
6. analyseren van gepubliceerde gerandomiseerde onderzoeken die het effect van een 
intensivering van chemotherapie op het overleven bij kleincellig longkanker hebben 
onderzocht. 
Hoofdstuk 1 bevat een algemene inleiding en de opzet van de dissertatie. 
De doelstellingen van de in deze dissertatie beschreven onderzoeken waren: 
3. beoordelen van het effect van profylactische antibiotica op het voorkómen van FL, 
4. evalueren van de kosten van profylactische antibiotica in verhouding tot 
kostenbesparingen als gevolg van de verwachte teruggang in het aantal 
ziekenhuisopnames voor FL, 
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De verschillende manieren om een intensivering van chemotherapie te bereiken, 
dosisescalatie tegenover densificatie van de behandeling, worden besproken in 
hoofdstuk 2.  
Het hoofdstuk is verdeeld in twee delen. Het eerste deel betreft onderzoek dat vóór de 
groeifactorperiode is uitgevoerd. De relatie dosis-respons voor afzonderlijke middelen in 
kleincellig longkanker wordt besproken. Om dit vraagstuk verder uit te diepen, wordt op 
vijf gerandomiseerde studies ingegaan die het effect van vroege of late dosisescalatie van 
gewoonlijk gebruikte middelen beoordeeld hebben. Twee van de vijf onderzoeken lieten 
een verbeterde (recidief-vrije) overlevingstijd zien. In die periode zijn er geen 
gerandomiseerde densificatiestudies gemeld waarin het enige verschil het interval tussen 
de kuren was.  
In het tweede deel wordt de rol van groeifactoren als toevoeging aan chemotherapie bij 
kleincellig longkanker besproken. Koloniestimulerende factoren zijn fysiologisch 
voorkomende glycoproteïnen die de proliferatie en differentiatie van multipotente en 
oorsprongsgebonden haematopoietische progenitorcellen reguleren en verder de 
functionele activatie van rijpe cellen bevorderen.  
Met het oog op de invloed van G-CSF en granulocyt-macrofaag koloniestimulerende 
factoren (GM-CSF) op neutropenie is het effect ervan op febriele neutropenie beoordeeld: 
in drie van de vier G-CSF-studies was het optreden van febriele neutropenie met bijna 50% 
verminderd in vergelijking met gevallen waarin geen ondersteuning was gegeven, terwijl 
er met GM-CSF tegenstrijdige resultaten werden gemeld.  
De toevoeging van groeifactoren aan schema’s met dosisescalatie of densificatie lijkt te 
resulteren in een relatieve DI van niet meer dan 150% in vergelijking met optimaal 
toegediende conventionele kuren. Opgemerkt dient te worden dat densificatie van de 
behandeling (verhoogde DI) vanwege cumulatieve trombocytopenie en anaemie alleen 
geschikt lijkt voor de eerste vier kuren. Dientengevolge kan de totale dosis in een 
gedensificeerd schema zelfs lager zijn dan in een conventioneel schema. In 1997 
concludeerden we dat het van gerandomiseerde fase III onderzoeken moest worden 
afgewacht of een dergelijke gematigde intensivering van chemotherapie de 
overlevingspercentages zou verbeteren.  
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Uit deze analyse werd duidelijk dat, ondanks de toepassing van haematopoietische 
groeifactoren, verschillende met myelotoxiciteit verband houdende problemen 
densificatie of acceleratie moeilijk maken. Daarom hebben we het effect van G-CSF 
priming op perifere bloedcelwaarden gedurende tweedelijns chemotherapie bij twaalf 
patiënten met recidief kleincellig longkanker geëvalueerd, elk behandeld met twee 
kuren standaarddosis chemotherapie (hoofdstuk 3). Zes patiënten kregen alleen G-CSF 
priming voor de eerste kuur (groep A) en de andere zes patiënten alleen voor de tweede 
kuur (groep B). Iedere patiënt diende als zijn eigen controle. Patiënten werden om de 4 
weken behandeld met cyclofosfamide, epirubicine en etoposide (CEE), of met vincristi-
ne, ifosfamide, mesna en carboplatine (VIMP). G-CSF werd subcutaan 5 µg/kg/dag 
gedurende 6 dagen toegediend tot 48 uur voor de eerste of tweede chemotherapiekuur.  
De priming veroorzaakte een vermindering van witte bloedcelwaarden. Er was een 
tendens voor een lagere bloedplaatjesnadir. G-CSF priming resulteerde bovendien in 
een langere duur van leukopenie en trombocytopenie.  
Concluderend versterkte de toediening van G-CSF tot 48 uur voor de volgende 
chemotherapiekuur de met chemotherapie gepaard gaande leukopenie en trombocy-
topenie. 
 
Het effect van profylactische antibiotica op het optreden van FL tijdens chemotherapie 
voor kleincellig longkanker is beschreven in hoofdstuk 4. Niet eerder met 
chemotherapie behandelde patiënten met kleincellig longkanker werden gerandomiseerd 
voor profylactische antibiotica (ciprofloxacine 750 mg plus roxithromycine 150 mg, 
b.i.d., dag 4-13) of voor placebo, waarbij de helft van de patiënten werd behandeld met 
standaard 3-wekelijkse CDE en de helft van de patiënten werd behandeld met 
geïntensiveerde 2-wekelijkse CDE chemotherapie in een 2x2 factorial design. 
Profylactisch ciprofloxacine plus roxithromycine tijdens CDE chemotherapie 
reduceerde het optreden van FL, het aantal infecties, het gebruik van therapeutische 
antibiotica en het aantal ziekenhuisopnames wegens FL met ongeveer 50%, met een 
verminderd aantal door infecties veroorzaakte sterfgevallen. De randomisering tussen 
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profylactische antibiotica tegenover placebo werd daarom voortijdig gestopt (n=163 
patiënten), op advies van een onafhankelijke commissie.  
Geconcludeerd werd dat voor patiënten met een vergelijkbare kans op FL het 
profylactisch gebruik van antibiotica in overweging genomen dient te worden. 
 
Om vast te stellen of de kosten van profylactische antibiotica tijdens chemotherapie 
opwegen tegen de kostenbesparing vanwege verminderd optreden van FL, is een 
economische beoordeling gemaakt waarbij de kosten en effecten van patiënten die 
antibiotica nemen tegenover patiënten die placebo nemen werden onderzocht 
(hoofdstuk 5). Het gebruik van medische voorzieningen werd prospectief 
gedocumenteerd, bij 33 patiënten van 1 centrum in Nederland en bij 49 patiënten van 1 
centrum in Duitsland. De beoordeling werd gemaakt vanuit het perspectief van de 
ziektekostenverzekeringen en vanuit het perspectief van de ziekenhuizen.  
In tegenstelling tot de bevindingen in het hoofdonderzoek was het optreden van FL in 
Duitsland door profylaxe niet verminderd. Dit resulteerde in een gemiddeld 
kostenverschil van slechts 35 Euro ten gunste van profylaxe (niet significant). In 
Nederland reduceerde profylaxe het optreden van FL met bijna 50%, vergelijkbaar met 
de resultaten van het hoofdonderzoek, resulterend in een kostenverschil van 2.706 Euro, 
hetgeen overeenkwam met een besparing ten gunste van profylactische antibiotica van 
bijna 45%.  
Geconcludeerd kan worden dat het geven van orale profylactische antibiotica aan 
patiënten met kleincellig longkanker die chemotherapie ondergaan zowel in Duitsland 
als in Nederland de dominante strategie is, waarbij zowel kostenbesparingen als een 
betere werkzaamheid worden aangetoond. Sensitiviteitsanalyses geven aan dat er, met 
een werkzaamheid van profylaxe van 50%, en met verwachte kosten van antibiotische 
profylaxe van 500 Euro of minder, kostenbesparingen zullen ontstaan over een breed 
terrein van basisrisico’s op FL, te weten een risico van meer dan 10% tot 20% op FL 
per kuur. 
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Het verdubbelen van de DI van CDE chemotherapie door dosisescalatie en 
chemotherapiedensificatie is met de toevoeging van G-CSF haalbaar gebleken. Om het 
effect van intensivering van chemotherapie op de overleving te beoordelen, zijn 244 
patiënten met kleincellig longkanker zonder eerdere behandeling, ECOG performance 
status 0-1 en 18-70 jaar oud gerandomiseerd voor standaard CDE (C 1000mg/m  dag 1, 
D 45mg/m  dag 1, E 100mg/m2 dag 1-3, 5 kuren à 3 weken) of intensieve CDE (C 
1250mg/m , D 55mg/m , E 125mg/m2 dag 1-3 met G-CSF 5 µg/kg/dag dag 4-13, 4 
kuren à 2 weken). De geraamde totale dosis was bijna identiek, terwijl de geraamde DI 
in de groep met intensieve CDE bijna 90% hoger was. De eerste 163 patiënten waren 
eveneens gerandomiseerd (2x2 factorial design) voor profylactische antibiotica of 
placebo om het effect ervan op FL te beoordelen. De resterende patiënten kregen 
allemaal profylactische antibiotica. Het effect van intensivering van chemotherapie op 
de overleving is beschreven in hoofdstuk 6. 
2
2 2
Op 5 september 2001 waren er 216 fatale gevallen opgetreden na een gemiddelde 
follow-up van 49 maanden in de standaardgroep en 57 maanden in de groep met 
verhoogde CDE. De groepen waren goed verdeeld. De mediane daadwerkelijk 
toegediende chemotherapie DI was 170% in de groep met intensieve CDE in 
vergelijking tot de standaardgroep. Trombocytopenie was ernstiger in de groep met 
intensieve CDE: trombocytopenie graad 4 kwam voor bij 11% van de patiënten in de 
standaardgroep, vergeleken met 44% in de groep met de intensieve CDE. De mediane 
overlevingstijd was 54 weken in de standaardgroep en 52 weken in de groep met 
intensieve CDE, met een 2-jaars overleving van respectievelijk 15% en 18% (P=0.885).  
Concluderend vertaalde een toename in DI van 70% met een vergelijkbare totale dosis 
CDE chemotherapie zich niet in een verschil in overleving bij patiënten met een 
kleincellig longkanker.  
 
In hoofdstuk 7 zijn 20 gerandomiseerde studies geanalyseerd, die in de periode 1980-
2001 zijn gepubliceerd, waarin de dosis of DI van de chemotherapie bij kleincellig 
longkanker de enige onderzochte variabelen waren.  
2
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De analyse liet de volgende resultaten zien: 1. Met een gereduceerde behandelingsduur 
tot drie à zes kuren was  de mediane  overlevingstijd  ongeveer twee maanden  korter.  
2. Een verbetering van de totale of recidief-vrije overleving werd in twee van de vijf 
onderzoeken met een hoge dosis waargenomen. 3. De mediane overlevingstijd nam toe 
met 0.6 tot 6.2 maanden in alle vier densificatiestudies. 4. Er was geen verbetering in 
overlevingstijd in studies die gebruik maakten van dosisescalatie en/of -densificatie van 
de chemotherapie in combinatie met een verminderd aantal kuren. De mediaan van de 
mediane overlevingstijd van de patiënten in de 20 geanalyseerde onderzoeken 
samengenomen was 9.8 maanden voor de standaardgroepen en 11.5 maanden voor de 
geïntensiveerde groepen. Na weglating van de twee onderzoeken met een verminderd 
aantal kuren in de zogenaamde ‘hoge dosis’ groep, was de mediaan van de mediane 
overlevingstijd respectievelijk 8.7 en 11.5 maanden. Er was slechts een lichte 
verbetering in 2-jaars overleving van 1% voor alle studies bij elkaar. Echter, wanneer 
alleen de hoge dosis en densificatiestudies werden bekeken, werd het verschil in 2-jaars 
overleving 19% (12% versus 31%). 
Concluderend blijkt dat het aantal kuren, de hoogte van de dosis, de dosisdensiteit en de 
cumulatieve dosis allemaal belangrijke factoren zijn voor het verbeteren van de 
overleving.  
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Eindconclusies en toekomstperspectieven 
Op grond van ons onderzoek komen wij tot de volgende conclusies: 
We hebben waargenomen dat de toediening van G-CSF tot 48 uur voor de volgende 
chemotherapiekuur de met chemotherapie gepaard gaande leukopenie en trombocy-
topenie versterkte. Andere onderzoekers hebben waargenomen dat 2 tot 4 dagen na de 
beëindiging van de behandeling met G-CSF, in tegenstelling tot GM-CSF, de 
progenitorcellen nog steeds snel prolifereren, de periode waarin de chemotherapie wordt 
toegediend. Dit verklaart waarschijnlijk het nadelige effect op perifere bloedcelwaarden 
van het voornoemde G-CSF priming-schema. Dit kan van bijzonder belang zijn voor 
chemotherapiekuren die met verkorte intervallen worden voorgeschreven, omdat G-CSF 
in deze kuren vaak slechts kort voor de volgende chemotherapiekuren wordt beëindigd. 
Merk op dat patiënten in de groep van intensieve 2-wekelijkse CDE in de EORTC 
08923 studie G-CSF kregen op dag 4-13, terwijl de volgende chemotherapiekuur alweer 
op dag 15 begon, dat is dus 48 uur na de laatste toediening van G-CSF. Een belangrijke 
implicatie van onze waarneming in de nevenstudie zou kunnen zijn dat het myelo-
beschermende effect van post-chemotherapie G-CSF in de groep met intensieve CDE in 
de EORTC 08923 studie mogelijk is gereduceerd door het negatieve effect van G-CSF 
priming.  
Om deze hypothese te onderzoeken voeren we momenteel een onderzoek uit bij 
patiënten met borstkanker (WKR-15), waarbij 2-wekelijks chemotherapie (dag 1 en 2) 
wordt toegediend met G-CSF ondersteuning. De patiënten dienen als hun eigen 
controle. Zij krijgen G-CSF ofwel op dag 3-10 in kuur één, op dag 3-13 in kuur twee en 
drie, en op dag 3-10 in kuur vier en vijf (groep A), ofwel G-CSF op dag 3-13 in kuur 
één, op dag 3-10 in kuur twee en drie, en op dag 3-13 in kuur vier en vijf (groep B). De 
myelotoxiciteit van kuur twee versus drie en van kuur vier versus vijf zullen met elkaar 
worden vergeleken. 
 
We hebben aangetoond dat het profylactisch gebruik van de antibiotica ciprofloxacine 
en roxithromycine goed wordt verdragen en effectief is in het reduceren van FL en 
infecties bij patiënten met kleincellig longkanker die CDE chemotherapie krijgen. Het 
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beschermend effect van antibiotica werd met name gezien bij patiënten die met 
intensievere chemotherapie behandeld werden. In deze patiëntenpopulatie met een 
uitstekende performance status liepen patiënten met een ‘extensive disease’ en een 
bejaarde leeftijd een verhoogd risico op FL. Antibiotica profylaxe (ciprofloxacine-
roxithromycine) wordt daarom geadviseerd ter voorkoming van infectieuze complicaties 
bij patiënten met een verhoogd risico op FL tijdens de chemotherapie. 
Uit de economische evaluatie kan worden geconcludeerd dat het verstrekken van orale 
profylactische antibiotica aan patiënten met kleincellig longkanker die chemotherapie 
ondergaan zowel in Duitsland als in Nederland de dominante strategie is, met zowel een 
kostenbesparing als een betere werkzaamheid. Sensitiviteitsanalyses geven aan dat er, 
met een werkzaamheid van profylaxe van 50%, en met verwachte kosten van 
antibiotische profylaxe van 500 Euro of minder, kostenbesparingen zullen ontstaan over 
een breed terrein van basisrisico’s op FL, te weten een risico van meer dan 10% tot 20% 
op FL per kuur.  
Gesteld kan worden dat antibiotica een goed alternatief voor G-CSF-profylaxe zijn bij 
het voorkomen van FL. Enige staving dat G-CSF en antibiotica vergelijkbare resultaten 
opleveren, kan in de literatuur worden gevonden. Door anderen is gerapporteerd dat 
profylaxe met G-CSF over het algemeen alleen kostenbesparingen oplevert in geval van 
een risico van meer dan 40% op FL per cyclus. 
We hebben de resultaten van het voornoemde onderzoek toegepast in de richtlijn 
‘Kleincellig Bronchuscarcinoom, anno 2001’ van de Tumorwerkgroep voor Longkanker 
van het Integraal Kankercentrum Oost, met het advies profylactische antibiotica te 
gebruiken in geval van een verhoogd risico op FL tijdens CDE chemotherapie (leeftijd 
≥ 60 jaar, ‘extensive disease’, performance status ≥ 2, en/of tweedelijns chemotherapie).  
Het is niet bekend of de toevoeging van G-CSF aan profylactische antibiotica bij 
patiënten met een verhoogd risico op FL van enigerlei waarde is. Om deze reden hebben 
we in december 2000 in Nederland een fase III onderzoek (Ontwikkelingsgeneeskunde 
project 99053) gestart, waarin patiënten met kleincellig longkanker met tenminste één 
risicofactor voor FL worden gerandomiseerd tussen alleen profylactische antibiotica 
tegenover profylactische antibiotica plus G-CSF tijdens CDE chemotherapie.  
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We hebben aangetoond dat standaard CDE, gegeven gedurende 5 kuren, vergeleken met 
gedensificeerd CDE, gegeven gedurende slechts vier kuren met een 25% hogere dosis 
per kuur met ondersteuning van G-CSF, resulteerde in een mediane toename van 
daadwerkelijk verstrekte DI chemotherapie van 70% bij de geïntensiveerde groep. Deze 
toename in DI van 70% met een vergelijkbare totale dosis, maar met een lager aantal 
cycli, vertaalde zich niet in een verschil in overlevingstijd. Om dit resultaat te begrijpen 
hebben we de literatuur kritisch bekeken. De mediaan van de mediane overlevingstijd 
van de patiënten in 20 geanalyseerde onderzoeken samengenomen was 9.8 maanden 
voor de standaardgroepen en 11.5 maanden voor de geïntensiveerde groepen. Na 
weglating van de twee onderzoeken met een verminderd aantal cycli in de zogenaamde 
‘hoge dosis’ groep, was de mediaan van de mediane overlevingstijd respectievelijk 8.7 
en 11.5 maanden. Van deze gerandomiseerde studies kan worden geleerd dat het aantal 
kuren blijkbaar ook relevant is voor de verbetering van de overlevingstijd. 
Geconcludeerd kan worden dat in het EORTC 08923 onderzoek het verwachte voordeel 
van de geplande densificatie en dosisescalatie van de chemotherapie mogelijk teniet is 
gedaan door het gereduceerde aantal kuren in de ‘geïntensiveerde’ groep, met een 
mogelijk lager dan verwachte toename in DI vanwege een verkeerde keuze van het G-
CSF schema.  
Een interessante resterende vraag is of het gebruik van (eerstelijns) G(M)-CSF 
profylaxe tijdens standaard-dosis chemotherapie geïndiceerd is, niet alleen om febriele 
complicaties te voorkomen, maar ook, belangrijker nog, om de overlevingstijd te 
verbeteren door het voorkómen van dosisreductie en/of dosisuitstel. Onlangs hebben wij 
het initiatief genomen voor het plannen van een meta-analyse waarbij het effect van 
G(M)-CSF tijdens standaard-dosis (en intensieve) chemotherapie op het overleven bij 
patiënten met kleincellig longkanker de primaire doelstelling is.  
Tot slot wordt benadrukt dat het wetenschappelijk onderzoek zich ook dient te 
concentreren op alternatieve methoden bij de behandeling van SCLC, aangezien 
dosisdensificatie en -escalatie slechts een bescheiden verbetering van de overlevingstijd 
lijken op te leveren. 
  205 
Chapter 8 
 
 206 
Dankwoord 
Dankwoord 
Van alle medewerking die ik van iedereen heb gehad is de bijdrage die de patiënten (en 
hun familie) in de studies geleverd hebben wel het meest belangrijke geweest. Ik ben 
hen daar erg dankbaar voor. 
Verder wil ik een aantal mensen bij naam noemen, zonder naar volledigheid te willen 
streven. Ik ga daarbij weer even terug in de tijd.  
Een ander voor mij belangrijk persoon is dr. J. Burghouts, internist-oncoloog in het 
Groot Ziekengasthuis (Jeroen Bosch Ziekenhuis) te ‘s-Hertogenbosch. Jos, mijn 
belangstelling voor de oncologie was reeds aanwezig, en jij hebt dat verder weten te 
stimuleren. Je gaf me de gelegenheid een presentatie bij de ‘Heelsum-meeting’ te geven, 
waaruit een studievoorstel voortvloeide. Uiteindelijk legde je daarmee de basis voor dit 
promotie onderzoek. Ik ben je veel dank verschuldigd. 
Vervolgens kom ik dan bij prof. dr. P.E. Postmus, longarts Vrije Universiteit Medisch 
Centrum, Amsterdam. Beste Piet, ik kan me nog goed de eerste keer dat ik je ontmoette, 
in 1992, herinneren. We hadden met een 6-tal mensen in een restaurant in Amsterdam 
afgesproken om het eerste concept van het EORTC studieprotocol, dat ik op papier had 
gezet, door te nemen. Dat was voor mij als 2
ervaring. Aan het eind van die avond vroeg je mij of ik geïnteresseerd was om een 
promotieonderzoek van dit onderwerp te maken. Onderweg naar huis had ik 
‘vleugeltjes’. Ik heb erg veel van je geleerd, en sta telkens weer versteld van de vele 
 
Velen ben ik mijn dank verschuldigd voor hun bijdrage aan dit onderzoek.  
Ik denk daarbij aan dr. B. Hellebrekers, longarts in het Groot Ziekengasthuis (Jeroen 
Bosch Ziekenhuis) te ’s-Hertogenbosch. Ben, op het eind van de dag (17.00 uur stipt) 
kwam je altijd nog even langs de afdeling, met een glaasje jus d’orange. Terwijl ik de 
lab - uitslagen inschreef, nam jij alle tijd om diverse zaken de revue te laten passeren, 
patiënt - gerelateerde problemen maar ook algemeen levensbeschouwelijke zaken. Ik 
heb veel van jou en je collegae longartsen geleerd, en kijk nog steeds met veel plezier 
terug naar die gezellige 1½ jaar ‘longziekten’. Mijn huidig aandachtsgebied heeft hier 
zeker iets mee te maken. 
e jaars arts-assistent een indrukwekkende 
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activiteiten die je keer op keer weer op je schouders neemt. Ik beschouw je als een groot 
voorbeeld! Mijn dank voor je prettige begeleiding. 
De sponsors van de onderzoeken zoals beschreven in dit proefschrift ben ik zeer 
erkentelijk. Een aantal fijne contacten heb ik hieraan overgehouden.  
Bij wie kan ik nu anders uitkomen dan bij prof. dr. D.J.Th. Wagener, medisch oncoloog 
UMC St Radboud, Nijmegen. Beste Theo, ik heb vroeger je colleges al altijd met veel 
plezier gevolgd. Toen ik bij je solliciteerde voor een opleidingsplaats in 1995 en voor 
een stafplaats in 1997, gaf je mij alle steun om een carrière op jouw afdeling in het 
Radboud op te bouwen. In de afgelopen jaren heb ik vaak bij je aangeklopt voor advies. 
Je stond altijd klaar als een ‘wijze raadgever’. Je hebt me gevormd tot de oncoloog die 
ik ben. Je schoof me vaak naar voren voor diverse functies. Ik ben je dan ook zeer veel 
dank verschuldigd. Je bent nu met emeritaat, maar we zullen zeker contact blijven 
houden. 
I like to acknowledge also the EORTC LCG Data Centre. The EORTC 08923 study 
involved a long period. In 1992, the first version of the protocol was written. It took 
then about 2 years to get the study really started. The patient accrual lasted till May 
1999. Subsequently, the final survival analysis could be performed in September 2001. 
So, a long breath was needed, but finally we were able to close the study successfully. 
In such a long period many people come and go. It is impossible to thank everybody by 
name. However, some people I like to mention here. Especially, I like to thank Lisa 
Tyndall, Sonia Dussenne and Channa Debruyne for careful data management and Tarek 
Sahmoud, Desmond Curran and Catherine Legrand for their statistical advise. I like to 
thank Sue Caleo and Ralph Crott for their assistance with the economic analysis. 
Further, I like to thank the board of the EORTC LCG for their support. And finally, I 
acknowledge the important contribution to patient accrual of the many investigators 
involved in this EORTC trial.  
Ook de verpleging, secretaresses en mijn collegae van de afdeling Medische Oncologie, 
en niet te vergeten van de afdeling Longziekten, wil ik bij deze bedanken voor de 
plezierige samenwerking. Speciaal wil ik hierbij noemen prof. dr. Pieter de Mulder,  dr. 
Louk Beex, dr. Stans Verhagen, dr. Jan Festen en de gebroeders Anton en Nico Cox. 
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Vrienden wil ik bedanken voor hun interesse in de voortgang van mijn onderzoek. 
Tenslotte kom ik dan bij mijn familie. Mijn oma overleed op 82 jarige leeftijd aan 
blaaskanker. Zij had altijd bij ons gewoond en was daardoor erg belangrijk voor mij. Ik 
was toen 16 jaar oud, en besloot om onderzoek te gaan doen naar kanker. Mijn vader is 
op 57 jarige leeftijd (1989) overleden aan de gevolgen van longkanker. Ook deze 
gebeurtenis  heeft mij zonder twijfel in mijn beroepskeuze gesterkt. Ik weet zeker dat hij 
trots op me zou zijn geweest als hij dit had kunnen meemaken. 
Mijn moeder wil ik bedanken voor de nimmer aflatende steun en haar vertrouwen in 
mijn mogelijkheden. Zij is de persoon die mijn vastberadenheid en ontwikkeling is 
blijven stimuleren. Mam, bedankt hiervoor! De kinderen vinden het altijd heerlijk om 
weer eens in Limburg te logeren, ‘want oma is zo lief’. 
Pa en ma Tjan, ook jullie wil ik bij deze bedanken voor jullie hartelijkheid en positief 
geïnteresseerde houding. Pa, ondanks uw 76 jarige leeftijd bent u nog steeds actief in 
uw onderzoek naar een middel tegen kanker. Geweldig vind ik dat. Ma, bij u kunnen 
wij altijd aankloppen als we een oppasprobleem hebben. De ‘soep van oma’ is voor de 
kids een begrip geworden. Mijn dank voor alles. 
Yong, wat zou ik zijn zonder jou. Ik hoor je in gedachten al zeggen ‘NIKS’. En dat is 
ook zo. Ik ben de internist, maar jij zorgt thuis het beste voor de inwendige mens. Je 
bent als bedrijfsarts niet minder carrière gericht dan ik, maar je hebt een meer 
relativerende insteek. Jouw analyse van en visie over de wijze van communiceren in het 
ziekenhuiswezen is altijd verhelderend. Met je humor en inventiviteit weet je aan vele 
zaken vaak weer een bijzondere draai te geven. Ik ben blij, dat we elkaar na bijna 20 
jaar nog steeds zoveel te vertellen hebben, zodat de kinderen dan ook regelmatig 
uitroepen ‘mogen wij nu wat zeggen?’. Yong, wat zou ik dus zijn zonder jou?! 
Bram, Martijn en Ramon, jullie zijn de zonnetjes in ons huis. Jullie plezier en blijdschap 
over de dagelijkse dingetjes en jullie onderlinge vriendschap dragen veel bij aan onze 
levensvreugde. Wij houden van jullie! 
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ABMT 
ANC 
CAV 
CDE 
CEE 
CODE 
CR 
Autologous Bone Marrow Transplantation 
Cyclophosphamide, Adriamycine, Vincristin 
Cyclophosphamide, Doxorubicin, Etoposide 
Cyclophosphamide, Epirubicin, Etoposide 
Cisplatin, Vincristin, Doxorubicine, Etoposide 
Absolute Neutrophil Count 
Complete Response 
DI 
DLT 
ED 
EORTC  
FEC 
FL 
FN 
G-CSF 
Dose-Intensity  
Dose-Limiting Toxicity 
Extensive Disease 
European Organisation for Research and Treatment of Cancer 
5-Fluorouracil, Epirubicin, Cyclophosphamide 
Febrile Leukopenia 
Febrile Neutropenia 
Granulocyte colony-stimulating factor 
GM-CSF 
HEM 
Hgb 
LD 
MTD 
MRC 
MST 
OR 
OS 
PE 
PE/ID 
PLT 
PR 
PS 
RBC 
SCLC 
TTP 
VICE 
WBC 
Granulocyte-macrophage colony-stimulating factor 
Hexamethylmelamine, Etoposide, Methotrexate 
Hemoglobine 
Limited Disease 
Maximum Tolerated Dose 
Medical Research Council 
Median Survival Time 
Objective Response 
Overall Survival 
Cisplatin, Etoposide 
Cisplatin, Etoposide/Ifosfamide, doxorubicin 
Platelet 
Partial Response 
Performance Status 
Red Blood Cell  
Small Cell Lung Cancer 
Time To Progression 
Vincristin, Ifosfamide, Carboplatin, Etoposide 
White Blood Cell 
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